






















# DEPARTMENT OF CELL BIOLOGY

## 2024-2025





## Picture Legends

1. **Query Lab:** Scheme for progression of pre-mRNA splicing, highlighting the different conformations required for the first and second catalytic steps; modulation of transition between the two catalytic steps by spliceosomal mutations results in altered splicing fidelity and splice site choice.
2. **Fyodorov & Skoultchi Labs:** *Drosophila melanogaster*, a model system to study biochemistry and genetics of chromatin.
3. **Gritsman Lab:** Spectral karyotyping analysis revealing multiple chromosomal abnormalities in hematopoietic cells from a PI3 kinase (PI3K) triple isoform knockout (TKO) mouse
4. **Schildkraut Lab:** Fluorescent antibodies showing replication fork direction in single DNA molecules labeled with halogenated nucleotides.
5. **Skoultchi Lab:** ChIP-Seq – Chromatin immunoprecipitation followed by massive parallel sequencing reveals differences in the DNA binding patterns of transcription factor PU.1 in normal red blood cells (ES-EP) and malignant erythroleukemia cells (MEL).
6. **Kitsis Lab:** Cell death. Healthy (left) and dying (right) HEK293 cells. Blue - Hoechst 33342 staining of nuclei. Red-tetramethyl rhodamine ethyl ester reflecting electrical potential difference across the inner mitochondrial membrane.
7. **Meier Lab:** Fluorescence image overlaid on a phase contrast image of an enlarged nucleus surrounded by cytoplasm. This stable cell line expresses a cyan fluorescent protein (CFP) with a peroxisomal targeting signal (blue) and a small nucleolar RNA (snoRNA, red) from an intron (green). In this fluorescence in situ hybridization (FISH) of RNA, the snoRNA is visualized in nucleoli (red) and together with the intron at the site of transcription (green/yellow). The spliced mRNA is exported to the cytoplasm and the translated CFP translocated into peroxisomes (blue).
8. **Ye Lab:** Immunofluorescence staining reveals that transcription factors BCL6 (red) and STAT3 (green) are expressed in separate populations of B cells within the germinal center, a dynamic microenvironment critical for T-cell dependent antibody response.
9. **Kielian lab:** Alphavirus- infected cells showing intercellular extensions that mediate virus cell-to-cell transmission. Confocal microscopy image of alphavirus-infected Vero cells, with virus glycoproteins shown in red and F-actin shown in green.

10. **Stanley Lab:** Male mice that cannot synthesize complex N-glycans due to removal of MGAT1 from germ cells do not have spermatozoa (Sz) in the epididymis and are infertile.

11. **LaFave Lab:** Multiplexed immunohistochemistry in a murine model with advanced lung adenocarcinoma. Whole tumor-burdened lungs were stained for Alveolar type 2 (AT2) (OPAL 520, green), Alveolar type 1 (AT1) (OPAL 690, red), and nuclear (DAPI) markers. Image generated by the LaFave lab.

12. **Edelmann Lab:** Organoids (upper left) generated from DNA mismatch repair deficient mouse colon cancers (upper left) to study TGF $\beta$  signaling (upper right: phosphorylation of SMAD3/2, EpCAM+ epithelial cells, DAPI+ nuclei); analysis of Aldh1a3 intestinal stem cells (GFP+) in colonic crypts (lower left) and their expansion in colon cancer organoids (lower right).

13. **Steidl Lab:** Study of hematopoietic stem cells and their progeny using multiplex single-molecule RNA-FISH. Each signal/dot represents a single molecule of RNA of 5 different key transcription factors (visualized by different fluorophores).

14. **Maryanovich lab:** Confocal imaging of vascular (CD31/CD144+; blue) and neural (tyrosine hydroxylase+ sympathetic nerves; red) networks within the thymus parenchyma, captured in the whole thymus following optical tissue clearing (OTC).

15. **Will Lab:** Asymmetrically dividing hematopoietic stem cell by confocal fluorescence microscopy. Blue pseudocolor: DAPI; Red pseudocolor: NUMB protein.

16. **Guo Lab:** Mammary mini-gland derived from a single mammary multipotent stem cell. Keratin 14 (green) and keratin 8 (red) staining show basal and luminal cells, respectively.

17. **Rhoda Hirsch/Craig Branch:** Hb, hemoglobin HbEKO, transgenic mouse Hb knockout expressing only human HbE; HbE-low  $\gamma$ , transgenic mouse Hb knockout expressing only human HbE and low amounts of human HbF; C57, control mouse; CBF, cerebral blood flow [from Min-Hui Cui, Craig Branch, & Rhoda Alison Hirsch [Blood (2021) 138, Supplement 1: 2034.]

18. **Nandakumar Lab:** Engineering leukemic NFE2 gain of function mutations in human hematopoietic stem cells by CRISPR/Cas9. (Left) AAV repair templates used to knock-in NFE2 mutations (Right) FACS strategy to isolate stem cells with heterozygous NFE2 mutations (Bottom) Successful knock-in of NFE2 mutation in human CD34+ cells confirmed by sequencing gDNA (in-out PCR product). [Jessica Jeejan, Research trainee, Nandakumar Laboratory].

19. **Ito Lab:** 3D images of mitochondria (in red) in single phenotypic hematopoietic stem cells (top), transmission electron microscopic images of mitochondrial cristae in leukemic cells (bottom) in wild-type (left) and NPM1 mutant (right), as well as extracellular vesicles derived from hematopoietic stem cells (top far right).

20. **San Martin Lab:** Scanning electron micrograph of a cluster of bone metastatic prostate cancer cells (MDaPCa2b-asterisk) growing on a titanium plate coated with an amorphous calcium phosphate matrix (ACP). Prostate cell lines cultured in this in-vitro model of the bone microenvironment can grow in the absence of testosterone.

21. **Aguirre-Ghiso:** Left: Ribbon diagram (in red) of NR2F1 LBD modeled using MODELLER v9.10 shown with the agonist C26 (sphere representation) docked in the binding site. Right: Close-up of C26 docked in the binding site; white dotted line represents the part of the helix that was removed for a better view of the binding site.

22. **Coleman Lab:** Live-cell super resolution microscopy showing the spatiotemporal dynamics of transcription initiation and elongation via single molecule imaging of TFIID (red) and RNA Polymerase II (green) in human osteosarcoma cells.

## **Department of Cell Biology**






Welcome to the Albert Einstein College of Medicine and the Department of Cell Biology. Our department is focused on molecular mechanisms in many important areas of cell biology, ranging from stem cells to viruses, DNA replication to RNA transcription and processing, gene expression to immunology, glycobiology to cancer. We share many common interests and enjoy an interactive and scientifically stimulating atmosphere that makes the Cell Biology Department a great place to work.

Graduate students in Cell Biology participate in a variety of departmental activities. The department meets every Friday for a “work-in-progress” seminar in which post-doctoral fellows and graduate students describe the progress of their current research and discuss future directions. The department hosts a bi-weekly seminar program of invited outside speakers, with many opportunities for students and postdocs to meet the speaker for discussion and lunch. There is a departmental journal club series in which students and postdocs present and discuss an original article from the upcoming seminar speaker. Weekly get-togethers every Friday afternoon encourage scientific interactions as well as social connections. Our yearly departmental retreat takes us all to an off-campus woodsy setting for a chance to talk about the big picture of our research, to enjoy poster presentations from students and postdocs, and to try to solve the zany puzzles organized by the skit committee.

On the following pages you will find information about the research programs of the individual faculty members, as well as listings of the current students and postdocs in the department. You can also find out more about the department and our research areas on our web page at <https://www.einsteinmed.edu/departments/cell-biology/> . Feel free to contact any of us for further discussions.

Enjoy your first year!

# Cell Biology Faculty

					
Julio Aguirre-Ghiso	Leonard Augenlicht	Barbara Birshtein	Eric Bouhassira	Nicholas Chiorazzi	Robert Coleman
					
John Condeelis	Winfried Edelmann	Dmitry Fyodorov	Matthew Gamble	Kira Gritsman	Wenjun Guo
					
Rhoda Hirsch	Keisuke Ito	Margaret Kielian	Richard Kitsis	Lindsay LaFave	Maria Maryanovich
					
U. Thomas Meier	Satish Nandakumar	Charles Query	Rebeca San Martin	Matthew Scharff	Carl Schildkraut
					
David Shafritz	Robert Singer	Arthur Skoultchi	Pamela Stanley	Ulrich Steidl	Kristy Stengel
					
Zijie Sun	Britta Will	Hilda Ye			

## Cell Biology Faculty

<b>Faculty</b>	<b>Title</b>	<b>Joint Appointment</b>	<b>Location</b>	<b>Ext.</b>	<b>Email Address</b>
Julio Aguirre-Ghiso	Professor		Price 210	1246	julio.aguirre-ghiso@einsteinmed.edu
Leonard Augenlicht	Professor		Ullman 909A	4247	leonard.augenlicht@einsteinmed.edu
Barbara Birshtein	Professor Emerita		Chanin 403A	2291	barbara.birshtein@einsteinmed.edu
Eric Bouhassira	Professor	Medicine/ Hematology	Ullman 903A	2188	eric.bouhassira@einsteinmed.edu
Nicholas Chiorazzi	Adjunct Professor		North Shore LIJ		nchizzi@northwell.edu
Robert Coleman	Associate Professor	Anatomy and Structural Biology	Forchheimer 628A	8623	robert.coleman2@einsteinmed.edu
John Condeelis	Professor	Anatomy and Structural Biology /Surgery	Forchheimer 602	8718	john.condeelis@einsteinmed.edu
Winfried Edelmann	Professor	Genetics	Price 279	1086	winfried.edelmann@einsteinmed.edu
Dmitry Fyodorov	Professor		Chanin 414A	4021	dmitry.fyodorov@einsteinmed.edu
Matthew Gamble	Professor	Molecular Pharmacology	Golding 203	2942	matthew.gamble@einsteinmed.edu
Kira Gritsman	Associate Professor	Medicine/ Oncology	Chanin 410	6707	kira.gritsman@einsteinmed.edu
Wenjun Guo	Professor Gottesman Stem Cell Institute		Price 122	1276	wenjun.guo@einsteinmed.edu
Rhoda Hirsch	Professor Emerita	Medicine	Ullmann 925	3604	rhoda.hirsch@einsteinmed.edu
Keisuke Ito	Professor Gottesman Stem Cell Institute	Medicine	Price 102	1278	keisuke.ito@einsteinmed.edu
Margaret Kielian	Professor		Chanin 515	3638	margaret.kielian@einsteinmed.edu
Richard Kitsis	Professor	Medicine/ Cardiology	Forchheimer G46	2609	richard.kitsis@einsteinmed.edu

Lindsay LaFave	Assistant Professor		Chanin 606	2090	lindsay.lafave@einsteinmed.edu
Maria Maryanovich	Assistant Professor		Price 120	1066	maria.marianovich@einsteinmed.edu
U. Thomas Meier	Professor	Anatomy and Structural Biology	Forchheimer 650A	3294	tom.meier@einsteinmed.edu
Satish Nandakumar	Assistant Professor		Ullmann 915	2246	satish.nandakumar@einsteinmed.edu
Charles Query	Professor		Chanin 415A	4174	charles.query@einsteinmed.edu
Rebeca San Martin	Assistant Professor	Department of Oncology (Medical Oncology)	Ullmann 713A	2099	rebeca.sanmartin@einsteinmed.edu
Matthew Scharff	Distinguished Professor		Chanin 404	3527	matthew.scharff@einsteinmed.edu
Carl Schildkraut	Professor		Chanin 416	2097	carl.schildkraut@einsteinmed.edu
David Shafritz	Professor Emeritus	Department of Medicine (Hepatology)	Ullmann 603	2098	david.shafritz@einsteinmed.edu
Robert Singer	Professor	Anatomy & Structural Biology/ Neuroscience	Golding 601	8646	robert.singer@einsteinmed.edu
Arthur Skoultchi	Professor		Chanin 402	2169	arthur.skoultchi@einsteinmed.edu
Pamela Stanley	Professor		Chanin 516	3346	pamela.stanley@einsteinmed.edu
Ulrich Steidl	Professor and Chair	Medicine/ Oncology	Chanin 601	3437	ulrich.steidl@einsteinmed.edu
Kristy Stengel	Assistant Professor		Chanin 403	2953	kristy.stengel@einsteinmed.edu
Zijie Sun	Director of MECC Prostate Cancer Research Program		Ullmann 213	2115	zijie.sun@einsteinmed.edu
Britta Will	Associate Professor	Medicine/ Oncology	Chanin 401	3786	britta.will@einsteinmed.edu
B. Hilda Ye	Associate Professor		Chanin 302C	3339	hilda.ye@einsteinmed.edu

## Junior Faculty

### Adjunct Assistant Professor

Name	Mentor	Location	Ext.	Email Address
Sulagna Das	Singer	Golding 601	8598	sulagna.das@einsteinmed.edu

### Adjust Senior Staff Scientist

Name	Mentor	Location	Ext.	Email Address
Kyoko Ito	Ito	Price 108	1279	kyoko_ito@einsteinmed.edu

### Instructors

Name	Mentor	Location	Ext.	Email Address
Deepak Singh	Aguirre-Ghiso	Price 250A	1109	deepak.singh@einsteinmed.edu
Jiahn Choi	Augenlicht	Ullmann 909	4247	jiahn.choi@einsteinmed.edu
Claudia Morganti	Ito	Price 108	1279	claudia.morganti@einsteinmed.edu
Peiqi Yin	Kielian	Chanin 515	3639	peiqli.yin@einsteinmed.edu

### Principal Staff Scientist

Name	Mentor	Location	Ext.	Email Address
Weihsan Li	Singer	Golding 601	3230	weihsan.li@einsteinmed.edu

### Research Assistant Professors

Name	Mentor	Location	Ext.	Email Address
Elena Tosti	Edelmann	Price 269	1087	elena.tosti@einsteinmed.edu
Young Yoon	Singer	Golding 614	8636	young.yoon@einsteinmed.edu

## Staff Scientists

Name	Mentor	Location	Ext.	Email Address
Alexander Emelyanov	Fyodorov	Chanin 414	4022	alexander.emelyanov@einsteinmed.edu
Rama Kadamb	Aguirre-Ghiso	Price 207	1110	rama.kadamb@einsteinmed.edu
Rajni Kumari	Steidl	Chanin 601	8953	rajni.kumari@einsteinmed.edu
Yuhong Ma	Will	Chanin 401	6431	yuhong.ma@einsteinmed.edu
Swathi-Rao Narayanagari	Steidl	Chanin 601	2915	swathi-rao.n@einsteinmed.edu
Hugo Pinto	Skoultchi	Chanin 402	3595	hugo.pinto@einsteinmed.edu
Colette Prophete	Frenette	Price 107	1204	colette.prophete@einsteinmed.edu
Nitya Nand Srivastava	Edelmann	Price 269	1087	nityanand.srivastava@einsteinmed.edu
Sriram Sundaravel	Steidl	Chanin 601	8573	sriram.sundaravel@einsteinmed.edu
Shoichiro Takeishi	Frenette	Price 107	1204	shoichiro.takeishi@einsteinmed.edu
Samuel Taylor	Steidl	Chanin 601	8953	samuel.taylor@einsteinmed.edu
Victor Thiruthuvanathan	Will	Chanin 302A	7983	victor.thiruthuvanathan@einsteinmed.edu
Lidiane Torres	Ito	Price 107	1204	lidiane.torres@einsteinmed.edu
Yong Wei Zhang	Edelmann	Price 269	1087	yongwei.zhang@einsteinmed.edu

# Postdoctoral Fellows

Name	Mentor	Location	Ext.	Email Address
Anna Adam-Artigues	Aguirre-Ghiso	Price 207	1110	anna.adamartigues@einsteinmed.edu
Yao Mawulikplimi Adzavon	Sun	Ullmann 205	3169	yaomawulikplimi.adzavon@einsteinmed.edu
Paulina Alatraste Gonzalez	Kielian	Chanin 402	3639	paulina.alatrastegonzalez@einsteinmed.edu
Mirjam Arnold	Stengel	Chanin 403	2710	mirjam.arnold@einsteinmed.edu
Elisa Balzano	Schildkraut	Chanin 416	3193	elisa.balzano@einsteinmed.edu
Randall Carpenter	Maryanovich	Price 107	1204	randall.carpenter@einsteinmed.edu
Joyeeta Chakraborty	Stengel	Chanin 403	2710	joyeeta.chakraborty@einsteinmed.edu
Ga Eul Chu	Sun	Ullmann 205	3169	gaeul.chu@einsteinmed.edu
Marcelo Coutinho de Miranda	Guo	Price 108	1277	marcelo.coutinhodemiranda@einsteinmed.edu
Pratyush Kumar Das	Kielian	Chanin 515	3639	pratyushkumar.das@einsteinmed.edu
Wenyan Fu	Guo	Price 108	1277	wenyan.fu@einsteinmed.edu
Shira Glushakow-Smith	Gritsman	Chanin 408	6708	shira.glushakow-smith@einsteinmed.edu
Sakshi Goel	LaFave	Chanin 606	4751	sakshi.goel@einsteinmed.edu
Juliane Grimm	Will	Chanin 401	6431	juliane.grimm@einsteinmed.edu
Malini Gupta	Will	Chanin 401	6431	malini.gupta@einsteinmed.edu
Dong-Woo Hwang	Singer	Golding 601	3230	dongwoo.hwang@einsteinmed.edu
Shoeb Ikhlal	Scharff	Chanin 404	2170	shoeb.ikhlas@einsteinmed.edu
Yun-Ruei Christine Kao	Will	Chanin 401	8953	yun-ruei.kao@einsteinmed.edu
Yunjeong Kim	Sun	Ullmann 205	3169	yunjeong.kim@einsteinmed.edu
Anupama Kumari	Schildkraut	Chanin 416	3193	anupama.kumari@einsteinmed.edu
Caroline Martin	Kielian	Chanin 515	3639	caroline.martin@einsteinmed.edu
Koceila Meznad	Meier	Forchheimer 650	2768	koceila.meznad@einsteinmed.edu
Kenta Nishitani	Guo	Price 108	1277	kenta.nishitani@einsteinmed.edu
Michael Papanicolaou	Aguirre-Ghiso	Price 207	1110	michael.papanicolaou@einsteinmed.edu
Tae Ju Park	Sun	Ullmann 205	3169	taeju.park@einsteinmed.edu
Ankita Saha	Skoultchi	Chanin 402	3595	ankita.saha@einsteinmed.edu
Deisy Segura-Villalobos	Aguirre-Ghiso	Price 207	1110	deisy.seguravillalobos@einsteinmed.edu
Lornella Seeneevassen	Aguirre-Ghiso	Price 207	1110	lornella.seeneevassen@einsteinmed.edu
Goichi Tatsumi	Steidl	Chanin 601	8573	goichi.tatsumi@einsteinmed.edu
Jingli Wang	LaFave	Chanin 606	4751	jingli.wang@einsteinmed.edu
Daozheng Yang	Will	Chanin 401	6431	daozheng.yang@einsteinmed.edu
Federica Zanotti	Ito	Price 108	1279	federica.zanotti@einsteinmed.edu

## Predoctoral Fellows

Name	Mentor	Location	Ext.	Email Address
Farzana Begum	Maryanovich	Price 107	1204	farzana.begum@einsteinmed.edu
Daniel Borger*	Gritsman	Price 107	1204	daniel.borger@einsteinmed.edu
Amber Buhagiar	Steidl	Chanin 601	8573	amber.buhagiar@einsteinmed.edu
Yessenia Cedeno Cedeno	Coleman	Forchheimer 628	2048	yessenia.cedeno@einsteinmed.edu
Alison Chafitz	San Martin	Ullmann 713	2099	alison.chafitz@einsteinmed.edu
Zhongxuan Chi	Query	Chanin 415	4174	zhongxuan.chi@einsteinmed.edu
Lionel Colon	Aguirre-Ghiso	Price 207	1110	lionel.colon@einsteinmed.edu
Justin Ferraro	LaFave	Chanin 606	4751	justin.ferraro@einsteinmed.edu
Anthony Griffen	LaFave	Chanin 606	4751	anthony.griffen@einsteinmed.edu
Nayem Haque	Coleman	Forchheimer 628	2048	nayem.haque@einsteinmed.edu
John Hobbs	Coleman/Steidl	F-628/Chanin	8573	john.hobbs@einsteinmed.edu
Jessie Larios Valencia*	Guo	Price 108	1277	jessie.lariosvalencia@einsteinmed.edu
Francesca LiCausi	Maryanovich	Price 107	1204	francesca.licausi@einsteinmed.edu
Eric Liu	Ye	Chanin 302C	3340	eric.liu@einsteinmed.edu
Shane Mitchell	Gritsman	Chanin 408	6708	shane.mitchell@einsteinmed.edu
Victor Morell	Stengel	Chanin 403	2710	victor.morell@einsteinmed.edu
Sara Mosavarpour	LaFave	Chanin 606	4751	sara.mosavarpour@einsteinmed.edu
Brendan Mullaley	LaFave	Chanin 606	4751	brendan.mullaley@einsteinmed.edu
Dror Perk	Will	Chanin 401	6431	dror.perk@einsteinmed.edu
Ariel Raskin	Stengel	Chanin 403	2710	ariel.raskin@einsteinmed.edu
Karl Roberts	Bouhassira	Ullmann 925	2188	karl.roberts@einsteinmed.edu
Akiva Rube	LaFave	Chanin 606	4751	akiva.rube@einsteinmed.edu
Alexandra Schurer	Gritsman	Chanin 408	6708	alexandra.schurer@einsteinmed.edu
Emily Schwenger*	Steidl	Chanin 601	8573	emily.schwenger@einsteinmed.edu
Mark Soto	Gritsman	Chanin 408	6708	mark.soto@einsteinmed.edu
Jacob Stauber*	Steidl	Chanin 601	8573	jacob.stauber@einsteinmed.edu
Tihomira Todorova	Steidl	Chanin 601	8953	tihomira.todorova@einsteinmed.edu
Brad Tricomi	Steidl	Chanin 601	8573	brad.tricomi@einsteinmed.edu
Luis Valencia Salazar	Aguirre-Ghiso	Price 207	1110	luis.valenciasalazar@einsteinmed.edu

\*MD/PhD Student

**JULIO A. AGUIRRE-GHISO, Ph.D.**

Rose C. Falkenstein Chair in Cancer Research

Professor of Cell Biology and Oncology

Founding Director of the Cancer Dormancy and Tumor Microenvironment Institute,

Co-Director of the Gruss-Lipper Biophotonics Center

Co-Leader Tumor Microenvironment and Metastasis Program, AECC



Price BLDG. – ROOM 220

**CANCER DORMANCY: UNDERSTANDING THE BIOLOGY OF METASTASIS**

The major challenge faced by physicians is the prevention and treatment of metastasis, the main reason for cancer mortality. Often, cancer patients presumed cured after primary tumor removal and therapy, can carry non-proliferating 'dormant' disseminated cancer cells (DCCs) for years before reactivating to form incurable metastasis. In addition, DCCs show resistance to standard treatments by reprogramming themselves in a niche-dependent manner. Our lab specifically focused on the dormant nature of minimal residual disease in cancer by understanding the biology of dormant DCCs and their reactivation, to target them and prevent relapse. We focus on identifying the mechanisms of microenvironmental cues and cross-talk with DCCs, epigenetic and immune regulation of DCCs, and developing therapeutic approaches to target DCCs clinically.

**1. Early dissemination and early DCC dormancy.** Our lab has discovered that dormant breast cancer DCCs and metastasis can originate very early during cancer evolution, disseminating during pre-malignant stages and aided by innate immune cells. We identified a mechanism for early dissemination whereby Her2 aberrantly activates a program similar to mammary ductal branching that spawns early DCCs (eDCCs) capable of forming metastasis after a dormancy phase. We also revealed how the HER2 oncogene activates through CCL2 signaling the recruitment of tissue resident macrophages that help eDCCs to enter circulation. Targeting these macrophages early in cancer evolution reduced metastasis late in cancer progression. Together, we try to understand how eDCCs orchestrate signals intrinsic to cancer cells and those from the microenvironment to remain dormant and persistent and how alterations of these signals lead to reactivation into outgrowing metastases. We also aim to identify markers that might pinpoint early DCCs vs. late DCCs and may allow selectively targeting these cells.

To this end we recently completed a full single cell sequencing study of early and late primary lesions as well as DCCs from matched early and late lungs identifying the transcriptional programs that drive early DCC dormancy. Understanding mechanisms of disseminated cancer cell (DCC) plasticity, represented by the transitions between epithelial and mesenchymal cell fates (EMT and MET), has been shown to closely associate with tumor cell proliferation, cancer dormancy, and metastasis. Our early DCC studies have identified the pluripotency regulator ZNF281 (aka Zfp281, ZBP99, GZP1) in controlling anterior-posterior axis formation and epiblast maturation through direct transcriptional and epigenetic regulation of Nodal/TGF $\beta$  signaling pathway, which is well known for its roles in EMT and cancer metastasis as well as in BCa stemness. ZNF281 induces a permissive state for heterogeneous mesenchymal-like (M-like) transcriptional programs. These programs carry a dormancy signature and are absent in proliferative primary tumors and metastasis.

- Harper, K, Sosa MS., et al., (2016) *Nature*. PMID 27974798
- Hosseini et al., (2016) *Nature*. PMID 27974799
- Linde and Casanova-Acebes et al., (2018) *Nat Commun*. PMID 29295986
- Nobre et al., (2022) *Nat Cancer*. PMID: 36050483

---

**2. Stem cell and niche biology in cancer dormancy.** We have explored why in many patients DCCs persist and remain dormant in the bone marrow and other organs. We found that the bone marrow contains high levels of TGF $\beta$ 2, which induced dormancy via TGF $\beta$ -RI/RII/RIII complexes and p38 signaling. We used mouse genetics to show that a key source of TGF $\beta$ 2 is the NG2+/Nestin+ mesenchymal stem cells (MSCs) that induce hematopoietic stem cell dormancy and self-renewal and also proved that these MSCs induce and maintain dormancy of breast cancer DCCs in the bone marrow. We also determined that the retinoic acid signaling via the nuclear receptor NR2F1 is required for survival of HNSCC DCCs in the bone marrow but it controls dormancy of these same DCCs in the spleen and lungs. Interestingly the expression of NR2F1 can be initiated in the primary site by a combination of hypoxic signals and the presence of specialized macrophages that coordinate the induction of NR2F1 and SOX9 and prime intravasating DCCs to enter dormancy post extravasation. We have also discovered that dormant tumor cells assemble their own pro-dormancy niche by coordinating the above signals with the upregulation of collagen-III and the assembly of curly collagen matrices that sustain dormancy via DDR1 signaling STAT1 signaling. We have also explored how in lung cancer niches orchestrated by tissue resident macrophages (TRMs) and how these are altered by early lung cancer cells and later recruited bone marrow derived macrophages regulate lung cancer growth initiation. This work revealed that TRMs orchestrate a tissue regenerative and immune evasive program that enables lung cancer initial growth. Together these studies have provided a molecular description of how a reciprocal interaction between DCCs and their niches are essential for survival and dormancy of DCCs across different cancers.

- Bragado, P., et al.,(2013). *Nat. Cell Bio.* PMID 24161934
- Sosa MS et al. (2015) *Nat Commun.* PMID 25636082
- Nobre AR et al., (2021) *Nat Cancer.* PMID: 34812843
- Di Martino Jet al., (2021) *Nat Cancer.* PMID: 35121989
- Casanova-Acebes, M., et al., (2021) *Nature.* PMID: 34135508
- Borriello L. et al., (2022) *Nat Commun.* PMID: 35110548

---

**3. Mechanism of uveal melanoma dormancy and therapy resistance.** The primary concern in uveal melanoma (UM) patient is the development of liver metastasis after primary tumor resection and the lack of effective treatment to treat the same. UM DCCs can leave the primary tumor at very early stages of progression as observed in other types of cancers, seed target organs and remain dormant for years, until some change “awakens” DCCs causing metastasis after 10-15 years. We hypothesize that dormant DCCs enter quiescence and cannot be eradicated by anti-proliferative therapies. We further hypothesize that these mechanisms could be targeted to prevent awakening and metastasis, as well as to identify biomarkers that could be used to predict dormant disease in patients and therapy response. This approach has not been attempted in uveal melanoma. The primary aim of this effort in the lab is to provide the preclinical basis for new treatment options for early as well as late-stage UM patients. TGF $\beta$ 2 signaling was found to be implicated in the dormancy of HNSCC DCCs in the bone marrow, demonstrated as being a ‘restrictive soil’ compared to the lungs for example. Interestingly, liver cells also express TGF $\beta$ 2. Thus, we hypothesize that TGF $\beta$ 2 could be maintaining UM DCCs dormancy in the liver for years until age-related changes in the liver ME induces their awakening. The lab is also currently exploring this aspect of dormancy-maintaining signaling as well as optimizing targeted therapies as a possible therapy option for UM patients.

- Lapadula et al., 2023 *Mol Cancer Ther.* PMID: 36223548

- Kadamb and Lopez-Anton et al., (2023) In Preparation
  - The et al., (2020) *Mol Cancer Ther* PMID: 32430489
  - Lapadula et al., (2019) *Mol Cancer Res* PMID: 30567972
- 

**4. Tissue homeostasis, aging, and dormancy:** We are dissecting out the interaction between tissue resident host cell populations in the metastatic niche and DCCs, and how this may regulate dormancy and re-awakening. Once DCCs arrive at distal sites they are exposed to niche-specific homeostatic processes. These processes are largely driven by stromal and immune cell populations. Given that dormancy is a long-lived process that can span many years, we hypothesize that these homeostatic processes likely induce dormancy, and that the loss of tissue homeostasis results in DCC re-awakening. Over the span of an organism's life, many age-related changes result in a loss of homeostasis which have been shown to affect DCC re-awakening. Age-induced modifications in pulmonary fibroblast WNT-signaling induces a dormancy-to-reactivation switch in melanoma DCCs resulting in efficient metastatic outgrowth in aged lungs. We are also beginning to investigate how age-related changes in the immune and stromal compartment may influence dormancy and re-awakening at distal sites and how specific factors that reverse aging phenotypes may affect the fate of DCCs and their switching from dormancy to reactivation in melanoma and breast cancer.

- Fane et al., (2022) *Nature*. PMID: 35650435
- 

**5. Epigenetic programs of dormancy and therapeutic targeting.** Targeting dormancy mechanisms for metastasis suppression: Analysis of the transcriptional and epigenetic mechanisms active in dormant DCCs pinpointed retinoic acid as a micro-environmental pro-dormancy cue. We found that the orphan nuclear receptor NR2F1, which regulates lineage commitment and is silenced in human tumors, is spontaneously upregulated in solitary dormant tumor cells. Retinoic acid induces TGF $\beta$ 2, NR2F1 expression, and dormancy of DCCs. We found that a transient treatment with a low dose of 5-azacytidine (AZA), followed by all-trans retinoic acid (atRA), restored the NR2F1-driven program and long-term in vivo quiescence of previously malignant cells. We showed that NR2F1-independent pathways induced in parallel upon reprogramming also play an important role in dormancy induction and they depend on TGF $\beta$ -SMAD4 signaling. This mechanism is due to specific remodeling of enhancers linked to TGF $\beta$ -SMAD4 signaling. The AZA+atRA strategy is currently being used in a clinical trial in prostate cancer. Our epigenetics work has also revealed that in melanoma mutations in the chromatin regulator ARID2 acquire a mesenchymal slow cycling but highly disseminating phenotype. Further analysis of epigenetic pathways focused on the histone variants macroH2A, especially the isoform macroH2A2, and we found this histone variant enforces a stable dormant phenotype in DCCs by activating dormancy and senescence genes that limit metastasis initiation. We showed that TGF $\beta$ 2 and p38a/ $\beta$  also upregulate macroH2A and thus induce DCC dormancy.

Recently, we capitalized on this knowledge and discovered an agonist of the NR2F1 that specifically activates dormancy programs or neural crest stem cell commitment that drives stably malignant cells into a persistent growth arrest in target organs. In addition, we discovered long ago that dormant cells depend on the unfolded protein response for survival and specifically on the PERK pathways. We have now identified an inhibitor the PERK pathway, which is required for the survival of dormant DCCs and when used in vivo blocks metastasis by eradicating dormant DCCs during quiescence. This inhibitor is currently in clinical trials.

- Ranganathan et al., (2006/2008) *Cancer Res.* PMIDs, 16452230; 18451152
- Bragado et al., (2012) *PLoS ONE* PMID: 22276135
- Sosa, M.S., et al.,(2015). *Nat Commun* PMID 25636082
- Sun D. et. al., (2022). *Science Advances* PMID: 36459552
- Khalil B.D. et al, (2022). *J. Exp. Med.* PMID 34812843
- Carcamo S., et a., (2022) *Cell Reports*. PMID 35385731
- Singh D.K. et al., (2023). *Cell Reports* PMID: 37267946
- Calvo, V., et al., (2023). *bioRxiv* <https://doi.org/10.1101/2021.07.30.454473>

**Leonard Augenlicht, Ph.D.**  
**Professor**  
**Medicine and Cell Biology**

**Ullmann, 909**  
**718-430-4247**  
**leonard.augenlicht@einsteinmed.edu**



**Key Words:** *intestinal homeostasis and cancer, diet, mouse models, inflammation, stem cells*

Our laboratory is focused on cellular and molecular mechanisms of intestinal homeostasis and perturbations that cause intestinal inflammation and tumor development. This encompasses development of mouse genetic models and the impact of environmental alterations linked to elevated risk for human inflammatory bowel disease and colon cancer.

We demonstrated an orchestrated reprogramming of intestinal epithelial cells as they migrate from the stem and progenitor cell compartment in the crypt and undergo maturation, normally eliminating cell cycling and promoting cell differentiation. We determined where key regulators of proliferation are active during this traverse of cells along the crypt-luminal axis, their oscillation along this axis, and effects of their disruption on mucosal homeostasis and tumor development.

**Diet and Aging Impact on intestinal stem cells and mucosal lineages:**

Colon cancer incidence in humans is strongly linked to long term dietary patterns. We model this in the mouse using a purified rodent diet (NWD1) that adjusts multiple key nutrients to mimic exposure to each at its level present in human populations with much higher incidence of colorectal cancer.

Feeding NWD1 accelerates and increases tumor development in mouse genetic models of intestinal cancer, regardless of etiology, mechanism, or altered genetic drivers, and can also influence site of tumor development in the small and large intestine. However, >70% of human colon tumors are sporadic, developing in the absence of known inherited genetic factors, and arising after 5-6 decades of life, with incidence largely determined by long term dietary patterns. Importantly, wild-type mice rarely, if ever, develop sporadic tumors when fed standard diets, but feeding wild-type mice NWD1 for 1-2 years causes sporadic small and large intestinal tumors with a lag, incidence, frequency and pathology similar to that of *sporadic* colon cancer in the human. This is the only mouse model of common sporadic tumors. Long before tumors develop, the mucosa, though seemingly normal, is altered at the cellular and molecular levels: there is increased immune cell infiltration, elevated serum cytokine levels, altered lineage specific markers, and elevated Wnt signaling and ectopic Paneth cell marker expression throughout the small intestinal and colonic mucosa.

Our recent work has focused on the profound role of nutritional exposures in determining which and how stem cells function in eventually giving rise to tumors, making extensive use of single cell technology and novel bioinformatic data analysis. NWD1 initiates mucosal remodeling by the epigenetic down-regulation of a key gene in the most common stem cells which alters their mitochondrial structure and function. This represses their stem cell functions, recruiting alternate stem cells to maintain the tissue, but this also reprograms mucosal cells to stimulate chronic inflammation, a key driver of tumor development. Strikingly, many of these nutritionally induced changes mimic those that cause human inflammatory bowel disease that also raises risk for tumor development. A major finding is that there is failure of cells to develop properly as they move through what we have termed a developmental restriction point in the tissue, triggering the alternate stem cell recruitment. We also discovered a similar compromise of stem cell function and failure of cell developmental maturation in the intestine of aging mice. In both systems this was dynamic, reversed by either nutritional shifts or drugs that target important pathways of metabolism. The finding that nutritional exposure has such a profound effect in determining which and how stem cells function raises an intriguing question: rapid evolutionary expansion of species and higher taxa to occupy new niches – termed “*adaptive radiation*” - depends on the ability of organisms to adapt to and utilize new food sources. Therefore, the plasticity of intestinal epithelial cells to adapt, including alterations determining how and which stem cells function as stem cells, may have arisen to provide this flexibility to organisms to function in new ecosystems.

**Collaborations:** The gut also harbors billions of bacteria, creating a complex ecosystem interacting with stem and progenitor cells and differentiated lineages of the mucosa. A collaboration with Libusha Kelly (Computational Biology) has pursued her discovery of gut microbe mediated synthesis of sulfide that is released into the gut lumen. The sulfide then can chemically reduce susceptible chemical bonds (e.g. azo bonds) in a wide range of compounds, altering effects of these compounds on the intestinal mucosa and also having systemic effects. The Kelly and Augenlicht labs established that this can be regulated by diet, both by major alterations of the intestinal microbe populations, and by altering level of the amino acid cysteine, a principal substrate for bacterial synthesis of sulfide. These reactions can be important in reprogramming intestinal stem cells and lineages in development of inflammation and tumor risk, in damaging the mucosa, and in potentially modifying drug efficacy. We also have important collaborations with Winfried Edelmann (Cell Biology) on mechanisms of nutritional-genetic interactions that drive tumor development, and with Vern Schramm (Biochemistry) in his pioneering work on development of novel transition state analogues as therapies for disease. This collaboration among Schramm, Augenlicht and Edelmann is investigating the efficacy and mechanism of one such drug for colon cancer, targeting a unique synthetic lethality of genes in methyl group metabolism that expands the range of colon and other tumors that can be effectively treated.

## **Selected Publications:**

Choi, J., Zhang, X., Li, W., Houston, M., Peregrina, K., Dubin, R., Ye, K., Augenlicht, L. (2023). Dynamic Intestinal Stem Cell Plasticity and Lineage Remodeling by a Nutritional Environment Relevant to Human Risk for Tumorigenesis. *Molecular Cancer Research*. In press for August 2023 publication.

Choi, J., Houston, M., Ye, K., Wang, R., Li, W., Zhang, X., Huffman, D.M., Augenlicht, L.H. (2023). Intestinal stem cell aging at single cell resolution: impairment of cell cycle and metabolic pathways and reversal by gerotherapeutics. *Aging Cell* 22, e13802.

Wolfson, S.J., Hitchings, R, Peregrina, K., Cohen, Z, Khan, S., Yilmaz, T. Malena, M. Goluch, E.D., Augenlicht, L., Kelly, L. (2022). Bacterial hydrogen sulfide drives cryptic redox chemistry in gut microbial communities. *Nature Metabolism*, 4, 1260- 1270.

Li, W., Houston, M., Peregrina, K. Ye, K, and Augenlicht, L. (2020). Effects of diet choice on stem cell function necessitate clarity in selection and reporting. *Cell Stem Cell* 27, 11-12.

Li, W., Zimmerman, S.E., Peregrina, K., Houston, M., Mayoral, J., Zhang, J., Maqbool, S., Zhang, Z., Cai, Y., Ye, K., Augenlicht, L.H. (2019). The nutritional environment determines which and how intestinal stem cells contribute to homeostasis and tumorigenesis. *Carcinogenesis*, 937-946.

Tadesse, S., Corner, G., Dhima, E., Houston, M., Guha, C., Augenlicht, L., and Velcich, A. (2017). MUC2 mucin deficiency alters inflammatory and metabolic pathways in the mouse intestinal mucosa. *Oncotarget*, 8, 71456 - 71470

Augenlicht, L.H. (2017). Environmental Impact on Intestinal Stem Cell Functions in Mucosal Homeostasis and Tumorigenesis. *J Cell Biochem.*, 118, 943-952.

Srinivasan, T., Walters, J., Bu, P., Than, E. B., Tung, K. L., Chen, K. Y., Panarelli, N., Milsom, J., Augenlicht, L., Lipkin, S. M., and Shen, X. (2016). NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer-Initiating Cells *Cancer Research*, 76, 3411-3421.

Srinivasan, T., Than, E. B., Bu, P., Tung, K. L., Chen, K. Y., Augenlicht, L., Lipkin, S. M. and Shen, X. (2016). Notch signaling regulates asymmetric division and inter-conversion between Lgr5 and bmi1 expressing intestinal stem cells. *Science Reports*, 6, 26069.

Peregrina, K, Houston, M, Daroqui, C, Dhima, E, Sellers, RS and Augenlicht, L H. (2016). Vitamin D is a determinant of mouse intestinal Lgr5 stem cell function. *Carcinogenesis* 36, 25-31.

Augenlicht, L.H. (2014). Hidden effects of chow diets. *Science* 346, 710.

Bastie, CC., Gaffney-Stomberg, E., Lee, T-W, Dhima, E, Pessin, JE., and Augenlicht, LH. (2012). Dietary cholecalciferol and calcium levels in a Western-style defined rodent diet alter energy metabolism and inflammatory responses in mice. *J. Nutrition*, 142, 859-865.

Wang,D., Peregrina, K. Dhima, E., Lin, E., Mariadason, JM, and Augenlicht, LH. (2011). Dietary induced risk for sporadic intestinal cancer in the mouse targets reprogramming of villus cells. *Proc. Nat. Acad. Sci, USA*. 108, 10272-10277.

Daroqui, MC. and Augenlicht, LH (2010). Transcriptional attenuation in colon carcinoma cells in response to butyrate. *Cancer Prevention Res.*, 3, 1292-1302.

Wang. D., Pezo, RC, Corner,G., Sison, C. Lesser, ML, Shenoy, SM, Mariadason, JM, Singer, RH, and Augenlicht, LH. (2010). Altered dynamics of intestinal cell maturation in *Apc*<sup>1638N/+</sup> mice. *Cancer Research.*, 70, 5348-5357.

Yang,K, Popova,N, Yang,WC, Lozonschi,I. Tadesse,S, Kent,S, Bancroft,L, Matise,I, Cormier,RT, Scherer,S, Edelmann,W, Lipkin,M, Augenlicht,L and Velcich,A (2008). Interaction of *Muc2* and *Apc* on Wnt signaling and in intestinal tumorigenesis: potential role of chronic inflammation. *Cancer Research*, 68, 7313-7322.

Guilmeau, S.,Flandez, M., Bancroft, L., Sellers, R., Tear, B., Stanley, P., and Augenlicht, L. (2008). Intestinal deletion of protein O-fucosyltransferase in the mouse inhibits Notch signaling and causes entero-colitis. *Gastroenterology* 135, 849-860

Yang, K., Newmark, H., Rigas, B., Bancroft, L., Corner, G., Livote, E., Lesser, M., Edelmann, W., Velcich, A., Lipkin, M. and Augenlicht, L.H. (2008). Dietary induction of colonic tumors in a mouse model of sporadic cancer. *Cancer Research* 68, 7803-7810.

**ERIC BOUHASSIRA, Ph.D.**  
**Professor**  
**Cell Biology, and Medicine Hematology**

**ULLMAN BLDG. – ROOM 903**  
**718-430-2188**  
**[eric.bouhassira@einsteinmed.edu](mailto:eric.bouhassira@einsteinmed.edu)**



**Key Words: Pluripotent Stem Cells, Hematopoietic Stem Cells Red Blood Cells, Sickle Cell Disease, Gene Therapy, Genome Modification.**

#### **CULTURED RED BLOOD CELLS:**

We have developed a method to produce genetically engineered human red blood cells by differentiation of human induced-Pluripotent Stem Cells. We have several ongoing projects aiming at producing large amount of genetically homogenous, genetically modified red blood cells that will be used as reagent red blood cells and for transfusion of allo-immunized sickle cell disease patients, and as carrier for replacement therapy of a variety of diseases including TTP and hemophilia A.

#### **GENE THERAPY:**

We are studying the biology of hematopoietic stem cells in the context of sickle cell disease and have developed a CRISPR-based methods to perform knock-in of mini-circles in human hematopoietic stem cells for gene therapy of hemoglobinopathies and other genetic disorders affecting erythroid cells.

**FOR MORE DETAILS:** <https://www.einstein.yu.edu/faculty/4981/eric-bouhassira/>

#### **Selected References:**

Olivier E, Zhang S, Yan Z, Bouhassira EE. **Stem cell factor and erythropoietin-independent production of cultured reticulocytes.** Haematologica. 2024 Apr 11. PMID: 38618684

Boulad F, Maggio A, Wang X, Moi P, Acuto S, Kogel F, Takpradit C, Prockop S, Mansilla-Soto J, Cabriolu A, Odak A, Qu J, Thummar K, Du F, Shen L, Raso S, Barone R, Di Maggio R, Pitrolo L, Giambona A, Mingoia M, Everett JK, Hokama P, Roche AM, Cantu VA, Adhikari H, Reddy S, Bouhassira E, Mohandas N, Bushman FD, Rivière I, Sadelain M. **Lentiviral globin gene therapy with reduced-intensity conditioning in adults with  $\beta$ -thalassemia: a phase 1 trial.** Nat Med. 2022 Jan;28(1):63-70.

Olivier EN, Zhang S, Yan S, Suzuka S, Roberts K, Wang K, Bouhassira EE. **PSC-RED and MNC-RED: Albumin-free and low-transferrin robust erythroid differentiation protocols to produce human enucleated red blood cells** Exp Hematol. 2019 Jul; 75:31-52. e15

Wang K, Guzman AK, Yan Z, Zhang S, Hu MY, Hamaneh MB, Yu YK, Tolu S, Zhang J, Kanavy HE, Ye K, Bartholdy B, Bouhassira EE. **Ultra-High-Frequency Reprogramming of Individual Long-Term Hematopoietic Stem Cells Yields Low Somatic Variant Induced Pluripotent Stem Cells.** Cell Rep. 2019 Mar 5;26(10):2580-2592.e7.

Bartholdy B, Lajugie J, Yan Z, Zhang S, Mukhopadhyay R, Grealley JM, Suzuki M, Bouhassira EE. **Mechanisms of establishment and functional significance of DNA demethylation during erythroid differentiation.** Blood Adv. 2018 Aug 14;2(15):1833-1852

**Robert Coleman, Ph.D.**  
**Associate Professor**

**Forchheimer 628**  
**718-430-8623**  
**robert.coleman2@einsteinmed.edu**



## **Single Molecule Imaging of Transcription Factors Involved in Cancer, Hematopoiesis and Ageing**

Human tumorigenesis is a complicated process marked by a loss of the cell's ability to regulate critical cellular processes, such as transcription, RNA processing and translation, leading to uncontrollable cell growth. As our understanding of tumorigenesis becomes more sophisticated, a combinatorial approach is necessary to better understand the dynamic coordinated action of very large multi-subunit enzymes and protein complexes controlling these key cellular processes. Recent advances in single-molecule imaging provide an unprecedented spatiotemporal window into probing dynamic functional interactions between these heterogeneous large multi-subunit transcription assemblies and chromatin in real-time. In addition, high-resolution cryo-electron microscopy and genome-wide binding assays allow us to rapidly survey detailed functional interactions on physiologically relevant substrates with limited amounts of samples. Armed with these advanced *in vitro* and *in vivo* approaches, our lab seeks to gain a mechanistic understanding of how transcription complexes dynamically regulate expression of tumor suppression, hematopoietic, and metabolic pathways and how these processes are altered in disease.

Specifically, we apply these tools to mechanistically dissect how transcription factors, including p53, communicate with multiple transcription assemblies, such as chromatin remodeling factors (PBAF), core promoter recognition factors (TFIID), PARP1 and RNA Polymerase II, to circumnavigate the repressive effects of chromatin on transcription. We are also applying these same strategies to study how oncogenic mutants of p53 and chromatin-remodeling complexes mechanistically function to promote tumor formation. Our long-term goal is to determine the molecular origin of cancer and additional diseases related to hematopoiesic dysfunction, eye development and ageing using our multi-disciplinary approach centered around advanced single molecule imaging, genome-wide studies, and structural biology.

### **Development of single molecule imaging systems to study how transcription factors alter chromatin structure and regulate transcriptional bursting**

To understand how proteins engage chromatin at high temporal and spatial resolution, our group has established numerous *in vitro* and *in vivo* systems utilizing high-resolution co-localization, single molecule FRET, and dynamic live cell imaging. Strikingly, our live cell imaging studies find that transcription factors, chromatin remodelers and metabolic enzymes, including p53, RNA Polymerase II, PBAF and NMNAT1, dynamically cycle on and off the genome in spatial hubs of activity on the timescale of seconds to minutes. The chromatin structure of underlying target sequences and enzymatic activities associated with the transcription factors/chromatin remodelers dictate their dynamic cycling and binding kinetics. Oncogenic mutations in transcription factors can also affect the binding kinetics of associated proteins that are being co-loaded onto the genome. In addition, we find that single molecule kinetic binding profiles of transcription factors are associated with different cellular states during development. Furthermore, we have developed imaging systems to directly assess the enzymatic activity of chromatin remodelers, metabolic enzymes, and Polymerases when bound to the genome.

In collaboration with Uli Steidl's and Rob Singer's labs at Einstein, we have also developed a live-cell multicolor single molecule imaging system to examine how our transcription factors dynamically regulate transcriptional bursting of genes. Using these imaging systems, we find that patterns of transcription factor binding and transcriptional bursting display memory effects to fine-tune expression of genes. Future work will develop mouse models and live-cell image based drug screening platforms that rapidly determine combinatorial effects of epigenetic inhibitors in different cell types and diseased cells.

## **Selected Publications:**

1. Kenworthy CA, Haque N, Liou S-H, Chandris P, Wong V, Dziuba P, Lavis LD, Liu WL, Singer RH, and **Coleman RA**. Bromodomains regulate dynamic targeting of the PBAF chromatin remodeling complex to chromatin hubs. *Biophys J*. 2022 Mar 30;S0006-3495(22)00237-5. doi: 10.1016/j.bpj.2022.03.027. PMID: [35364106](https://pubmed.ncbi.nlm.nih.gov/35364106/).
2. Senecal A, \*Singer RH and \***Coleman RA**. Transcriptional burst kinetics are linked to short term transcriptional memory. \*corresponding authors. **bioRxiv**. 2021 Nov. 2. doi: <https://doi.org/10.1101/2021.10.31.466715> .
3. Desai RV, Chen X, Martin B, Chaturvedi S, Hwang DW, Li W, Yu C, Ding S, Thomson M, Singer RH, **Coleman RA**, Hansen M, and Weinberger LS. Discovery of a Cellular Mechanism Regulating Transcriptional Noise. *Science*. 2021 July 22:eabc6505. doi: 10.1126/science.abc6506. Online ahead of print. PMID: [34301855](https://pubmed.ncbi.nlm.nih.gov/34301855/).
4. Liou S-H, Singh SK, Singer RH, \***Coleman RA**, and \*Liu WL. Structure of the p53/RNA Polymerase II Assembly. *Commun Biol*. 2021 Mar 25;4(1):397. doi: 10.1038/s42003-021-01934-4.PMID: [33767390](https://pubmed.ncbi.nlm.nih.gov/33767390/) \*corresponding authors.
5. Drosopoulos W, Vierra DA, Kenworthy CA, \***Coleman RA**, and \*Schildkraut CL. Dynamic assembly and disassembly of the human DNA Polymerase  $\delta$  on the genome *in vivo*. *Cell Rep*. 2020 Feb 4;30(5):1329-1341.e5. doi: 10.1016/j.celrep.2019.12.101. Pubmed PMID: [32023453](https://pubmed.ncbi.nlm.nih.gov/32023453/). \*corresponding authors
6. Carvajal LA, Ben Neriah D, Senecal A, Benard L, Thiruthuvanathan V, [Yatsenko T](https://pubmed.ncbi.nlm.nih.gov/32023453/), Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, **Coleman RA**, Verma A, and Steidl U. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. *Science Translational Medicine* 11 Apr 2018 Vol. 10, Issue 436, eaa03003. DOI: 10.1126/scitranslmed.aao3003. Pubmed PMID: [29643228](https://pubmed.ncbi.nlm.nih.gov/29643228/).
7. \***Coleman RA**, Zhen Q, Singh SK, Peng CS, Cianfrocco M, Zhang Z, Song L, Piasecka A, Aldeborgh H, Basishvili G, Rice W, and \*Liu WL. p53 dynamically directs TFIIID assembly on target DNA. *Mol Cell Biol.*, 2017 Jun 15;37(13). pii:e00085-17. Doi: 10.1128/MCB.00085-17. PubMed PMID: [28416636](https://pubmed.ncbi.nlm.nih.gov/28416636/). \*corresponding authors
8. Singh SK, Qiao Z, Song L, Jani V, Rice W, Eng E, **Coleman RA**, and Liu WL. Structural visualization of the p53/RNA Polymerase II assembly. *Genes Dev*. 2016 Nov 15;30(22) 2527-2537. PubMed PMID: [27920087](https://pubmed.ncbi.nlm.nih.gov/27920087/).

**John S. Condeelis, Ph.D.**  
**Professor**

**Lab: Forchheimer, Rm. 602**  
**Phone: 718-430-8996**

**E-mail: [john.condeelis@einsteinmed.edu](mailto:john.condeelis@einsteinmed.edu)**  
**<https://www.einsteinmed.org/faculty/6712/john-condeelis/>**



## **Tumor MicroEnvironment of Metastasis**

### **Areas of Research:**

Cell biology and biophysics, cancer biology, and the integration and validation of clinical imaging platforms with high resolution intravital multiphoton microscopy. Development of multiphoton imaging technology to identify tumor cell dissemination mechanisms in both primary and secondary tumor sites during metastatic progression. Development of new optical microscope technology in the Gruss Lipper Biophotonics Center.

### **Professional Interests:**

John Condeelis' research interests are in optical physics, cell biology and biophysics, cancer biology and mouse models of cancer. He and his collaborators developed the multiphoton imaging technology and animal models used to identify invasion and intravasation micro-environments in mammary tumors. Integration of intravital multiphoton imaging with computational /systems analysis of living breast tumors identified the dominant tumor cell phenotypes contributing to invasion and dissemination during metastasis. This led to the discovery and verification of the paracrine interaction between tumor cells and macrophages in vivo, the role of macrophages in the migration of tumor cells during HGF-dependent tumor cell streaming to blood vessels and the mechanism of tumor cell dissemination from primary tumors via TMEM (Tumor MicroEnvironment of Metastasis) doorways to distant metastatic sites. Based on these results, cell collection techniques, including the in vivo invasion assay were developed for the collection of migrating and disseminating macrophages and tumor cells. This led to the discovery of the mouse and human invasion signatures, and the TMEM doorway, MenaCalc and MenaINV markers for assessing risk of metastasis and prediction of response in breast cancer patients to both chemotherapy, and receptor tyrosine kinase and tyrosine kinase inhibitors used to suppress metastasis.

John Condeelis has devised optical microscopes for uncaging, biosensor detection and multiphoton imaging for these studies and has used novel caged- enzymes and biosensors to test, in vivo, the predictions of the invasion signatures regarding the mechanisms of tumor cell dissemination and metastasis. He is one of the founding co-directors of the Integrated Imaging Program (IIP) dedicated to the integration and validation of clinical imaging platforms, including digital pathology, with high resolution optical imaging in the Gruss Lipper Biophotonics Center. He is now the co-Director of the Integrated Imaging Program (IIPCR). The IIPCR is dedicated to curing metastatic cancer. He has authored more than 360 scientific papers on various aspects of his research.

**For a complete list of publications please visit <https://www.einsteinmed.edu/labs/john-condeelis/publications/>**

## Publications 2023 - 2024

Gina Kim, Burcu Karadal-Ferrena, Jiyue Qin, Ved P. Sharma, Isabelle S. Oktay, Yu Lin, Xianjun Ye, Saeed Asiry, Jessica M. Pastoriza, Esther Cheng, Nurfiza Ladak, John Condeelis, Esther Adler, Paula Ginter, Timothy D'Alfonso, David Entenberg, Xiaonan Xue, Joseph A. Sparano, and Maja H. Oktay (2023) Racial Disparity in Pro-metastatic Tumor Microenvironment and Distant Recurrence-Free Survival in Residual Breast Cancer after Neoadjuvant Chemotherapy. Nature PJ Breast Cancer 2023; 9: 52. Published online 2023 Jun 13. doi: 10.1038/s41523-023-00547-w. PMCID: PMC10264351 PMID: 37311792

Friedman-DeLuca M, Patel PP, Karadal-Ferrena B, Barth ND, Duran CL, Ye X, Papanicolaou M, Condeelis JS, Oktay MH, Borriello L, Entenberg D. Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion. J Vis Exp. (2023). doi: 10.3791/65732 PMID: 37486129

Stefan Linder, S., Cervero, P., Eddy, R., Condeelis, J. Mechanisms and roles of podosomes and invadopodia (2023) Nature Reviews | Molecular Cell Biology (Cover Article) <https://doi.org/10.1038/s41580-022-00530-6>

Duran CL, Karagiannis GS, Chen X, Sharma VP, Entenberg D, Condeelis JS, Oktay MH. Cooperative NF- $\kappa$ B and Notch1 signaling promotes macrophage-mediated Men1<sup>Δ</sup> expression in breast cancer. Breast Cancer Res. 2023 Apr 6;25(1):37. doi: 10.1186/s13058-023-01628-1. PMID: 37024946. PMCID: PMC10080980

Genna, A.; Duran, C.L.; Entenberg, D.; Condeelis, J.; Cox, D. Macrophages Promote Tumor Cell Extravasation across an Endothelial Barrier through Thin Membranous Connections. Cancers 2023, 15, 2092. <https://doi.org/10.3390/cancers15072092>.

Petersen J, Du W, Adkisson C, Gravekamp C, Oktay MH, Condeelis J, Panarelli NC, McAuliffe JC, Entenberg D. Stabilized Window for Intravital Imaging of the Murine Pancreas. J Vis Exp. 2023(200). Epub 20231006. doi: 10.3791/65498. PubMed PMID: 37870314.

Barth, Oktay, Condeelis, Brunton and Entenberg (2024) Ex vivo models to study the interaction of immune cells and cancer cells under therapy. Nature Protocols <https://doi.org/10.21203/rs.3.pex-2544/v1>.

Bianchi AC, Anastasiadou DP, Cui MH, Condeelis JS, Branch CA, Karagiannis GS. Assessment of Metastatic Dissemination in Mouse Breast Carcinoma Models Using Magnetic Resonance Imaging (MRI). Methods Mol Biol. 2024; Invited Submission for Special Issue "Imaging of Metastasis". Doi pending.

**WINFRIED EDELMANN, Ph.D.**  
Professor

Price BLDG. – ROOM 269/277  
718 678-1086  
winfried.edelmann@einsteinmed.edu



## Genomic Instability and Cancer in Murine Models

The maintenance of genomic integrity in all organisms requires multiple DNA repair pathways that are involved in the processes of DNA replication, repair and recombination. Perturbations in these pathways can lead to increased mutation rates or chromosomal rearrangements that ultimately result in cancer. DNA mismatch repair (MMR) is one of the repair systems that mammalian cells employ to maintain the integrity of its genetic information by correcting mutations that occur during erroneous replication. Mutations in MMR genes are linked to one of the most prevalent human cancer syndromes, Lynch syndrome and a significant number of sporadic colorectal cancers. At the molecular level tumors that develop in these patients display increased genomic mutation rates as indicated by increased mutations at microsatellite repeat sequences (termed microsatellite instability, MSI). MMR in eukaryotes is complex and involves several homologs of the bacterial MutS and MutL proteins. In mammals, the initiation of the repair process requires two complexes formed by three different MutS homologs (MSH): A complex between MSH2-MSH6 for the recognition of single base mismatches and a complex between MSH2-MSH3 for the recognition of insertion/deletions. The repair reaction also requires a complex between the two MutL homologs MLH1 and PMS2 that interacts with the MSH complexes to activate subsequent repair events which include the excision of the mismatch carrying DNA strand and its re-synthesis. In addition to correcting DNA mismatches, the MMR system mediates an apoptotic response to DNA damage and both of these functions are thought to be important for genome maintenance and tumor suppression. We have generated gene targeted mouse lines with inactivating mutations in all the different MutS and MutL homologs, and also in genes that function in the later MMR steps to study their roles in genome maintenance and tumor suppression. In addition, we have generated knock-in mouse lines with missense mutations and conditional knockout mouse lines that inactivate specific MMR functions and/or model mutations found in humans. Our studies indicate that specific MMR functions play distinct roles in maintaining genome stability and that defects in these functions have important consequences for tumorigenesis. These studies have also revealed that MMR proteins play essential roles in class switch recombination and somatic hypermutation during antibody maturation and the control of meiotic recombination in mammals. We are currently studying the functions of MMR in intestinal stem cells (ISCs) and cancer stem cells (CSCs) in preclinical mouse models and how loss of MMR in stem cells affects tumorigenesis and the response of tumors to novel anticancer treatments including immune therapeutic approaches.

### Selected References:

Milano CR, Holloway JK, Zhang Y, Jin B, Smith C, Bergmann A, Edelmann W\* and Cohen PE. 2019. Mutation of the ATPase Domain of MutS Homolog-5 (MSH5) Reveals a Requirement for a Functional MutSy Complex for All Crossovers in Mammalian Meiosis. *G3* (Bethesda). **g3**.400074.2019. doi: 10.1534/g3.119.400074. PMID: 30944090 (\*corresponding author).

Loss of MMR and TGFBR2 increases the susceptibility to microbiota-dependent inflammation-associated colon cancer. Tosti E, Almeida AS, Tran TT, Barbachan e Silva M, Ó Broin P, Dubin R, Beck AP, Mclellan AS, Golden A, O'Toole PW and Edelmann W. 2022. *Cell Mol Gastroenterol Hepatol*. 2022 Jun 7:S2352-345X(22)00095-9. doi: 10.1016/j.jcmgh.2022.05.010. Online ahead of print. PMID: 35688320.

Role of EXO1 nuclease activity in genome maintenance, the immune response and tumor suppression in *Exo1<sup>D173A</sup>* mice. Wang S, Lee K, Gray S, Zhang Y, Tang C, Morrish RB, Pesenti E, Tosti E, van Oers J, Cohen PE, MacCarthy T, Roa S, Scharff M, Edelmann W\* and Chahwan R. *Nucleic Acid Research* 2022 Jul 18:gkac616. doi: 10.1093/nar/gkac616. Online ahead of print. PMID: 35849338. (\*corresponding author).

Vaccination and microbiota manipulation approaches for colon cancer prevention in rodent models. Tosti E, Srivastava N and Edelmann. *Cancer Prev Res (Phila)* 2023 April. CAPR-23-0015 PMID: 37012205.

**DMITRY FYODOROV, Ph.D.**  
**Professor**

**CHANIN BLDG. – ROOM 414**  
**718 430-4022**  
**dmitry.fyodorov@einsteinmed.edu**



## **BIOCHEMISTRY AND GENETICS OF CHROMATIN TRANSITIONS IN *DROSOPHILA***

Hundreds of millions of base pairs of nuclear DNA are packed into chromosomes. Chromatin, the nucleoprotein filament of a chromosome, has many organization levels. It is the natural state of DNA in the nucleus and the native substrate for DNA-directed reactions, such as DNA replication, recombination, repair and transcription. The assembly of chromatin and dynamic conversion between its different forms are critical steps in the maintenance and regulation of the eukaryotic genome. The goal of our research is to understand how chromosomes are assembled and how this process regulates the structure and activity of eukaryotic chromosomes. The crucial first step in this direction is a systematic study of factors that mediate this process. To this end, we use biochemical approaches to analyze their contributions to chromatin assembly. We also dissect their function *in vivo* by methods of *Drosophila* genetics. More globally, we are trying to elucidate the roles nuclear enzymes in the hierarchical organization of the chromosome.

### **1. Nucleosome assembly mechanisms and biological functions of chromatin assembly factors**

*In vivo*, canonical nucleosomes are assembled by two families of proteins, core histone chaperones, such as NAP-1, and ATP-dependent motor factors, such as ACF (ATP-utilizing Chromatin assembly Factor). ACF consists of a SNF2-like ATPase ISWI and a polypeptide termed Acf1. We study ATP-dependent chromatin assembly *in vitro* to elucidate molecular events that take place during the formation of nucleosomes.

In addition to ACF, two other ISWI-containing complexes, ToRC (comprising Tou, ISWI and CtBP) and RSF (Rsf1 and ISWI), mediate similar reactions and can functionally substitute ACF *in vivo*. Our genetic and cytological analyses implicate the network of ATP-dependent, ISWI-containing chromatin assembly factors in diverse, partially redundant pathways of regulation of chromatin structure and activity. SNF2-like protein CHD1 is another ATP-dependent nucleosome assembly factor. It is required for replication-independent deposition of histones into chromatin *in vivo*. Specifically, CHD1 is essential during early embryonic development for deposition of replacement histone H3.3 into paternal chromatin.

### **2. Mass spectrometry tools for the analyses of chromatin structure and stable protein complexes**

The factors of nuclear DNA metabolism rarely act as individual polypeptides but, rather, within stable multi-subunit complexes. The existing methods to characterize native complexes suffer from several drawbacks. Tag-affinity purification of ectopically expressed subunits is prone to an unacceptably high rate of false-positive IDs. On the other hand, conventional chromatography to achieve apparent homogeneity is time-consuming and can only be applied to abundant proteins. We have devised, implemented and validated a highly innovative, streamlined method termed MS-Enabled Rapid protein Complex Identification (MERCi) to rapidly identify stable native complexes. It relies on partial enrichment of a target protein in sequential FPLC steps, quantitative shotgun proteomics of chromatographic fractions and correlation analyses. MERCi allows rapid identification of scarce complexes without a loss of the precision emblematic of the classical FPLC approach. It makes characterization of native complexes a routine laboratory technique and allows characterization of trace amounts of protein complexes with a virtually assured result.

### **3. Higher-order chromatin forms**

To reconstitute higher-order chromatin structures, we supplement the *in vitro* assembly system with modified core histones, histone variants, linker histone (H1) and heterochromatin proteins, such as *Drosophila* HP1a. Chromatin vectors can turn into useful tools in research and therapy. These studies will also eventually lead to the discovery of techniques to reconstitute functional metazoan chromosomes.

We examined phenotypes associated with the depletion of H1 by RNAi in flies. We discovered that H1 is the major component of heterochromatin and is required to establish its biochemical identity and functional properties. For instance, H1 recruits HMT Su(var)3-9, which mediates methylation of lysine 9 of histone H3 (H3K9), a signature heterochromatin-specific epigenetic mark. We have also demonstrated that H1 is essential for the faithful regulation of DNA endoreplication in *Drosophila* larval cells. H1 negatively regulates DNA replication in conjunction with a SNF2 ATPase SUUR that forms a native complex (SUMM4) with an insulator protein Mod(Mdg4).

A prevalent view of heterochromatic silencing is that its physical compaction results in steric exclusion of

regulatory proteins, such as RNA polymerases. In collaboration with G. Karpen (LBNL), we have recently shown that the formation of heterochromatin domains is also mediated by liquid-liquid phase separation that gives rise to a non-membrane-bound nuclear compartment. We demonstrated that HP1a and H1 undergo demixing *in vitro* and nucleate into foci that display liquid properties during heterochromatin domain formation in early *Drosophila* embryos. We propose that biophysical properties associated with phase-separated systems are critical to understanding the behavior of heterochromatin and, potentially, other chromatin forms that regulate essential nuclear functions.

#### 4. Sperm chromatin assembly and remodeling

In sperm, DNA is compacted with cysteine-rich protamines and protamine-like sperm nuclear basic proteins (SNBPs) to form enzymatically static sperm “chromatin”. We have begun to analyze protein factors that mediate SNBP deposition during spermatogenesis and their removal from DNA after fertilization. It turns out that sperm chromatin assembly and remodeling is mediated by a group of factors that are similar to core histone chaperones.

Upon deposition on sperm DNA, protamines/SNBPs are extensively crosslinked via interchain disulfide bonds. After fertilization, the egg has to reverse the crosslinks for efficient eviction of SNBPs. This nuclear reaction is mediated by specific thioredoxin (TRX) and thioredoxin reductase (TRXR) molecules. Thus, we are investigating biological roles of the evolutionary conserved thioredoxin system in sperm chromatin metabolism and female fertility. A number of chemical compounds are known to specifically inhibit the function of TRX and TRXR proteins. We are studying their ability to suppress fertilization in the egg *in vivo* and testing their utility as novel, non-hormone agents for female contraception.

#### Selected publications

- Andreyeva, E.N., Emelyanov, A.V., Nevil, M., Sun, L., Vershilova, E., Hill, C.A., Keogh, M.C., Duronio, R.J., Skoultchi, A.I., and **Fyodorov, D.V.** (2022). SUMM4 complex couples insulator function and DNA replication control. *eLife* **11**, e81828.
- Schoberleitner, I., Bauer, I., Huang A, Andreyeva, E.N., Sebald, J., Pascher, K., Rieder, D., Brunner, M., Podhraski, V., Ömer, G., Cázarez Garcia, D., Rieder, L., Keller, M.A., Winkler, R., **Fyodorov, D.V.** †, and Lusser, A.† (2021). CHD1 controls H3.3 incorporation in adult brain chromatin to maintain metabolic homeostasis and normal lifespan. *Cell Reports* **37**, 109769.
- Strom, A.R., Emelyanov, A.V., Mir, M., **Fyodorov, D.V.**, Darzacq, X., and Karpen, G.H. (2017). Phase separation drives heterochromatin domain formation. *Nature* **547**, 241-245.
- Andreyeva, E.N., Bernardo, T.J., Kolesnikova, T.D., Lu, X., Yarinich, L.A., Bartholdy, B.A., Guo, X., Posukh, O.V., Heaton, S., Willcockson, M.A., Pindyurin, A.V., Zhimulev, I.F., Skoultchi, A.I., and **Fyodorov, D.V.** (2017). Regulatory functions and chromatin loading dynamics of linker histone H1 during endoreplication in *Drosophila*. *Genes Dev.* **31**, 603-616.
- Emelyanov, A.V., and **Fyodorov, D.V.** (2016). Thioredoxin-dependent disulfide bond reduction is required for protamine eviction from sperm chromatin. *Genes Dev.* **30**, 2151-2156.
- Emelyanov, A.V., Rabbani, J., Mehta, M., Vershilova, E., Keogh, M.C., and **Fyodorov, D.V.** (2014). *Drosophila* TAP/p32 is a core histone chaperone that cooperates with NAP-1, NLP, and nucleophosmin in sperm chromatin remodeling during fertilization. *Genes Dev.* **28**, 2027-2040.
- Lu, X., Wontakal, S.N., Kavi, H., Kim, B.J., Guzzardo, P.M., Emelyanov, A.V., Xu, N., Hannon, G.J., Zavadil, J., **Fyodorov, D.V.**†, and Skoultchi, A.I.† (2013). *Drosophila* H1 regulates the genetic activity of heterochromatin by recruitment of Su(var)3-9. *Science* **340**, 78-81.
- Emelyanov, A.V., Vershilova, E., Ignatyeva, M.A., Pokrovsky, D.K., Lu, X., Konev, A.Y., and **Fyodorov, D.V.** (2012). Identification and characterization of ToRC, a novel ISWI-containing ATP-dependent chromatin assembly complex. *Genes Dev.* **26**, 603-614.
- Konev, A.Y., Tribus, M., Park, S.Y., Podhraski, V., Lim, C.Y., Emelyanov, A.V., Vershilova, E., Pirrotta, V., Kadonaga, J.T., Lusser, A., and **Fyodorov, D.V.** (2007). CHD1 motor protein is required for deposition of histone H3.3 into chromatin in vivo. *Science* **317**, 1087-1090.

**MATTHEW GAMBLE, Ph.D.**  
**Associate Professor**

**Golding BLDG. – ROOM 203**  
**718 430-2942**  
**matthew.gamble@einsteinmed.edu**



### **MacroH2As, histone variants with diverse roles in gene expression and DNA damage responses**

– The macroH2A-type histone variants (which include macroH2A1.1, macroH2A1.2 and macroH2A2) have roles in tumor suppression, cellular senescence, activation and repression of transcription, promotion of DNA repair and suppression of the reprogramming of differentiated cells into stem cells. MacroH2As are typified by a histone H2A-like region fused by a flexible linker to a C-terminal macrodomain, a ligand-binding domains whose functions is modulated by binding to poly(ADP-ribose) produced by a family of poly(ADP-ribose) polymerases. MacroH2A1 regulates the expression of genes found within its large chromatin domains which can span hundreds of kilobases. Through changes in its expression and/or alterations in its genomic localization, disruption of macroH2A1's tumor suppressive functions are common in cancer; alterations of macroH2A transcription and splicing occur in a variety of cancers including those of lung, breast, colon, ovaries, endometrium, bladder, testicles, and melanocytes. Consistently, macroH2A1 loss in primary cells is sufficient to trigger an oncogenic gene expression profile. We are interested in many aspects of macroH2A biology. 1) How are macroH2As targeted to specific regions of the genome? 2) How does macroH2A1.1 in collaboration with PARPs regulate gene expression? 3) How does macroH2A1 regulate chromatin accessibility at enhancers? 4) How does macroH2A participate in DNA repair? 5) What regulates macroH2A1's alternative splicing?

**Chromatin dynamics during oncogene-induced senescence and cancer** – Oncogene-induced senescence (OIS) is an important tumor suppressive mechanism whereby a cell harboring an oncogenic mutation enters a stable proliferative arrest. At the same time the senescent cell secretes a host of inflammatory cytokines, chemokines and metalloprotease called the senescence-associated secretory phenotype (SASP), which serves to recruit immune cells to clear the senescent cells from tissues. The histone variant macroH2A1 plays a critical role in the transcriptional regulation of SASP genes during senescence. We are currently studying the mechanism by which macroH2A regulates the SASP response. We hypothesize that changes in macroH2A1 expression, seen in many cancers, allows these cells to bypass senescence and proceed on the pathway towards transformation.

**Interplay between transcriptional elongation rates and alternative splicing** – Alternative splicing is a crucial aspect of gene expression, allowing a gene to yield functionally distinct products, the abundance of which are regulated by cellular cues. Splicing dysregulation is central to several cancers and developmental diseases. Alternative splicing can be regulated through the recruitment of splicing factors which promote or repress distinct splicing events. Splicing largely occurs co-transcriptionally, and so, splicing outcomes are also affected by aspects of the transcription process and chromatin environment. The local elongation rate of RNA polymerase II is one aspect of transcription with important consequences on splicing outcomes. A barrier to progress in the field has been the lack of a high-throughput assay to measure splicing rates in mammalian cells. To address this, we have developed SKaTER-seq (Splicing Kinetics and Transcript Elongation Rates through sequencing). With this assay, we are exploring a myriad of factors that regulate splicing, including elongation rate, gene architecture, binding sites for RNA binding factors, chromatin structure and histone modifications. With this powerful approach we will determine the underlying causes of splicing alterations in disease.

### **Selected References:**

Ruiz, P.D., Hamilton, G.A., Park, J.W., **Gamble, M.J.** (2019) MacroH2A1 regulation of Poly(ADP-ribose) synthesis and stability prevents necrosis and promotes DNA repair. *Mol Cell Biol.* 40:e00230-19.

Kim, J., Sun, C., Tran, A.D., Chin, P.J., Ruiz, P.D., Wang, K., Gibbons, R.J., **Gamble, M.J.**, Liu, Y., Oberdoerffer, P. (2019) The macroH2A1.2 histone variant links ATRX loss to alternative telomere lengthening. *Nat Struct Mol Biol.* 26:213-219.

Ruiz, P.D., **Gamble, M.J.** (2018) MacroH2A1 chromatin specification requires its docking domain and acetylation of H2B lysine 20. *Nat. Commun.* 9:5143.

Hodge, D.Q., Cui, J., **Gamble, M.J.** Guo, W. (2018) Histone variant macroH2A1 plays an isoform-specific role in suppressing epithelial-mesenchymal transition. *Sci. Rep.* 8:841.

Chen, H., Ruiz, P.D., McKimpson, W.M., Novikov, L., Kitsis, R.N. and **Gamble, M.J.** (2015) MacroH2A1 and ATM play opposing roles in paracrine senescence and the senescence-associated secretory phenotype. *Molecular Cell* 59:719-31.

Chen, H., Ruiz, P.D., Novikov, L., Casill, A.D., Park, J.W. and **Gamble, M.J.** (2014) MacroH2A1.1 and PARP-1 cooperate to regulate transcription by promoting CBP-mediated H2B acetylation. *Nat. Struct. Mol. Biol.* 21:981.

Hussey, K.M., Chen, H., Yang, C., Park, E., Hah, N., Erdjument-Bromage, H., Tempst, P., **Gamble, M.J.\***, Kraus, W.L.\* (2014) "The histone variant macroH2A1 regulates target gene expression in part by recruiting the transcriptional coregulator PELP1." *Mol Cell Biol.* 34:2437-49. (\*co-corresponding authors)

**Gamble M.J.**, (2013) Expanding the functional repertoire of macrodomains. *Nat. Struct. Mol. Biol.* 20:407-8.

Zhang, T., Berrocal, J.G., Yao, J., DuMond, M.E., Krishnakumar, R., Ruhl, D.D., **Gamble, M.J.**, and Kraus, W.L. (2012) "Regulation of poly(ADP-ribose) polymerase-1-dependent gene expression through promoter-directed recruitment of a nuclear NAD<sup>+</sup> synthase." *J. Biol. Chem.* 287:12405-16

Novikov L., Park J.W., Chen H., Klerman H., Jalloh A.S., and **Gamble M.J.** (2011) QKI-mediated alternative splicing of the histone variant macroH2A1 regulates cancer cell proliferation. *Mol. Cell Biol.* 31:4244-55.

Zhang X.\*, **Gamble M.J.\***, Stadler S., Cherrington B.D., Causey C.P., Thompson P.R., Roberson M.S., Kraus, W.L., Coonrod S.A. (2011) Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells. *PLoS Genet* 7(6): e1002112. (\* equal contribution).

**Gamble, M.J.**, Frizzell, K.M., Yang C., Krishnakumar, R. and Kraus, W.L. (2010) The histone variant macroH2A1 marks repressed autosomal chromatin, but protects target genes from silencing. *Genes Dev* 24:21-31.

Frizzell, K.M., **Gamble, M.J.**, Zhang, T., Berrocal, J.G., Zhang, T., Krishnakumar, R., Cen, Y., Sauve, A.A., and Kraus, W.L. (2009) "Global Analysis of Transcriptional Regulation by Poly(ADP-ribose) Polymerase-1 and Poly(ADP-ribose) Glycohydrolase in MCF-7 Human Breast Cancer Cells." *J. Biol. Chem.* 284:33926-28. (61 citations)

Zhang, T., Berrocal, J.G., Frizzell, K.M., **Gamble, M.J.**, Dumond, M.E., Krishnakumar, R., Yang, T., Sauve, A.A., Kraus, W.L. (2009) "Enzymes in the NAD<sup>+</sup> Salvage Pathway Regulate SIRT1 Activity at Target Gene Promoters." *J. Biol Chem.* 284:20408-17.

Krishnakumar, R.\*, **Gamble, M.J.\***, Frizzell, K.M., Berrocal, J.G., Kininis, M. and Kraus, W.L. (2008) Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. *Science* 319:819-21. (\* equal contribution).

***Kira Gritsman, M.D., Ph.D.***  
***Associate Professor***

***Chanin BLDG-room 410***  
***kira.gritsman@einsteinmed.edu***



## **Kinase signaling pathways in adult blood development and blood cancers**

My lab studies the signal transduction pathways that affect the early fate decisions of adult hematopoietic stem cells (HSCs) as they progress from an undifferentiated multipotent state to the generation of differentiated blood cells. When these early fate decisions go awry, this can lead to the formation of leukemic stem cells, which can initiate leukemia and contribute to relapse after treatment. We use a combination of genetically modified mice, cell lines, and patient samples to explore the mechanisms by which signaling pathways maintain both normal and leukemic hematopoiesis.

## **Roles of the PI3 kinase isoforms in adult blood development**

PI3 kinase (PI3K) is a lipid kinase that is important for the regulation of metabolism, the cell cycle, apoptosis, protein synthesis, and autophagy. In hematopoietic cells, there are four isoforms of the catalytic subunit of PI3K, each encoded by a separate gene. Emerging evidence suggests that these isoforms have unique functions in normal and cancer cells, but may substitute for each other in some contexts. We have generated a series of mouse knockout models that allow us to study the roles of each of these isoforms individually in adult hematopoiesis. For example, we have found that the p110alpha isoform is most important for red cell development, but is not required in normal blood stem cells. We have now also generated compound knockout mice to determine the redundant roles of the PI3K isoforms in blood development. We have found that deletion of multiple PI3K isoforms impacts normal HSC function, including self-renewal, proliferation after infection or chemotherapy treatment, and differentiation along different blood lineages. Strikingly, we found that deletion of all 3 PI3K isoforms that are needed to transduce cytokine and growth factor signals results in a phenotype resembling human myelodysplastic syndrome (MDS). We are now using this PI3K triple knockout mouse model to study the mechanisms of MDS initiation and progression to acute myeloid leukemia (AML).

## **Roles of kinase of signaling pathways in blood malignancies**

AML is a genetically diverse disease, but activation of the PI3K pathway has been reported in up to 80% of cases. We are using several different mouse models of AML to examine the roles of individual PI3K isoforms in leukemic stem cells (LSCs), which is the cell population in AML patients that has self-renewal activity, and has been implicated in relapse. In particular, we are exploring how PI3K cooperates with epigenetic regulators in LSCs, and how PI3K in LSCs can promote evasion of the immune system. We are also studying the roles of PI3K and other signaling molecules in the normal and leukemic bone marrow microenvironment, including the immune microenvironment.

In addition, we recently discovered that RON kinase can be a new potential therapeutic target in a different blood cancer called myeloproliferative neoplasms (MPN). Future work will focus on understanding the mechanisms of RON signaling and regulation in MPN cells, and on strategies for therapeutic targeting of RON in this disease.

## Selected Publications

Kharas, M.G., Okabe, R., Ganis, J.J., Gozo, M., Khandan, T., Paktinat, M., Gilliland, D.G., and **Gritsman, K.** Constitutively Active AKT Depletes Hematopoietic Stem Cells and Induces Leukemia in Mice. *Blood* 2010; 115(7): 1406-15

**Gritsman, K.**, Yuzugullu, H., Von, T., Yan, H., Clayton, L., Fritsch, C., Maira, S.-M., Hollingworth, G., Choi, C., Khandan, T., Paktinat, M., Okabe, R.O., Roberts, T.M., and Zhao, J.J. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha. *Journal of Clinical Investigation* 2014;124(4):1794–1809.

Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., Weigert, O., Kopp, N., Wu, S.-C., Kim, S.S., Liu, H., Tivey, T., Christie, A.L., **Gritsman, K.**, Gotlib, J., Deininger, M.W., Turley, S., Tyner, J.W., Marto, J.A., Weinstock, D.M., and Lane, A.A. Mutations in G-protein beta subunits promote transformation and kinase inhibitor resistance. *Nature Medicine* 2014, Dec 8. doi: 10.1038/nm.3751

Yuzugullu, H., Baitsch, L., Von, T., Steiner, A., Tong, H., Ni, J., Clayton, L., Bronson, R., Roberts, T<sup>1</sup>., **Gritsman, K.**<sup>1</sup>, and Zhao, J.J<sup>1</sup>. A p110β-Rac signaling loop mediates Pten-loss-induced perturbation of hematopoiesis and leukemogenesis. *Nature Communications* 2015, Oct 7;6:8501 doi:10.1038/NCOMMS9501

Hemmati, S., Haque, T., and **Gritsman, K.** Inflammatory Signaling Pathways in Pre-leukemic and Leukemic Stem Cells, *Frontiers in Oncology* 2017 Nov 13;7:265. doi: 10.3389/fonc.2017.00265

Hemmati, S., Sinclair, T., Tong, M., Bartholdy, B., Okabe, R.O., Ames, K., Ostrodka, L., Haque, T., Kaur, I., Mills, T. S., Agarwal, A., Pietras, E.M., Zhao, J.J., Roberts, T.M., and **Gritsman, K.** PI3 kinase alpha and delta promote hematopoietic stem cell activation, *JCI Insight* 2019. doi.org/10.1172/jci.insight.125832

Gurska, L., Ames, K., and **Gritsman, K.** Signaling Pathways in Leukemic Stem Cells, In: Zhang H., Li S. (eds) Leukemia Stem Cells in Hematologic Malignancies. *Advances in Experimental Medicine and Biology*, vol 1143. Springer, Singapore, July 24, 2019, doi: [https://doi.org/10.1007/978-981-13-7342-8\\_1](https://doi.org/10.1007/978-981-13-7342-8_1)

Gurska, L.M., Okabe, R., Schurer, A., Tong, M.M., Soto, M., Choi, D., Ames, K., Glushakow-Smith, S., Montoya, A., Tein, E., Miles, L.A., Cheng, H., Hankey-Giblin, P., Levine, R.L., Goel, S., Halmos, B., and **Gritsman, K.** Crizotinib has Preclinical Efficacy in Philadelphia-negative Myeloproliferative Neoplasms, *Clinical Cancer Research* 2022 Dec 20:CCR-22-1763. doi: 10.1158/1078-0432.CCR-22-1763. PMID: 36537918

Ames, K., Kaur, I., Shi, Y., Tong, M., Sinclair, T., Hemmati, S., Glushakow-Smith, S.G., Tein, E., Gurska, L., Steidl, U., Dubin, R., Shan, J., Montagna, C., Pradhan, K., Verma, A., and **Gritsman, K.** Deletion of PI3-Kinase Promotes Myelodysplasia Through Dysregulation of Autophagy in Hematopoietic Stem Cells, *Science Advances* 2023. doi: 10.1126/sciadv.ade8222\_ PMID: 36812307

Folgado Marco, V., Ames, K., Chuen, J., **Gritsman, K.** & Baker, N., Haploinsufficiency of the essential gene *RpS12* causes defects in erythropoiesis and hematopoietic stem cell maintenance, *eLife* 2023 Jun 5;12:e69322. doi: 10.7554/eLife.69322. PMID: 37272618

Ames K, **Gritsman, K.** Unraveling the Link between Class 1A PI3-Kinase, Autophagy, and Myelodysplasia. *Autophagy*. 2023 Jun 8. doi: 10.1080/15548627.2023.2221922. PMID: 37289024

Gurska L, **Gritsman, K.** Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia. *Cancer Drug Resist* 2023;6. <https://dx.doi.org/10.20517/cdr.2023.39>

**Wenjun Guo, Ph.D.**  
**Professor**

**Price BLDG. – Room 122**  
**wenjun.guo@einsteinmed.edu**



**Key Words:** *cancer stem cells, mammary stem cells, tumor immune microenvironment, immunotherapy, cellular plasticity, metastasis, therapeutic resistance*

My lab is interested in two interlocking areas of stem cell biology and cancer biology: the molecular pathways that regulate the normal stem-cell fate in the mammary gland, and the role of stem cell fate/pathway dysregulation in breast cancer pathogenesis.

### **Role of stem cell plasticity in tumorigenesis**

Using in vitro organoid culture and in vivo lineage tracing strategies, we have identified novel unipotent stem/progenitor cells that are responsible for the development of distinct mammary epithelial cell lineages and may serve as origins of distinct breast cancer subtypes. We have also uncovered a crucial role of de-differentiation of these unipotent cells to multipotent stem-like cells in breast cancer malignant progression. Our ongoing work focuses on determining the mechanisms of de-differentiation to multipotency, dissecting the interaction of de-differentiated stem-like cells with the host immune system, developing strategies for targeting these pre-cancer stem cells.

### **Function of stem-cell pathways in breast cancer progression and metastasis**

Emerging evidence suggests that normal stem-cell pathways often get activated aberrantly in cancers and contribute to aggressive cancer behaviors. Identification of key normal stem cell regulators provides us a framework to understand how breast cancer stem cells are regulated. We are particularly interested in understanding the role of stem-cell regulators in controlling metastatic colonization, a rate-limiting step of the metastatic cascade that involves cancer stem cells. We recently identified a key role of epigenetic regulator MLL3 mutation in enhancing stem cell activity and promoting the formation of aggressive cancer cells with hybrid epithelial-mesenchymal characteristics. In addition, we are interested in how cancer stem cells are regulated by and interact with the tumor immune microenvironment.

### **Selected Publications**

Liu Y, ..., Zang X\*, and **Guo W\***. A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression. *Developmental Cell* 2023; 58(23):2700-2717.e12.

Cui J, ..., **Guo W**. MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state. *Nature Cell Biology* 2023; 25(1):145-158.

Cui J, ..., and **Guo W**. Targeting ABCA12-controlled ceramide homeostasis inhibits breast cancer stem cell function and chemoresistance. *Science Advances* 2023; 9(48):eadh1891.

Christin JR, ..., **Guo W**. (2020) Stem cell determinant SOX9 promotes lineage plasticity and progression in basal-like breast cancer. *Cell Reports* 31(10):107742. doi: 10.1016/j.celrep.2020.107742.

Wang C, Christin JR, Oktay MH, **Guo W**. (2017) Lineage-biased stem cells maintain estrogen-receptor-positive and -negative mouse mammary luminal lineages. *Cell Reports* 18: 2825 – 2835.

Zhang Z, Christin JR, Wang C, Ge K, Oktay MH, **Guo W**. (2016) Mammary-stem-cell-based somatic mouse models reveal breast cancer drivers causing cell fate dysregulation. *Cell Reports* 16: 3146-3156.

**Guo W**, ..., Weinberg RA. (2012) Slug and Sox9 cooperatively determine the mammary stem cell state. *Cell* 148: 1015-1028.

Mani SA\*, **Guo W\***, ..., Weinberg RA. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 133: 704-715. (\*: equal contribution.)

**Keisuke Ito, M.D., Ph.D.**

**Professor**

**Director of Scientific Resources of the Stem Cell Institute**

**Price Center**

**Room 108 (Lab)**

**718-678-1279 (Lab)**



**Key Words: Hematopoietic stem cell and its cell fate, Mitochondria, Leukemia, Myelodysplastic syndrome, Sickle cell disease**

The central research goal of the Ito Lab is the expansion of our understanding of the regulatory pathways **controlling the equilibrium of healthy and malignant hematopoietic stem cells**. At the core of our work is the process of stem cell division, and the resulting balance between **self-renewal and differentiation**, which directly impacts tissue homeostasis. We are also devoting increased attention to targeting **cellular metabolism** and/or **mitochondrial physiology** as a therapeutic strategy and are cutting a path along the leading edge of research into the role of **epigenetic-microRNA crosstalk**, including physiologically relevant Ten-eleven translocation, in the pathogenesis of **myelodysplastic syndrome**. We believe our expertise in stem cell biology, hematology, and the bone marrow microenvironment, combined with our development of **single cell approaches** and **live imaging to track stem cell fate in vivo** and **leukocyte behavior in sickle cell disease** animal models will facilitate a major contribution to the improvement of transplantation efficiency and the development of new therapies, and potentially even cures, for many forms of **hematologic pathology**.

**Selected Original research and Theoretical treatises;**

1. Wu Q, Zhang J et al., Resilient anatomy and local plasticity of naive and stress haematopoiesis. **Nature**. 2024 Mar;627(8005):839-846. doi: 10.1038/s41586-024-07186-6. Epub 2024 Mar 20. PMID: 38509363.
2. Bonora M\*, Morganti C\*, van Gastel N\*, Zanolla I, Ferroni L, Zhang Y, Jung Y, Sales G, Martini P, Nakamura T, Lasorsa FM, Finkel T, Lin CP, Zavan B, Pinton P, Georgakoudi I, Romaldi C, Scadden DT, **Ito K**. A mitochondrial NADPH-cholesterol axis regulates extracellular vesicle biogenesis to support HSC fate. *Cell Stem Cell*. Mar 7;31(3):359-377.e10. doi: 10.1016/j.stem.2024.02.004. PMID: 38458178.
3. Flores JC\*, Ito K\* et al., Comparative analysis of Tet2 catalytic deficient and knockout bone marrow over time. **Exp Hematol**. 2023 May 22:S0301-472X(23)00227-8. PMID: 37225048.
4. Morganti C et al., NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss. **EMBO Rep**. 2022 May 4;23(5):e54262.
5. Schönberger K et al., Multilayer omics analysis reveals a non-classical retinoic acid signaling axis that regulates hematopoietic stem cell identity. **Cell Stem Cell**. 2022 Jan 6;29(1):131-148.e10.
6. Wu HC et al., Actinomycin D targets NPM1c-primed mitochondria to restore PML-driven senescence in AML therapy. **Cancer Discovery**. 2021 Dec 1;11(12):3198-3213.
7. Morganti C, Bonora M, Ito K, **Ito K**. Electron transport chain complex II sustains high mitochondrial membrane potential in hematopoietic stem and progenitor cells. *Stem Cell Res*. **Stem Cell Res**. 2019 Oct;40:101573.
8. Ito K\*, Lee J\* et al., Non-catalytic roles of Tet2 are essential to regulate hematopoietic stem and progenitor cell homeostasis. **Cell Rep**. 2019 Sep 3;28(10):2480-2490.e4.
9. Ito K, Turcotte R, Cui J, Zimmerman SE, Pinho S, Mizoguchi T, Arai F, Runnels JM, Alt C, Teruya-Feldstein J, Mar JC, Singh R, Suda T, Lin CP, Frenette PS, **Ito K**. Self-renewal of a purified Tie2+ hematopoietic stem cell population relies on mitochondrial clearance. **Science**. 2016 Dec 2;354(6316):1156-1160.

**Selected Invited publications;**

1. Torres LS et al., Recent advances in “Sickle and Niche” research. **Stem Cell Reports**. 2022 Jul 12;17(7):1509-1535.
2. Morganti C et al., Metabolic Regulation of Hematopoietic Stem Cells. **HemaSphere**. July 2022 6(7) p e740.
3. **Ito K**, Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. **Nat Rev Mol Cell Biol**. 2014 Apr;15(4):243-56.

**MARGARET KIELIAN, Ph.D.**  
**Professor**

**CHANIN BLDG. – ROOM 515**  
**718 430-3638**

[margaret.kielian@einsteinmed.edu](mailto:margaret.kielian@einsteinmed.edu)



## **Molecular Mechanisms of Virus Entry and Exit.**

For more information, please see our lab homepage:

<https://sites.google.com/site/kielianlab/>

All enveloped viruses use the essential steps of membrane fusion to enter a host cell, and membrane budding to exit. Molecular information on the entry and exit processes is critical to understanding the lifecycle of enveloped viruses and how they exploit the host cell machinery, and as an important model for cellular membrane fusion and budding reactions.

Our research focuses on the molecular mechanisms of virus entry and exit using alphaviruses and the closely related virus rubella virus. The alphaviruses include important human pathogens such as chikungunya virus, which causes millions of human infections each year. There are no antiviral therapies for alphaviruses, and new strategies are urgently needed.

Alphaviruses and rubella virus enter cells by endocytic uptake and then fuse their membrane with the endosome membrane in a reaction triggered by the low pH of the endocytic vesicle. The membrane fusion proteins of these viruses are structurally related proteins and refold during fusion to a homotrimer conformation that mediates virus fusion and infection. Recent studies have also shown that structurally similar proteins are expressed in plants and in many animals, where they mediate cell-cell fusion of gametes and during development. Many important questions on the molecular mechanism of membrane fusion remain for both viruses and cells.

We are defining host proteins involved in rubella virus entry. During alphavirus biogenesis, a companion protein forms a dimer with the fusion protein and protects it from low pH and premature fusion during exocytic transport. This companion protein must then dissociate to permit virus fusion. The pH protection mechanisms for many other viruses are unknown, and we are using rubella virus as a system to define novel mechanisms of pH protection and the pH-dependent control mechanisms for the rubella virus fusion reaction.

Alphaviruses exit by budding through the plasma membrane of the infected host cell. Little is known about alphavirus assembly and budding, although it is clear that these processes are highly regulated to produce organized virus particles of high specific infectivity. How does this happen and what are the roles of cellular and viral factors? We seek to determine how the internal viral RNA-capsid core is assembled, how the virus excludes host RNAs, and how the nascent capsid/nucleocapsid is transported to the budding site. We are using a novel capsid protein retrieval strategy to identify and characterize host factors involved in alphavirus nucleocapsid assembly. We have developed fluorescently tagged alphaviruses to follow virus assembly and budding in real time in infected cells. We are investigating how alphaviruses spread from cell to cell, a process that protects the virus from antibody neutralization. The cell plasma membrane and cytoskeletal network are dramatically remodeled during budding and we are defining the mechanisms and signaling pathways that mediate remodeling.

We are also defining small molecules in cell culture and in vivo that can inhibit infection by medically important alphaviruses such as chikungunya virus.

## Complete List of Published Work:

<https://www.ncbi.nlm.nih.gov/sites/myncbi/margaret.kielian.1/bibliography/45469240/public/?sort=date&direction=descending>

## Selected references:

- R. S. Brown, D.G. Anastasakis, M. Hafner, and M. Kielian. (2020) "Multiple Capsid Protein Binding Sites Mediate Selective Packaging of the Alphavirus Genomic RNA" *Nature Communications*, 11:4693. PMID: PMC7499256
- Das, P.K. and M. Kielian. (2021) "The Enigmatic Capsid Protein of an Encephalitic Rubivirus," *J. Virol.* 95: e02294-20. PMID: PMC8103679
- Das, P.K. and M. Kielian. (2021) "Molecular and Structural Insights into the Life Cycle of Rubella Virus," *J. Virol.* 95:e02349-20. PMID: PMC8139664
- Brown, R.S., L. Kim, and M. Kielian (2021). "Specific Recognition of a Stem-Loop RNA Structure by the Alphavirus Capsid Protein," *Viruses* 13:1517. PMID: PMC8402798
- Martin CK, Kielian M. (2022) Identification of human and mosquito receptors for alphaviruses. *Nature* 602(7897):388-390. (Invited commentary).
- Yin P, Davenport BJ, Wan JJ, Kim AS, Diamond MS, Ware BC, Tong K, Couderc T, Lecuit M, Lai, JR, Morrison TE, Kielian M. (2023) "Chikungunya virus cell-to-cell transmission is mediated by intercellular extensions *in vitro* and *in vivo*." *Nature Micro.* 8: 1653-1667. [Selected for Journal Cover]
- Das, P.K., Alatraste Gonzalez, P., Jangra, R, Yin, P and Kielian. M. (2024) "A single point mutation in the rubella virus E1 glycoprotein promotes rescue of recombinant vesicular stomatitis virus." *mBio*: 15(3):e0237323. PMC10936182
- Yin, P., N. A. May, L. S. Lello, A. Fayed, M. G. Parks, A.M. Drobish, S. Wang, M. Andrews, Z. Sticher, A. A. Kolykhalov, M. G. Natchus, G. R. Painter, A. Merits, M. Kielian<sup>#</sup> and T. E. Morrison<sup>#</sup>. (<sup>#</sup> co-corresponding authors) (2024) "4'-Fluorouridine inhibits alphavirus replication and infection *in vitro* and *in vivo*." *mBio*15(6):e0042024. doi: 10.1128/mbio.00420-24

**DR. RICHARD N. KITSIS**


Professor

Departments of Cell Biology and Medicine (Cardiology)

Golding Building- Room G46

718 430-2609.

[richard.kitsis@einsteinmed.edu](mailto:richard.kitsis@einsteinmed.edu)



## **Cell Death and Mitochondrial Biology: Fundamental Mechanisms and Roles in Human Disease**

The most basic decision that any cell makes is to grow (proliferate or hypertrophy), differentiate, or die. Our laboratory studies fundamental mechanisms of cell death and the roles of cell death in normal biology and human disease. At least a dozen cell death programs have been recognized to date (*Cell Death Differ*, 2018; *Physiol Rev*, 2019). Little is understood about how they interconnect mechanistically or functionally to bring about cell death. The overarching goal of our work is to create a *unified model of cell death* that integrates seemingly “individual” cell death programs. Our hypothesis is that these cell death programs, which often undergo activation in the same cell, are components of an integrated cell death response that has arisen over evolution. Thus far, we have elucidated basic aspects of cell death biology including mechanisms that mediate apoptosis and regulated forms of necrosis, molecular interconnections among these programs, and connections with other aspects of mitochondrial biology (*Mol Cell*, 2004; *PNAS*, 2007; *JBC*, 2007; *PNAS*, 2012; *Cell Death Differ*, 2014; *Nature*, 2016; *Science*, 2018; *Nat Commun*, 2022; *PNAS*, 2023; *Mol Cell* (in press)).

Although our primary focus is basic mechanisms, we are also interested in translational implications. While some of our work has involved models of cancer (*Cell Death Differ*, 2005; *JBC*, 2010; *Cancer Res*, 2011, *PLOS One*, 2015) and diabetes (*Diabetes*, 2013; *Sci Rep*, 2017; *Dev Cell*, 2021), our primary translational focus is heart disease, the major cause of mortality worldwide. A number of years ago, our lab provided the first evidence that regulated forms of cell death play critical roles in the pathogenesis of myocardial infarction (“heart attack”) (*Circulation*, 2000; *JMCC*, 2000; *AJP*, 2003) and heart failure (*JCI*, 2003). More recently, the lab has contributed to the development of small molecule and peptide drug prototypes that modulate cell death and may provide the basis for new therapies for heart diseases and other conditions (*Nat Chem Biol*, 2019; *Nat Cancer*, 2020). We continue to use cell and *in vivo* myocardial infarction models in our current work aimed at unifying cell death mechanisms because at least 7 cell death programs are activated in this syndrome.

### Current projects

#### 1. A novel platform for caspase-9 activation to bring about necrosis – not apoptosis

We have identified a new molecular platform – distinct from the apoptosome – for caspase-9 activation, which brings about necrosis rather than apoptosis. This pathway appears to operate generally in a variety of cell types as well as in cardiomyocytes during myocardial infarction *in vivo*. We are currently characterizing the activating complex structurally, activating signals, and downstream pathway (manuscript in preparation).

#### 2. Role of necroptosis in myocardial infarction

Necroptosis, a regulated form of necrosis defined by RIPK3 → MLKL signaling, is important in cardiac damage during myocardial infarction. In many paradigms, RIPK3 is activated by RIPK1. However, we believe that, during myocardial infarction, RIPK3 activation is triggered by the presence of double stranded nucleic acids in the Z-conformation in the cytoplasm. We are currently delineating this pathway, which we suspect may be a prototype for roles of Z-nucleic acids in other aspects of cell signaling. We are also developing a novel small molecule RIPK3 inhibitor as a potential therapeutic in myocardial infarction.

#### 3. Function of the mitochondrial ATP synthase *in vivo*

The mitochondrial ATP synthase catalyzes the generation of >90% of ATP in eukaryotic cells, but its necessity for maintaining cellular energetics has not been defined in an intact organism. We devised an *in vivo* strategy to progressively deplete the entire 28-subunit mitochondrial ATP synthase monomer, and dimers thereof, in heart muscle cells, a cell type chosen because of its high energetic demands. Unexpectedly, mice whose heart muscle cells contain 5-15% of the monomeric complex and <2% of dimers remain clinically indistinguishable from controls for weeks, retain normal cardiac function, and exhibit only moderate exercise deficits. Cardiac mitochondrial ATP synthesis rates and concentrations are reduced ~50%, roughly equivalent to those in end-stage human heart failure. Following this period of compensation, all mice transition precipitously to heart failure and die, but remarkably this occurs without further decreases in ATP synthesis rates and ATP concentrations. Experiments are currently underway to understand the compensatory changes that allow mice to cope with such marked depletion of the mitochondrial ATP synthase in an energetically demanding cell type and to delineate the mechanisms that mediate the transition to heart failure.

A second part of this work has been to test a hypothesis that has been advanced by others that the mitochondrial ATP synthase serves a second function as a mitochondrial permeability transition pore, a channel in the inner mitochondrial membrane that mediates necrotic cell death. Our data in isolated mitochondria, cells, and intact mice demonstrate that, rather than serving as the mitochondrial permeability transition pore, the assembled mitochondrial ATP synthase is in fact a negative regulator of this pore (*PNAS*, 2023).

#### 4. Interrelationships between cellular senescence and cell death in aging

We have performed a genome-wide CRISPR screen to identify proteins that direct cells under stress toward a senescent versus cell death fate. We are currently studying these molecules in models of senescence relevant to aging. The long-term goals are to understand the determinants of senescence versus cell death as cellular reactions to stress and to devise novel senotherapeutics to divert damaged cells from a senescent toward a cell death fate.

#### 5. ER/SR-mitochondrial relationships in regulating necrotic cell death and metabolism

We have previously created novel peptides and small molecules that conformationally active or inhibit mitofusins (MFNs) (*Nature*, 2016; *Science*, 2018), which are large GTPases involved in mitochondrial fusion and ER/SR-mitochondrial tethering. We are now using these reagents to perturb the physical distance and interactions between ER/SR and mitochondria. We have shown that MFN inhibitors limit infarct size during myocardial ischemia/reperfusion even when dosed at the time of reperfusion (manuscript in preparation). We are also attempting to do the opposite: augment ER-mitochondrial interactions and Ca<sup>2+</sup> transfer to boost myocardial metabolism during heart failure.

#### 6. Regulation of ferroptosis by OPA1

We have discovered that OPA1 markedly sensitizes cells to ferroptosis, an iron-dependent form of necrotic cell death mediated by hydroperoxidation of phospholipids in cellular membranes. Unexpectedly, this sensitization to ferroptosis is independent of the ability of OPA1 to promote mitochondrial fusion. Rather, by maintaining mitochondrial homeostasis and function, OPA1 both stimulates the generation of mitochondrial lipid ROS and suppresses an ATF4-mediated integrated stress response that would otherwise upregulate mechanisms that inhibit ferroptosis (*Molecular Cell*, accepted). This axis has potential implications for several diseases.

## **Selected Publications**

Link to publications:

<https://pubmed.ncbi.nlm.nih.gov/?term=kitsis+rn&sort=date>

Link to current NIH funding:

<https://reporter.nih.gov/search/evTFsgrZrkiK9bKr9tpWVA/projects?projects=Active>

**Lindsay LaFave, Ph.D.**  
**Assistant Professor**

**Chanin Building Room 606**  
**[lindsay.lafave@einsteinmed.edu](mailto:lindsay.lafave@einsteinmed.edu)**



### **Gene regulatory mechanisms that mediate lung cancer evolution**

Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer and remains a leading cause of cancer-related death. Next-generation sequencing studies have identified a number of recurrent genetic drivers (such as mutations in *KRAS* and *TP53*); however, this somatic variation does not fully explain key features of cancer evolution including progression toward metastasis and intratumoral heterogeneity. Our group aims to understand how non-genetic mechanisms contribute to lung cancer initiation and progression through the lens of chromatin biology.

In genetically engineered mouse modeling studies, cell-type specific transformation of alveolar type II (AT2) cells with *Kras*<sup>G12D</sup> and loss of *Tp53* lead to a natural cancer evolution process that recapitulates phenotypic hallmarks of human disease. Using this model, our recent work employed single-cell epigenomics to study dysregulation of chromatin state across lung cancer evolution. We identified a continuum of heterogeneous chromatin states with reproducible epigenomic features across individual lung tumors, suggesting conserved routes of cancer progression. Using both functional and computational approaches, we annotated transcription factor (TF) regulators and downstream gene programs associated with these diverse chromatin profiles. These discernable gene regulatory modules were linked to certain aspects of cancer progression including loss of cellular identity, inflammation, and metastasis. Our work also identified the emergence of a pre-metastatic gene regulatory program that arises in a rare cell population in primary tumors and primes cells for metastatic seeding. We identified RUNX2 as an important regulator of this cell state and are developing new models to study the role of RUNX TF biology in lung cancer progression.

Cellular identity is dictated by chromatin structure, which is maintained by a complex network of *cis*- (e.g., enhancer, promoters, and insulators), and *trans*- (e.g., chromatin modifiers, TFs, and adaptors) factors. Our previous work found that early stages of LUAD progression are associated with the loss of AT2 identity and the acquisition of epigenomic states similar to developmentally related cell types. We seek to further understand how lung cancer initiation ultimately leads to decoupling from an AT2 cell identity and increased epigenomic plasticity. In addition, we are interested in investigating how disruption of the tumor microenvironment influences LUAD cell state. To address these questions, we pair lung cancer modeling with epigenomic technologies (including single-cell ATAC-sequencing, single-cell multiomic analysis, and spatial approaches) to dissect mechanisms important for the maintenance and persistence of dysregulated cell states in lung cancer. We flexibly utilize genetically engineered mouse models, alveolar human and murine organoids, and cell-based assays to perform functional studies. We continue to expand our technological and modeling toolkit to study early and late stages of lung cancer progression with the overarching goal of better understanding and targeting lung cancer progression.

#### **Research directions in the lab:**

1. Perturbation of candidate chromatin regulators associated with aberrant cell states in lung cancer
2. Interrogation of mechanisms that drive epigenomic plasticity and cell identity shifts in LUAD
3. Investigation of the role of the tumor microenvironment and loss of tissue homeostasis in shaping cell state in lung cancer cells
4. Utilization of varied single-cell epigenomic technologies to decipher gene regulatory networks in normal lung and lung cancer cells

### **Selected Publications:**

\*Co-first; ^Co-corresponding authors

LaFave LM<sup>^</sup>, Savage RE, Buenrostro JD<sup>^</sup>. Single-cell epigenomic reveals mechanisms of cancer progression. *Ann. Review of Cancer Biology*. Apr 6:167-185.

Del Priore I\*, Ma S\*, Strecker J, Jacks T, **LaFave LM<sup>^</sup>**, Buenrostro JD<sup>^</sup>. Protocol for single-cell ATAC sequencing using combinatorial indexing in mouse lung adenocarcinoma. *STAR Protoc.* 2021 Jun 18;2(2):100583.

**LaFave LM<sup>^</sup>**, Buenrostro JD<sup>^</sup>. Unlocking PDAC initiation with AP-1. *Nat Cancer*. 2021 Jan 13; 2:14-15.

Ma S, Zhang B, **LaFave LM**, Earl AS, Chiang Z, Hu Y, Ding J, Brack A, Kartha VK, Tay T, Law T, Lareau C, Hsu YC, Regev A, Buenrostro JD. Chromatin Potential Identified by Shared Single-Cell Profiling of RNA and Chromatin. *Cell*. 2020 Nov 12;183(4):1103-1116.e20.

**LaFave LM**, Kartha VK, Ma S, Meli K, Del Priore I, Lareau C, Naranjo S, Westcott PMK, Duarte FM, Sankar V, Chiang Z, Brack A, Law T, Hauck H, Okimoto A, Regev A, Buenrostro JD<sup>^</sup>, Jacks T<sup>^</sup>. Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma. *Cancer Cell*. 2020 Aug 10;38(2):212-228.e13.

**LaFave LM**, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL. Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". *Nat Med*. 2016 Jun 7;22(6):578-9.

**LaFave LM**, Levine RL. Targeting a regulator of protein homeostasis in myeloproliferative neoplasms. *Nat Med*. 2016 Jan;22(1):20-1.

**LaFave LM**, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL. Loss of BAP1 function leads to EZH2-dependent transformation. *Nat Med*. 2015 Nov;21(11):1344-9. doi: 10.1038/nm.3947.

Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR, Kuscu C, Hricik T, Ndiaye-Lobry D, **LaFave LM**, Koche R, Shih AH, Guryanova OA, Kim E, Li S, Pandey S, Shin JY, Telis L, Liu J, Bhatt PK, Monette S, Zhao X, Mason CE, Park CY, Bernstein BE, Aifantis I, Levine RL. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. *J Exp Med*. 2013 Nov 18;210(12):2641-59.


Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, Kirkpatrick DS, Pham VC, Lill JR, Bakalarski CE, Wu J, Phu L, Katavolos P, **LaFave LM**, Abdel-Wahab O, Modrusan Z, Seshagiri S, Dong K, Lin Z, Balazs M, Suriben R, Newton K, Hymowitz S, Garcia-Manero G, Martin F, Levine RL, Dixit VM. Loss of the tumor suppressor BAP1 causes myeloid transformation. *Science*. 2012 Sep 21;337(6101):1541-6.

Abdel-Wahab O\*, Adli M\*, **LaFave LM\***, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, Melnick A, Nimer SD, Jaffe JD, Aifantis I, Bernstein BE, Levine RL. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. *Cancer Cell*. 2012 Aug 14;22(2):180-93.

**Maria Maryanovich, Ph.D.**  
**Assistant Professor**

**Price Building**  
**Room: 107/113 (lab), 120 (office)**  
**718-678-1066**

[maria.marianovich@einsteinmed.edu](mailto:maria.marianovich@einsteinmed.edu)  
<https://www.maryanovich-lab.com/>



## **Hematopoietic niches at the crossroads of aging and hematologic malignancies**

Our goal is to understand the cellular and molecular regulators of stem cell niches in the hematopoietic system. We focus on primary lymphoid organs, the bone marrow, which provides a supportive niche for hematopoietic stem cells (HSCs), and the thymus, which is essential for the lifelong production of T cells.

HSCs are long-lived stem cells responsible for generating billions of red blood cells, white blood cells, and platelets. These critically important cells reside within the bone marrow in a microenvironment ("niche") that supports their survival, proliferation, and differentiation. Improper control of HSC maintenance results in a wide range of clinical conditions, including anemia, thrombocytopenia, immune dysfunction, and hematological malignancies. A fundamental aspect of thymopoiesis is the migration of early T cell progenitors (ETPs) from the bone marrow to the thymus and settling in specialized niches that coordinate T cell lineage commitment, TCR gene rearrangement, positive and negative selection, yielding mature T cell subsets. Disruption in the thymic niche and dysregulation of thymopoiesis is a common feature of aging and leads to immune system dysfunction.

Lab projects cover a wide scope of hematopoiesis biology, from neural and circadian regulation of hematopoiesis and thymopoiesis to redox signaling and mitochondrial dynamics in niche cells. Our lab's major focus is teasing apart the interactions between stem and progenitor cells and their niche. We hope that our novel discoveries will provide a roadmap for the development of treatment strategies to help millions of individuals and their families suffering from hematological diseases and immune disorders.

### **Lab projects:**

- I. Circadian oscillation of hematopoietic stem cells (HSCs) and progenitor egress to peripheral blood is regulated by the Sympathetic nervous system (SNS). Signals from sympathetic nerves control circadian rhythms by targeting mesenchymal stem cells (MSCs) and vascular endothelial cells to express chemokines/cytokines and adhesion molecules, respectively. We seek to decipher the mechanisms of circadian oscillation in the HSC niche and their impact on hematopoiesis and its contribution to pathologies such as aging and myeloproliferative disorders.
- II. Our previous work established that signals from SNS control hematopoietic aging and highlight niche-derived factors as critical regulators of HSC longevity, the rejuvenation of which can directly benefit aged stem cells (*Maryanovich et al., Nature Medicine 2018*). Future efforts are oriented toward identifying targets downstream of the SNS that control niche and HSC aging.

- III. Myeloid malignancies elicit alterations to the HSC niche that promote oncogenic expansion and eradication of healthy stem cells. The SNS was shown to be protective against myeloproliferation, as sympathetic denervation or deletion of  $\beta$ -adrenoreceptors accelerated the development of myeloproliferative disease (*Hanoun et al., Cell Stem Cell 2014*). Our work has shown that SNS signals control the homeostasis of niche-derived ROS and that leukemic progression favors high oxidative stress, suggesting that SNS signals may mitigate ROS levels in the BM microenvironment to protect HSC niches during leukemogenesis.
- IV. Metabolic activity of niche constituents and perturb their ability to support hematopoiesis. We seek to decipher the role of mitochondrial dynamics and metabolism in dictating MSC function both in vitro and in vivo. We are particularly interested in many aspects of mitochondrial function and their role in dictating MSC phenotypes and HSC support.
- V. We are interested in the role of the SNS in regulating thymus seeding by early T cell progenitors (ETPs) and are further investigating the role of the SNS in controlling T cell lineage commitment and thymic niche function. We are developing tools to study thymus innervation and thymic niche constituents in the context of thymus regeneration and age-dependent thymic involution.

#### **Selected Publications:**

Randall S. Carpenter, **Maria Marvanovich**. *Systemic and local regulation of haematopoietic homeostasis in health and disease*. Review article. *Nature Cardiovascular Research*. 2024 June 12 doi: 10.1038/s44161-024-00482-4

Maria K. Lagou, Dimitrios G. Argyris, Stepan Vodopyanov, Leslie Gunther-Cummins, Alexandros Hardas, Theofilos Poutahidis, Christos Panorias, Sophia DesMarais, Conner Entenberg, Randall S. Carpenter, Hillary Guzik, Xheni Nishku, Joseph Churaman, **Maria Marvanovich**, Vera DesMarais, Frank P. Macaluso, George S. Karagiannis. *Morphometric Analysis of the Thymic Epithelial Cell (TEC) Network Using Integrated and Orthogonal Digital Pathology Approaches*. BioRxiv 2024.03.11.584509; doi: 10.1101/2024.03.11.584509. *Preprint*.

Pinho S, Wei Q, **Maryanovich M**, Zhang D, Pierce H, Nakahara F, Di Staulo A, Bartholdy B, Xu J, Borger D, Verma A and Frenette PS. VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells. **Nature Cell Biology**. 2022 Mar;24(3):290-298

Nakahara F, Borger DK, Wei Q, Pinho S, **Maryanovich M**, Zahalka AH, Suzuki M, Cruz CD, Wang Z, Xu C, Boulais PE, Ma'ayan A, Grealley JM, Frenette PS. *Engineering a haematopoietic stem cell niche by revitalizing mesenchymal stromal cells*. **Nature Cell Biology**. 2019 May;21(5):560-567

**Maryanovich M**, Zahalka AH, Pierce H, Pinho S, Nakahara F, Asada N, Wei Q, Wang X, Ciero P, Xu J, Leftin A, Frenette PS. *Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche*. **Nature Medicine**. 2018 May 7; 24:782–791

**Maryanovich M**, Takeishi S, Frenette PS. *Neural Regulation of Bone and Bone Marrow*. **Cold Spring Harb Perspect Med**. 2018 Mar 2. pii: a031344

Zahalka AH, Arnal-Estapé A, **Maryanovich M**, Nakahara F, Cruz CD, Frenette PS. *Adrenergic nerves activate an angio-metabolic switch in prostate cancer*. **Science**. 2017 Oct 20; 358(6361):321-326

**Maryanovich M**, Zaltsman Y, Ruggiero A, Goldman A, Shachnai L, Zaidman SL, Porat Z, Golan K, Lapidot T, Gross A. *A MTCH2 pathway repressing mitochondria metabolism regulates haematopoietic stem cell fate*. **Nature Communications**. 2015 Jul 29; 6:7901

Hanoun M\*, **Maryanovich M**\*, Arnal-Estapé A\*, Frenette PS. *Neural Regulation of hematopoiesis, inflammation and Cancer*. **Neuron**. 2015 Apr 22; 86(2):360-73. Review. (\*Co-first author)

**Maryanovich M**, Gross A. *A ROS rheostat for cell fate regulation*. **Trends in Cell Biology**. 2013 Mar; 23(3):129-34

**Maryanovich M**, Oberkovitz G, Niv H, Vorobiyov L, Zaltsman Y, Brenner O, Lapidot T, Jung S, Gross A. *The ATM-BID Pathway regulates quiescence and survival of haematopoietic stem cells*. **Nature Cell Biology**. 2012 Mar 25; 14(5):535-41

**U. Thomas Meier, Ph.D**

**Professor**

**Laboratory: Forchheimer 650**

**Phone: 718-430-3294**


E-Mail: [tom.meier@einsteinmed.edu](mailto:tom.meier@einsteinmed.edu)



## RNA MODIFICATION AND ORGANELLE FORMATION IN HUMAN DISEASE AND REPRODUCTION

All ribosomal and other stable RNAs are heavily modified by small nucleolar ribonucleoproteins (snoRNPs). We are studying these processes and how they contribute to the formation of the nucleolus and other nuclear organelles through phase separation. Amino acid substitutions in some of the snoRNP proteins cause genetic diseases, e.g., the bone marrow failure syndrome dyskeratosis congenita with a predisposition to cancer. We are investigating the mechanisms underlying these diseases on a cellular level.

SnoRNPs rely on short guide RNAs to specify nucleotides for modification in target RNAs. There are two major classes of snoRNAs, H/ACA and C/D, guiding pseudouridylation ( $\psi$ ) and 2'-O-methylation ( $\text{CH}_3$ ) of RNA, respectively. Each of these several hundred RNAs are stabilized by the same four snoRNP core proteins for each class. Some of the core proteins share similar intrinsically disordered domains (IDRs), that are highly charged and rich in nuclear localization signals (NLSs) or glycine-arginine-rich (GAR). The nucleolar snoRNP chaperone Nopp140 binds to both the NLS and GAR IDRs of the snoRNP core proteins. Additionally, we identified a similar charged NLS IDR in the C-terminal tail of the RNA polymerase I subunit PAF49 that also binds to Nopp140 and can mediate interaction with snoRNPs. Since RNA polymerase I exclusively transcribes ribosomal DNA, this interaction network links the rRNA modification machinery to rDNA transcription explaining the cotranscriptional modification of rRNA. All these reactions and interactions occur in the densely packed yet highly dynamic dense fibrillar component (DFC) of the nucleolus. Transmission electron micrographs of wild type, Nopp140 knockdown and rescue cells confirm that the dense organization of the DFC depends on the presence of Nopp140. We are analyzing this phase separated organelle in vitro and in vivo to understand the basic mechanism of ribosome biogenesis.



We are also investigating the roles of snoRNPs and Nopp140 in other nuclear phase separated bodies, Cajal bodies, where they modify spliceosomal small nuclear RNAs (snRNAs), required for pre-mRNA splicing, and where they stabilize telomerase RNA, required for telomere length maintenance.

Finally, we study the function of nucleolar channel systems (NCSs) in human reproduction. NCSs are micron-sized membranous organelles in the normally membrane-free nucleus. During each menstrual cycle, they transiently develop during the height of receptivity in endometrial epithelial cells. NCSs are implicated in the preparation of the endometrium for uterine attachment of the fertilized egg. We identified molecular markers for NCSs and exploit them to understand the cellular biology of these enigmatic organelles and their regulation and function in uterine biology, e.g., the timing of embryo transfer in in vitro fertilization cycles to boost IVF success rates.

## **Selected References**

**Meier, U.T.** (2022) The daunting task of modifying ribosomal RNA. *RNA* 28:1555-1557.

**Meier, U.T.** (2022) Guide RNA acrobatics: the one-for-two shuffle. *Genes Dev* 36: 1-3.

Bizarro, J., Deryusheva, S., Wacheul, L., Gupta, V., Ernst, F.G.M., Lafontaine, D.L.J., Gall, J.G., and **Meier, U.T.** (2021). Nopp140-chaperoned 2'-O-methylation of small nuclear RNAs in Cajal bodies ensures splicing fidelity. *Genes Dev* 35: 1123-1141.

Gerber, R.S., Buyuk, E., Zapantis, G., Lieman, H., and **Meier, U.T.** (2021). Presence of endometrial nucleolar channel systems at the time of frozen embryo transfer in hormone replacement cycles with successful implantation. *F S Sci* 2, 80–87.

Bizarro, J., Bhardwaj, A., Smith, S., and **Meier, U.T.** (2019) Nopp140-mediated concentration of telomerase in Cajal bodies regulates telomere length. *Mol Biol Cell* 30: 3136-3150.

Meng, F., Zapantis, G., Williams, S.Z., Lieman, H.J., Buyuk, E., and **Meier, U.T.** (2018) The status of nucleolar channel systems in uterine secretions accurately reflects their prevalence – a marker for the window of implantation – in simultaneously obtained endometrial biopsies. *Fertil Steril* 109: 165-171.

Bizarro, J. and **Meier, U.T.** (2017) Inherited SHQ1 mutations impair interaction with NAP57/dyskerin, a major target in dyskeratosis congenita. *Mol Genet Genomic Med* 5: 805-808.

**Meier, U.T.** (2016) RNA modification in Cajal bodies. *RNA Biol* 10:1–8.

Yu, Y.-T. and **Meier, U.T.** (2014) RNA-guided isomerization of uridine to pseudouridine – pseudouridylation. *RNA Biol* 11: 1483–1494.

Nejat, E.J., Ruiz-Alonso, M., Simón, C., and **Meier, U.T.** (2014) Timing the window of implantation by nucleolar channel system prevalence matches the accuracy of the endometrial receptivity array. *Fertil. Steril.* 102: 1477-1481.

Nejat, E.J., Szmyga M.J., Zapantis G., and **Meier U.T.** (2014) Progesterone Threshold Determines Nucleolar Channel System Formation in Human Endometrium. *Reprod Sci.* 21: 915–920.

Zapantis G, Szmyga MJ, Rybak E, and **Meier U.T.** (2013) Premature formation of nucleolar channel systems indicates advanced endometrial maturation following controlled ovarian hyperstimulation. *Hum Reprod* 28: 3292-3300.

Szmyga MJ, Rybak EA, Nejat EJ, Banks EH, Whitney KD, Polotsky AJ, Heller DS, and **Meier U.T.** (2013) Quantification of nucleolar channel systems: uniform presence throughout the upper endometrial cavity. *Fertil Steril* 99: 558–564.

Machado-Pinilla, R., Liger, D., Leulliot, N., and **Meier, U.T.** (2012) Mechanism of the AAA+ ATPases pontin and reptin in H/ACA RNP biogenesis. *RNA* 18: 1833–1845.

Walbott, H., Machado-Pinilla, R., Liger, D., Blaud, M., Rety, S., Grozdanov, P.N., Godin, K., van Tilbeurgh, H., Varani, G., **Meier, U.T.**, and Leulliot, N. (2011) The H/ACA RNP assembly factor SHQ1 functions as an RNA mimic. *Genes Dev* 25: 2398–2408.

**Meier, U.T.** (2011) Pseudouridylation goes regulatory. *EMBO J* 30: 3-4.

**SATISH NANDAKUMAR, MBBS, Ph.D.**  
**Assistant Professor**  
**Chanin Bldg.- Room 413**

satish.nandakumar@einsteinmed.edu  
718.430.2246  
<http://nandakumarlab.org>



## **Genetics of hematopoietic stem cell (HSC) clonal dynamics and leukemia predisposition**

Every day, each one of us produce hundreds of billions of specialized blood cells through a process of hematopoietic differentiation originating from a pool of long-lived hematopoietic stem cells (HSCs). As we age, some HSCs acquire mutations that causes them and their progeny to expand resulting in the formation of their own distinct “clones”. This condition known as clonal hematopoiesis is ubiquitous with advancing age affecting 10%-20% of population by the age of 70 years. Individuals with clonal hematopoiesis have an increased risk hematological malignancies such as leukemia and myelodysplastic syndromes. If we could identify and prevent such clones from expanding this can dramatically reduce risk for blood cancers. Despite its importance, we still don't understand why these clones emerge only in some individuals and why only a small subset of such carriers' eventually progresses to cancer?

Our laboratory leverages human genetic studies such as genome-wide association studies (GWAS) and studies on rare families to address these questions. Our goal is to identify and experimentally study germline risk variants that predispose individuals to clonal hematopoiesis and myeloid malignancies. Our recent work has uncovered a previously unappreciated mechanism by which inherited genetic variants influence clonal blood disorders by modulation of HSC function and self-renewal (Bao et al., *Nature* 2020; Bick et al., *Nature* 2020).

Our approach is to model genetic risk variants into primary human hematopoietic stem and progenitor cells using CRISPR/Cas9 approaches and study their impact on stem cell function and clonal expansion of mutant HSCs. We are developing engineered mouse models to study mechanisms of blood cancer predisposition. Since the majority of these genetic variants are in noncoding genomic regions, we are employing high throughput approaches that we have developed to systematically test their effects on transcriptional activity (Ulirsch et al., *Cell* 2016). Our studies will provide critical insights into how germline variants influence the emergence of clonal hematopoiesis and its progression to hematological malignancies.

### **Research Directions**

- 1) Mechanisms of germline predisposition to clonal hematopoiesis and leukemia.
- 2) Investigation of the role of interactions between germline and somatic variants in shaping hematopoietic stem cell clonal fitness.
- 3) Genome engineering of human normal, preleukemic and leukemic hematopoietic stem and progenitor cells using CRISPR/Cas9.
- 4) Application of multiplexed functional assays and genetic screens to prioritize germline genetic variants underlying clonal blood disorders.

### **Selected Publications**

Brown DW, Cato LD, Zhao Y, **Nandakumar SK**, Bao EL, Gardner EJ, Hubbard AK, DePaulis A, Rehling T, Song L, Yu K, Chanock SJ, Perry JRB, Sankaran VG, Machiela MJ. Shared and distinct genetic

etiologies for different types of clonal hematopoiesis. *Nat Commun.* (2023) DOI: [10.1038/s41467-023-41315-5](https://doi.org/10.1038/s41467-023-41315-5).

Voit RA, Tao L, Yu F, Cato LD, Cohen B, Fleming TJ, Antoszewski M, Liao X, Fiorini C, **Nandakumar SK**, Wahlster L, Teichert K, Regev A, Sankaran VG. A genetic disorder reveals a hematopoietic stem cell regulatory network co-opted in leukemia. *Nat Immunol.* (2023) DOI: [10.1038/s41590-022-01370-4](https://doi.org/10.1038/s41590-022-01370-4).

Bao EL\*, **Nandakumar SK\***, Liao X\*, Bick A, Karjalainen J, Tabaka M, Gan OI, Havulinna A, Kiiskinen TT, Lareau CA, FinnGen, 23andMe Research Team, Million Veteran Program, Regev A, Palotie A, Neale BM, Dick JE, Natarajan P, O'Donnell C, Daly MJ, Milyavsky M, Kathiresan S and Sankaran VG. Inherited myeloproliferative neoplasm risk impacts hematopoietic stem cells. *Nature.* (2020) \*Denotes equal contribution DOI: [10.1038/s41586-020-2786-7](https://doi.org/10.1038/s41586-020-2786-7)

Bick A\*, Weinstock J\*, **Nandakumar SK**, Fulco CP, Bao EL, Zekavat SM, Szeto MD, Liao X, .... Kitzman JO, Lander ES, Engreitz J, Ebert BL, Reiner AP, Jaiswal S, Abecasis G, Sankaran VG, Kathiresan S, Natarajan P. Inherited causes of clonal hematopoiesis in 97,691 whole genomes. *Nature.* (2020) DOI: [10.1038/s41586-020-2819-2](https://doi.org/10.1038/s41586-020-2819-2)

**Nandakumar SK\***, Liao X\*, Sankaran VG. In The Blood: Connecting Variant to Function In Human Hematopoiesis. *Trends in Genetics.* (2020) DOI: [10.1016/j.tig.2020.05.006](https://doi.org/10.1016/j.tig.2020.05.006)

**Nandakumar SK\***, McFarland SK\*, Mateyka LM, Lareau CA, Ulirsch JC, Ludwig LS, Agarwal G, Engreitz JM, Przychodzen B, McConkey M, Cowley GS, Doench JG, Maciejewski JP, Ebert BL, Root DE, Sankaran VG. Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis. *eLife.* (2019) DOI: [10.7554/eLife.44080](https://doi.org/10.7554/eLife.44080).

Guo MH\*, **Nandakumar SK\***, Ulirsch JC, Zekavat SM, Buenrostro JD, Natarajan P, Salem RM, Chiarle R, Mitt M, Kals M, .... Metspalu A, Lander ES, Kathiresan S, Hirschhorn JN, Esko T, Sankaran VG. Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms. *Proceedings of the National Academy of Sciences.* (2017) \*Denotes equal contribution DOI: [10.1073/pnas.1619052114](https://doi.org/10.1073/pnas.1619052114).

Ulirsch JC\*, **Nandakumar SK\***, Wang L, Giani FC, Zhang X, Rogov P, Melnikov A, McDonel P, Do R, Mikkelsen TS, Sankaran VG. Systematic Functional Dissection of Common Genetic Variation Affecting Red Blood Cell Traits. *Cell.* (2016) \*Denotes equal contribution DOI: [10.1016/j.cell.2016.04.048](https://doi.org/10.1016/j.cell.2016.04.048).

**Nandakumar SK\***, Ulirsch JC\*, Sankaran VG. Advances in understanding erythropoiesis: evolving perspectives. *British Journal of Haematology.* (2016) DOI: [10.1111/bjh.13938](https://doi.org/10.1111/bjh.13938).

**Nandakumar SK#**, Johnson K, Throm SL, Pestina TI, Neale G, Persons DA. Low-level GATA2 overexpression promotes myeloid progenitor self-renewal and blocks lymphoid differentiation in mice. *Experimental hematology.* (2015) DOI: [10.1016/j.exphem.2015.04.002](https://doi.org/10.1016/j.exphem.2015.04.002). #Corresponding author.

**Google Scholar Link**

<https://scholar.google.com/citations?hl=en&user=26VxhU0AAAAJ>

Charles Query, M.D., Ph.D

Professor

CHANIN BLDG. – ROOMS 415 & 415B


718 430-4174

charles.query@einsteinmed.edu



## RNA Processing – Mechanisms and Disease

Intron removal, a defining feature of eukaryotic cell biology, is catalyzed in two chemical steps by the spliceosome, a 60S complex composed of 5 snRNAs and >100 proteins. We study spliceosome function and spliceosomal mutations. We think about it as a complex engine and want to understand how it works.




**Do variant snRNAs make variant spliceosomes?** One ‘black hole’ in RNA biology is the identification of 50-300nt RNAs, missing in modern-day sequencing datasets. Vertebrate genomes reveal hundreds of snRNA gene loci; with few exceptions, only the most abundant canonical snRNAs have been investigated. We found that expression of variant-snRNAs changes greatly during development. We are investigating how this impacts spliceosome function.

snRNA	Mature Length	Annotated Loci
U1	163	143
U2	190	70
U4	143	91
U5	116	32
U6	106	1333
U4atac	127	18
U6atac	126	41

**Catalytic center interactions.** RNA–RNA base pairing of U2 snRNA to the intron branch site (BS) is essential for spliceosome assembly and first-step catalysis. We developed an orthogonal system, wherein a second-copy U2 with grossly substituted BS-U2 base-pairs mediates splicing of a cognate reporter gene. This produces a non-essential second spliceosome that can be characterized in vivo. These properties allowed us to test whether the BS-U2 duplex exists at the time of first-step catalysis. (It does.)

**What is the second-step catalytic core?** The BS-U2 duplex does not remain for the second step. We are using our orthogonal systems to elucidate a 3'SS binding site within the second-step core, demonstrating that the first-step branch structure becomes partially unpaired from U2-GUAGUA, allowing the 3'SS to bind on U2 snRNA.




**Splicing and disease.** U2 snRNP protein SF3b1 and other U2 proteins are highly mutated in myelodysplastic syndromes, AML, and other cancers. However, there has been no information regarding U2 snRNA mutations. Our analysis of U2 variant loci and novel bioinformatic pipelines allowed us to interrogate U2 RNA mutations in >1000 whole genome sequences (WGS) from the Cancer Genome Atlas (TCGA). We identified mutations in both U2-1 and U2-2 snRNAs, within the branch-recognition stem-loop (BSL), recurrent in bladder cancer (BLCA); we identified the same mutations in bladder cancer organoid lines (Lee et al., Cell 2018). The BSL contributes to recognition of the branch site as well as 3'SS. Using CRISPR-Cas9 edited human cell lines, we are investigating molecular

consequences of these U2 mutations and the mechanism of resultant splicing changes, which so far suggests previously unsuspected functions for U2 snRNP.

BLCA

● U2-1  
● U2-2



BSL = branch recognition stem-loop

BMSL = branch helix-mimicking stem-loop: Wojtek Galej, Science 2022

## Recent Publications (selected)

Maron, M.I., Casill, A.D., Gupta, V., Roth, J.S., Sidoli, S., Query, C.C., Gamble, M.J., and Shechter, D. (2022). Type I and II PRMTs inversely regulate post-transcriptional intron detention through Sm and CHTOP methylation. *Elife*: e72867. doi: 10.7554/eLife.72867. PMID34984976 PMC8765754

Shao, W., Ding, Z., Zheng, Z.-Z., Shen, J.-J., Shen, Y.-X., Pu, J., Fan, Y.-J., Query, C.C. and Xu, Y.-Z. (2020). Prp5–Spt8/Spt3 interaction mediates a reciprocal coupling between splicing and transcription. *Nucleic Acids Research* **48**, 5799–5813. PMID32399566 PMC7293005

Highlighted as a “Breakthrough Paper”: <http://www.narbreakthrough.com/2020/05/13/prp5>.

Kosmyna, B.T., Gupta, V., and Query, C.C. (2020). Transcriptional analysis supports the expression of human snRNA variants and reveals U2 snRNA homeostasis by an abundant U2 variant. *bioRxiv* doi: <https://doi.org/10.1101/2020.01.24.917260>.

Bowman, T.V. and Query, C.C. (2020). Are all splicing mutations the same? *Blood* **135**, 978–979. [Blood Comment] doi:10.1182/blood.2020005032. PMID32219349.

Tang, Q.\*, Rodriguez Santiago, S.\*, Wang, J., Pu, J., Yuste-Rivero, A., Gupta, V., Moldón, A., Xu, Y.-Z., and Query, C.C. (2016). SF3B1/Hsh155 HEAT motif mutations affect interaction with the spliceosomal ATPase Prp5, resulting in altered branch site selectivity in pre-mRNA splicing. *Genes & Development* **30**, 2710–2723. PMID28087715 PMC5238730.

Kosmyna, B., and Query, C.C. (2016). Structural Biology: Catalytic spliceosome captured. *Nature* **537**, 175–176. PMID27509853.

Wu, G., Adachi, H., Stephenson, D., Query, C.C., and Yu, Y.-T. (2016). Pseudouridines in U2 snRNA stimulate the ATPase activity of Prp5 during spliceosome assembly. *EMBO Journal* **35**, 654–667. PMID26873591 PMC4801943.

Basak, A. and Query, C.C. (2014). A pseudouridine residue in the core of the spliceosome is part of the filamentous growth program in yeast. *Cell Reports* **8**, 966–973. PMC4425566.

Query, C.C. and Konarska, M.M. (2013). Structural Biology: Spliceosome’s core exposed. *Nature* **493**, 651–616. PMID19325619.

Yang F., Wang, X.-Y., Zhang, Z.-M., Pu, J., Fan, Y.-J., Zhou, J., Query, C.C., and Xu, Y.-Z. (2013). Splicing proofreading at 5' splice sites by ATPase Prp28p. *Nucleic Acids Research* **41**, 4660–4670. PMID23462954 PMC3632134.

Query, C.C. and Konarska, M.M. (2012) CEF1/CDC5 alleles modulate transitions between catalytic conformations of the spliceosome. *RNA* **18**, 1001–1013. PMID22408182 PMC3334688.

Trcek, T., Larson, D.R., Moldón, A., Query, C.C., and Singer, R.H. (2011). Single molecule mRNA decay measurements reveal promoter regulated mRNA stability in yeast. *Cell* **147**, 1473–1483. PMID22196726 PMC3286490.

Moldón, A., and Query, C.C. (2010). Crossing the exon. *Molecular Cell* **38**, 159–161. PMID20417595.

Smith, D.J., Konarska, M.M., and Query, C.C. (2009). Insights into branch nucleophile positioning and activation from an orthogonal pre-mRNA splicing system in yeast. *Molecular Cell* **34**, 333–343. PMID19450531 PMC2730498.

Smith, D., Query, C.C., and Konarska, M.M. (2008). Nought may endure but mutability: Spliceosome Dynamics and the Regulation of Splicing. *Molecular Cell* **30**, 657–666. PMID18570869.

Xu, Y.-Z. and Query, C.C. (2007). Competition between the ATPase Prp5 and branch region–U2 snRNA pairing modulates fidelity of spliceosome assembly. *Molecular Cell* **28**, 838–849. PMID18082608 PMC2246091.

Liu, L., Query, C.C., and Konarska, M.M. (2007). Opposing classes of prp8 alleles modulate the transition between the catalytic steps of pre-mRNA splicing. *Nature Struct. Mol. Biol.* **14**, 519–526. PMID17486100.

Konarska, M.M., Vilardell, J. and Query, C.C. (2006). Repositioning of the reaction intermediate within the catalytic center of the spliceosome. *Molecular Cell* **21**, 543–553. PMID16483935.

**MATTHEW D. SCHARFF, M.D.**  
**Professor**

**CHANIN BLDG. – ROOM 404**  
**718 430-3527**  
**matthew.scharff@einsteinmed.edu**



Our laboratory is studying how antibody-forming cells respond to antigen by undergoing somatic hypermutation and class switch recombination so that they can produce higher affinity protective antibodies with more useful effector functions. To examine the detailed molecular mechanisms of variable region hypermutation, we are studying how mutation is targeted to antibody genes in a human Burkitt's lymphoma cell line that is undergoing activation deaminase (AID) induced variable region mutation in culture. The analysis of these events also involves the examination of how changes in the DNA sequence of antibody genes, chromatin structure and transcriptional elongation lead to the targeting and regulation of AID. The role and evolution of the antibody V region sequence is also being analyzed computationally using large data bases of the human antibody responses.

We are also the schoolwide Hybridoma Facility that helps investigators throughout the institution to make their own monoclonal antibodies.

### **Selected References:**

- 1) Recombinase-mediated cassette exchange as a novel method to study somatic hypermutation in Ramos cells. Baughn LB, Kalis SL, MacCarthy T, Wei L, Fan M, Bergman A, Scharff MD. *MBio*. 2011 Oct 11;2(5). pii: e00186-11. doi: 10.1128/mBio.00186-11. Print 2011. PMID: 21990614 [PubMed - in process] **Free Article**
- 2) Intra-clonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Calissano C, Damle RN, Marsilio S, Yan XJ, Yancopoulos S, Hayes G, Emson C, Murphy EJ, Hellerstein MK, Sison C, Kaufman MS, Kolitz JE, Allen SL, Rai KR, Ivanovic I, Dozmorov IM, Roa S, Scharff MD, Li W, Chiorazzi N. *Mol Med*. 2011 Sep 23. doi: 10.2119/molmed.2011.00360. [Epub ahead of print] PMID: 21968788 [PubMed - as supplied by publisher] **Free Article**
- 3) The ATPase activity of MLH1 is required to orchestrate DNA double-strand breaks and end processing during class switch recombination. Chahwan R, van Oers JM, Avdievich E, Zhao C, Edelmann W, **Scharff MD**, Roa S. *J Exp Med*. 209:671-8, 2012
- 4) AIDing antibody diversity by error-prone mismatch repair. Chahwan R, Edelmann W, Scharff MD, Roa S. *Semin Immunol*. 2012 Aug;24(4):293-300. Epub 2012 Jun 14. PMID: 22703640 PMC3422444
- 5) IGHV unmutated and mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. Patten PE, Chu CC, Albesiano E, Damle RN, Yan XJ, Kim D, Zhang L, Magli AR, Barrientos J, Kolitz JE, Allen SL, Rai KR, Roa S, Mongini PK, MacCarthy T, **Scharff MD**, Chiorazzi N. *Blood*. 2012 Oct 15. [Epub ahead of print] PMID: 23071276 PMC352062
- 6) AID and Apobec3G haphazard deamination and mutational diversity. Jaszczur M, Bertram JG, Pham P, **Scharff MD**, Goodman MF. *Cell Mol Life Sci*. 2012 Nov 22. [Epub ahead of print] PMID: 23178850 [PubMed - as supplied by publisher]
- 7) A source of the single stranded DNA substrate for activation induced deaminase during somatic hypermutation. Xiaohua Wang, Manxia Fan, Susan Kalis, Lirong Wei, **Matthew D. Scharff** *Nat. Communications* 2014 Jun 13;5:4137. doi: 10.1038/ncomms5137. PMID: 24923561 PMCID: PMC4154566

- 8) Overlapping hotspots in CDRs are critical sites for V region diversification. Wei L, Chahwan R, Wang S, Wang X, Pham PT, Goodman MF, Bergman A, **Scharff MD**, MacCarthy T. *Proc Natl Acad Sci U S A*. 2015 Feb 17;112(7):E728-37. doi: 10.1073/pnas.1500788112. Epub 2015 Feb 2. PMID: PMC4343087
- 9) Human Immunodeficiency Virus Tat Protein Aids V Region Somatic Hypermutation in Human B Cells. Wang X, Duan Z, Yu G, Fan M, **Scharff MD**. *MBio*. 2018 Apr 17;9(2). pii: e02315-17. doi: 10.1128/mBio.02315-17. PMID: 29666292 **Free PMC Article**
- 10) CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation. Bartholdy BA, Wang X, Yan XJ, Pascual M, Fan M, Barrientos J, Allen SL, Martinez-Climent JA, Rai KR, Chiorazzi N, **Scharff MD**, Roa S. *Blood Adv*. 2020 Mar 10;4(5):893-905..PMID: 32150608 **Free PMC Article**
- 11) AID overlapping and Polη hotspots are key features of evolutionary variation within the human antibody heavy chain (IGHV) genes. 2020. Catherine Tang<sup>1</sup>, Davide Bagnara<sup>2,3</sup>, Nicholas Chiorazzi<sup>2</sup>, **Matthew D. Scharff**<sup>4</sup>, Thomas MacCarthy<sup>1</sup> *Front Immunol*. 2020 Apr 30;11:788. doi: 10.3389/fimmu.2020.00788. eCollection 2020.PMID: 32425948
- 12) Post-transformation IGHV-IGHD-IGHJ mutations in chronic lymphocytic leukemia B cells: Implications for mutational mechanisms and impact on clinical course. Davide Bagnara, Catherine Tang, Jennifer Brown, Siddha Kasar, Stacey Fernandes, Monica Colombo, Stefano Vergani, Andrea Mazzarello, Fabio Ghiotto, Silvia Bruno, Fortunato Morabito, Kanti R Rai, Jonathan E Kolitz, Jacqueline C Barrientos, Steven L Allen, Franco Fais, **Matthew D Scharff**, Thomas MacCarthy, Nicholas Chiorazzi; *Front Oncol*. 2021 May 25;11:640731. doi: 10.3389/fonc.2021.640731. eCollection 2021.
- 13) [Role of Dot1L and H3K79 methylation in regulating somatic hypermutation of immunoglobulin genes.](#) Duan Z, Baughn LB, Wang X, Zhang Y, Gupta V, MacCarthy T, **Scharff MD**, Yu G. *Proc Natl Acad Sci U S A*. 2021 Jul 20;118(29):e2104013118. doi: 10.1073/pnas.2104013118. PMID: 3425361\*
- 14) A Bayesian model based computational analysis of the relationship between bisulfite accessible single-stranded DNA in chromatin and somatic hypermutation of immunoglobulin genes. Guojun Yu, Yingru Wu, Zhi Duan, Catherine Tang, Haipeng Xing, Matthew D Scharff, **Thomas MacCarthy** *PLoS Comput Biol*. 2021 17:e1009323. PMID: 34491985.
- 15) The role of HIRA-dependent H3.3 deposition and its modifications in the somatic hypermutation of immunoglobulin variable regions Guojun Yu, Yongwei Zhang, Varun Gupta, Jinghang Zhang, Thomas MacCarthy, Zhi Duan, Matthew D. Scharff, *Proc Natl Acad Sci U S A*. 2021 Dec 14;118(50):e2114743118. doi: 10.1073/pnas.2114743118.PMID: 34873

**CARL SCHILDKRAUT, Ph.D.**  
**Professor**

**CHANIN BLDG. – Room 416**  
**(718) 430-2097**  
**carl.schildkraut@einsteinmed.edu**



**Our laboratory is a part of the Einstein Center for Human Embryonic Stem Cell Research and the Cancer Center.**

## **Molecular Analysis of DNA Replication and Repair in Alzheimer's Disease and at Cancer-Associated Sites in the Human Genome**

A major interest of our lab is the organization and regulation of the DNA replication program in mammalian cells and its effect on gene expression. One area we have been concentrating on the role of DNA replication in neuronal diseases such as Alzheimer's. Alzheimer's disease (AD) is a neuro-degenerative disease that has been studied for more than three decades. Surprisingly after all this effort, there is still no unequivocal treatment, and the cause is not known.

We are also focused on understanding the role of genomic instability at human chromosomal fragile sites in cancer and aging.


Genome instability occurs in the early development of many cancers and other diseases and is thought to be caused by replication fork stalling. This is clinically relevant since most current cancer therapies are based on radiation or chemotherapeutic agents that stall or block forks. Manipulating cellular responses to fork stalling may therefore prove crucial in improving effectiveness of current chemotherapies.

### **Long term interests:**

- Difficult to replicate regions accumulate secondary structures which, if not properly resolved, may block DNA replication fork movement and lead to genome instability. We are studying mechanisms to resolve these barriers for efficient and faithful DNA replication.
- The role of DNA replication of genes involved in neurological diseases such as Alzheimer's. We will examine critical genes in the brain that undergo mutations with aging.
- Genome protection by telomeres.
- Aneuploidy leading to infertility and pregnancy loss.
- Mechanisms leading to breaks at sites that result in chromosomal rearrangements frequently detected in cancer cells.

### **Current projects include a wide range of interests:**

- The replication of two repeated sequence DNAs that are involved in Alzheimer's disease: alpha satellite DNA and the ribosomal DNA genes.
- The DNA2 nuclease/helicase can cleave G-quadruplex structures which are one of the most common non-B structures present in DNA. We study the effect on the deletion of DNA2 on DNA replication.
- Replication of the alpha satellite DNA at centromeres of specific human chromosomes. These include chromosome 21 and the Y chromosome. The Y chromosome is lost with aging, and we are studying the



**INDIVIDUAL FLUORESCENT DNA  
MOLECULES FROM CELLS SHOWING  
DIRECTION OF REPLICATION**


replication of this chromosome to understand more about this loss. Chr 21 undergoes trisomy in Down syndrome and people with Down syndrome have a higher risk of getting Alzheimer's symptoms.

#### SELECTED PUBLICATIONS:

1. Twayana S, Bacolla A, Barreto-Galvez A, De-Paula RB, Drosopoulos WC, Kosiyatrakul ST, Bouhassira EE, Tainer JA, Madireddy A, **Schildkraut CL**. 2021. Translesion polymerase eta both facilitates DNA replication and promotes increased human genetic variation at common fragile sites. *Proc Natl Acad Sci U S A*. 118 PMID: 34815340.
2. Mei Y, Deng Z, Vladimirova O, Gulve N, Johnson FB, Drosopoulos WC, Schildkraut CL, Lieberman PM. (2021). TERRA G-quadruplex RNA interaction with TRF2 GAR domain is required for telomere integrity. (2021) *Sci Rep*. 11:3509. doi: 10.1038/s41598-021-82406-x. PMID: 33568696.
3. Drosopoulos WC, Vierra DA, Kenworthy CA, Coleman RA and Schildkraut CL. (2020). Dynamic assembly and disassembly of the human DNA polymerase  $\delta$  holoenzyme on the genome in vivo. *Cell Reports*, 30 1329-1341.e5. PMID: 32023453.
4. Chakraborty A, Jenjaroenpun P, Li J, McCulley A, El Hilali S, Haarer B, Hoffman EA, Belak A, Thorland A, Hehnly H, Schildkraut CL, Chen C, Kuznetsov VA, and Feng W. (2020) Replication stress induces global chromosome breakage in the Fragile X genome. *Cell Reports*. 32. Article 108179.
5. Drosopoulos WC, Deng Z, Twayana S, Kosiyatrakul ST, Vladimirova O, Lieberman PM, Schildkraut CL. 2020 TRF2 Mediates Replication Initiation within Human Telomeres to Prevent Telomere Dysfunction. *Cell Rep*.33:108379. doi: 10.1016/j.celrep.108379. PMID: 33176153.
6. Pan X, Drosopoulos WC, Sethi L, Madireddy A, Schildkraut CL, Zhang D (2017) FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres.. *Proc Natl Acad Sci U S A* :E5940-E5949. PMID: 28673972
7. Madireddy, A., Kosiyatrakul, S., Boisvert, R.A., Moyano, E.H., García-Rubio, M.L., Gerhardt, J., Vuono, E.A., Owen, N., Yan, Z., Olson, S., Aguilera, A., Howlett, N., and Schildkraut, C.L. (2016). FANCD2 facilitates replication through common fragile sites. *Molecular Cell*. 2016; 64:388-404. PMID: 27768874.
8. Gerhardt, J., M. J. Tomishima, N. Zaninovic, D. Colak, Z. Yan, Q. Zhan, Z. Rosenwaks, S. R. Jaffrey, and C. L. Schildkraut. (2013). The DNA Replication Program is Altered at the FMR1 Locus in Fragile X Embryonic Stem Cells. *Mol Cell*. 2014 ;153 19-31. PMCID: PMC3920742
9. Verma, S. C., J. Lu, Q. Cai, S. Kosiyatrakul, M. E. McDowell, C. L. Schildkraut, and E. S. Robertson. (2011). Single Molecule Analysis of Replicated DNA Reveals the Usage of Multiple KSHV Genome Regions for Latent Replication. *PLoS Pathog* 7:e1002365. PMCID: 3207954.
10. Sfeir, A., S. T. Kosiyatrakul, D. Hockemeyer, S. L. MacRae, J. Karlseder, C. L. Schildkraut, and T. de Lange. (2009). Mammalian Telomeres Resemble Fragile Sites and Require TRF1 for Efficient Replication. *Cell* 138:90-103. PMCID: 2723738.
11. Norio, P., Schildkraut, C.L. (2001). Visualization of DNA Replication on Individual Epstein-Barr Virus Episomes. *Science* 294: 2361-2364

**Dr. Robert H. Singer**  
**Professor**

**Golding 601**  
**Phone: 718-430-8646**  
**[einsteinmed.edu/labs/robert-singer](http://einsteinmed.edu/labs/robert-singer)**




## FOLLOWING THE TRAVELS OF RNA

Our work is focused on the expression and travels of RNA within the cell: from the site of its birth to its ultimate biological destiny in the cytoplasm where it makes proteins in specific locations.


Our new technology, based on in situ hybridization allows us to visualize specific nucleic acid sequences within individual cells. Synthetic nucleic acid probes are labeled with fluorochromes. Subsequently these molecules are hybridized to the cell and detected using high resolution digital imaging microscopy.

We have developed imaging methodologies and algorithms capable of detecting a single RNA molecule within a cell. This enables the detection of specific nucleic acid molecules for comparison between normal or cancer cells. This method of molecular diagnosis is the clinical application of the technology. As an additional result of this approach, we have found specific RNA sequences located in particular cellular compartments. An example is the messenger RNA for beta-actin, which is located in the periphery of the cell where actin protein is needed for cell motility. These transcripts are not free to diffuse, and appear to be associated with a cellular matrix or skeleton from the moment of their synthesis through translation.



We are investigating how this spatial information is encoded within the gene and how the RNA transcript is processed within the nucleus and then transported to its correct compartment in the cytoplasm, resulting in asymmetric protein distribution.

RNA localization also occurs in yeast. During budding, a nuclear factor represses mating type switching asymmetrically, only in the daughter cell. This is because the factor is synthesized only in the bud because the mRNA was transported there by a motor, myosin. This discovery has provided a model by which to investigate the mechanisms responsible for moving RNA within the cell. For example, we have constructed genetically altered yeast and vertebrate cells in order to elucidate the sequences responsible for mRNA localization. A reporter gene can be "delivered" to a variety of cellular compartments by using specific sequences, or "zipcodes" from the mRNAs found in those compartments. These "zipcodes" consist of short sequences in the 3' untranslated region of the mRNA.



*Detection of mRNA movement in living yeast (Bertrand et al, 1998)*

Recently we have developed technology that allows us to image RNA movement in living cells and tissues and characterize how the motors connect with and drive the RNA. Recent developments have allowed us to visualize transcription and RNA life cycle from birth to death in transgenic mice, including translation of single mRNAs. We have labelled a number of genes in mice that are important in neuronal function and can image their mRNAs in cultured neurons and in brain tissue. The imaging reveals a complicated pathway for the mRNAs to arrive at sites of synaptic contact and translate in order to consolidate proteins into local "hotspots". This represents the molecular basis of memory formation.

## **Selected Publications:**

Das S, Lituma PJ, Castillo PE, Singer RH. Maintenance of a short-lived protein required for long-term memory involves cycles of transcription and local translation. *Neuron*. 2023 Apr 19;S0896-6273(23)00267-2. doi: 10.1016/j.neuron.2023.04.005. Epub ahead of print. PMID: 37100055.

Desai RV, Chen X, Martin B, Chaturvedi S, Hwang DW, Li W, Yu C, Ding S, Thomson M, Singer RH, Coleman RA, Hansen MMK, Weinberger LS. "A DNA repair pathway can regulate transcriptional noise to promote cell fate transitions." *Science*. 2021 Aug 20;373(6557):eabc6506.

Wheat JC, Sella Y, Willcockson M, Skoultchi AI, Bergman A, Singer RH, Steidl U. "Single-molecule imaging of transcription dynamics in somatic stem cells." *Nature*. 2020 Jul;583(7816):431-436.

Wu B, Eliscovich C, Yoon YJ, Singer RH (2016). "Translation dynamics of single mRNAs in live cells and neurons." *Science* 352(6292):1430-1435

Halstead, J. M., T. Lionnet, J. H. Wilbertz, F. Wippich, A. Ephrussi, R. H. Singer and J. A. Chao (2015). "Translation. An RNA biosensor for imaging the first round of translation from single cells to living animals." *Science* 347(6228): 1367-1671

Wu, B., Buxbaum AR, Katz ZB, Yoon YJ, Singer RH, (2015) Quantifying Protein-mRNA Interactions in Single Cell Live Cells. *Cell* 162(1):211-20

Buxbaum AR, Wu B, Singer RH, (2014) Single  $\beta$ -Actin mRNA Detection in Neurons reveals a Mechanism for Regulating Its Translatability. *Science* 343(6169):419-422

Park HY, Lim H, Yoon YJ, Follenzi A, Nwokafor C, Lopez-Jones M, Meng X, Singer RH, (2014) Visualization of Dynamics of Single Endogenous mRNA Labeled in Live Mouse. *Science* 343(6169):422-424

Trcek T, Larson DR, Moldón A, Query CC, Singer RH, (2011) Single-Molecule mRNA Decay Measurements Reveal Promoter-Regulated mRNA Stability in Yeast. *Cell* 147:1484-1497

Larson DR, Zenklusen D, Wu B, Chao JA, Singer RH, (2011) Real-Time Observation of Transcription Initiation and Elongation on an Endogenous Yeast Gene. *Science* 332:475-478

Grünwald D, Singer RH, (2010) In vivo imaging of labelled endogenous  $\beta$ -actin mRNA during nucleocytoplasmic transport. *Nature* 467:604-607

Huttelmaier S, Zenklusen D, Lederer M, Dichtenberg J, Lorenz M, Meng X, Bassell GJ, Condeelis J, Singer RH, (2005) Spatial regulation of beta-actin translation by Src-dependent phosphorylation of ZBP1. *Nature* 438:512-515.

Shav-Tal Y, Darzacq X, Shenoy SM, Fusco D, Janicki SM, Spector DL, Singer RH (2004) Dynamics of single mRNPs in nuclei of living cells. *Science* 304:1797-1800

Janicki SM, Tsukamoto T, Salghetti SE, Tansey WP, Sachidanandam R, Prasanth KV, Ried T, Shav-Tal Y, Bertrand E, Singer RH, Spector DL. (2004) From silencing to gene expression: Real-time analysis in single cells. *Cell* 116:683-698

Levsky JM, Shenoy SM, Pezo RC, Singer RH. (2002) Single-cell gene expression profiling. *Science* 297: 836-840

Singer RH. (1998) Triplet-repeat transcripts: A role for RNA in disease. *Science* 280:696-697

Femino AM, Fay FS, Fogarty K, Singer RH. (1998) Visualization of single RNA transcripts in situ. *Science* (Cover Article) 280:585-590

**ARTHUR I. SKOULTCHI, Ph.D.**

**Professor of Cell Biology**

**Judith and Burton P. Resnick Endowed Chair**     **CHANIN CANCER CENTER**

**ROOM 402**

**718-430-2169**

***arthur.skoultchi@einsteinmed.edu***



***Key Words: Chromatin, epigenetics, transcription, proliferation, differentiation, leukemia***

Our laboratory is interested in understanding the mechanisms controlling mammalian development and cell differentiation. We study the epigenetic functions of chromatin proteins and transcription factors in control of gene expression in embryonic stem cells, in red blood cells, and in *Drosophila*. Our approaches involve directed gene inactivation and transgenesis in mice and *Drosophila*. We also study control of proliferation and differentiation in red blood cell progenitors and in leukemia cells in which normal development is disrupted. Currently there are two major projects underway in the lab.

**Role of H1 Linker Histones and Chromatin Remodeling Factors in Chromatin Structure, DNA Methylation, the Histone Code, Gene Expression and Development in Mice and *Drosophila*.** Recent studies show that posttranslational modifications of core histones (H2A, H2B, H3, H4) (the Histone Code) play a very important role in control of gene expression. The H1 linker histones are more diverse than the core histones. Mice contain 8 H1 histone subtypes including differentiation-specific and tissue-specific subtypes, whereas *Drosophila* has only one type of H1. H1's are thought to be responsible for the final level of packaging DNA into the compact chromatin structure but we know very little about their role in gene expression and development. We are studying the functional roles of H1 linker histones by inactivating (knocking-out) specific H1 genes in mice and the single H1 in *Drosophila*. We are also reintroducing mutant H1 linker histones into H1 depleted mouse cells and flies, to perform structure-function studies. We have also established a new role for H1 histone in DNA methylation, genomic imprinting and establishment of the histone code. We are also studying the chromatin remodeling factor that assembles H1 histone into chromatin.

**Control of Proliferation and Differentiation in Normal and Leukemic Blood Cells:** In this project we are investigating how cell proliferation and differentiation are coordinated in normal blood cell development and how this coordination is disrupted in leukemia. We have investigated the molecular mechanisms for the cross talk between these two cellular programs in normal and leukemic blood cells. Our studies are focused on the relationships between the master transcription factors that control blood cell development and the cell cycle regulators (cyclins, cyclin-dependent kinases (cdks), cdk inhibitors and RB) that regulate the cell division cycle proliferation. This project includes genome-wide approaches involving chromatin immunoprecipitation and high throughput sequencing (ChIP-Seq) and gene expression profiling by RNA-Seq.

### **Selected Publications:**

Willcockson, M. A., S. E. Heaton, C. N. Weiss, B. A. Bartholdy, Y. Botbol, L. N. Mishra, D. S. Sidhwani, T. J. Wilson, H. B. Pinto, M. I. Maron, K. A. Skalina, L. N. Toro, J. Zhao, C. H. Lee, H. Hou, N. Yusufova, C. Meydan, A. Osunsade, Y. David, E. Cesarman, A. M. Melnick, S. Sidoli, B. A. Garcia, W. Edelmann, F. Macian and A. I. Skoultchi (2021). "H1 histones control the epigenetic landscape by local chromatin compaction." *Nature* 589(7841): 293-298.

Yusufova, N., et al. (2021). "Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture." *Nature* 589(7841): 299-305.

Heaton, S. E., H. D. Pinto, L. N. Mishra, G. A. Hamilton, J. C. Wheat, K. Swist-Rosowska, N. Shukeir, Y. Dou, U. Steidl, T. Jenuwein, M. J. Gamble and A. I. Skoultchi (2020). "H1 linker histones silence repetitive elements by promoting both histone H3K9 methylation and chromatin compaction." *Proc Natl Acad Sci U S A* 117(25): 14251-14258.

Sollberger, G., R. Streeck, F. Apel, B. E. Caffrey, A. I. Skoultschi and A. Zychlinsky (2020). "Linker histone H1.2 and H1.4 affect the neutrophil lineage determination." *Elife* 9.

Willcockson, M. A., S. J. Taylor, S. Ghosh, S. E. Healton, J. C. Wheat, T. J. Wilson, U. Steidl and A. I. Skoultschi (2019). "Runx1 promotes murine erythroid progenitor proliferation and inhibits differentiation by preventing Pu.1 downregulation." *Proc Natl Acad Sci U S A* 116(36): 17841-17847.

Fyodorov, D. V., B. R. Zhou, A. I. Skoultschi and Y. Bai (2018). "Emerging roles of linker histones in regulating chromatin structure and function." *Nat Rev Mol Cell Biol* 19(3): 192-206.

Andreyeva, E. N., T. J. Bernardo, T. D. Kolesnikova, X. Lu, L. A. Yarinich, B. A. Bartholdy, X. Guo, O. V. Posukh, S. Healton, M. A. Willcockson, A. V. Pindyurin, I. F. Zhimulev, A. I. Skoultschi and D. V. Fyodorov (2017). "Regulatory functions and chromatin loading dynamics of linker histone H1 during endoreplication in *Drosophila*." *Genes Dev* 31(6): 603-616.

Kokavec J, et al. (2017). The ISWI ATPase Smarca5 (Snf2h) Is Required for Proliferation and Differentiation of Hematopoietic Stem and Progenitor Cells. *Stem Cells*. 35(6):1614-1623.

Kavi, H., Emelyanov A.C., Fyodorov D.V. and A.I. Skoultschi (2016). Independent Biological and Biochemical Functions for Individual Structural Domains of *Drosophila* Linker Histone H1. *J Biol Chem* 291(29):15143-15155.

Geeven, G., Zhu Y., Kim B.J., Bartholdy B.A., Yang S.M., Macfarlan T.S., Gifford W.D., Pfaff S.L., Verstegen M.J., Pinto H., Vermunt M.W., Creighton M.P., Wijchers P.J., Stamatoyanopoulos J.A., Skoultschi A.I., and W. de Laat. (2015). Local compartment changes and regulatory landscape alterations in histone H1-depleted cells. *Genome Biol* 16: 289.

Xu N., Emelyanov A.V., Fyodorov D.V., and Skoultschi A.I. (2014). *Drosophila* linker histone H1 coordinates STAT-dependent organization of heterochromatin and suppresses tumorigenesis caused by hyperactive JAK-STAT signaling. *Epigenetics Chromatin*. Jul 28;7:16.

Lu, X., Wontakal S.N., Kavi H., Kim B.J., Guzzardo P.M., Emelyanov A.V., Xu N., Hannon G.J., Zavadil J. Fyodorov D.V. and A.I. Skoultschi (2013). *Drosophila* H1 regulates the genetic activity of heterochromatin by recruitment of Su(var)3-9. *Science* 340(6128): 78-81.

Yang S.M., Kim B.J., Norwood-Toro L., A.I. Skoultschi. (2013) H1 linker histone promotes epigenetic silencing by regulating both DNA methylation and histone H3 methylation. *Proc Natl Acad Sci U S A*, 110(5):1708-13

Wontakal S.N., Guo X., Smith C., MacCarthy T., Bresnick E.H., Bergman A., Snyder M.P., Weissman S.M., Zheng D., A.I. Skoultschi (2012). A core erythroid transcriptional network is repressed by a master regulator of myelo-lymphoid differentiation. *Proc Natl Acad Sci USA* 6; 109(10):3832-7

Wontakal S.N., Guo X., Will B., Shi M., Raha D., Mahajan M.C., Weissman S., Snyder M., Steidl U., Zheng D., and A.I. Skoultschi. (2011). A Large Gene Network in Immature Erythroid Cells Is Controlled by the Myeloid and B Cell Transcriptional Regulator PU.1. *PLoS Genet* 7(6), e1001392.

Maclean, J.A., et al. (2011). The rbox homeobox gene cluster is imprinted and selectively targeted for regulation by histone h1 and DNA methylation. *Mol Cell Biol* 31,1275-1287.

Choe, K. S., O. Ujhelly, S. N. Wontakal, and A.I. Skoultschi (2010). PU.1 directly regulates CDK6 gene expression, linking the cell proliferation and differentiation programs in erythroid cells. *J. Biol. Chem.* 285(5):3044-3052 (Epub December 2, 2009).

Papetti, M., S. N. Wontakal, T. Stopka, and A.I. Skoultschi (2010). GATA-1 directly regulates p21 gene expression during erythroid differentiation. *Cell Cycle* 9(10):1972-1980. (Epub May 18, 2010).

Lu, X., S. N. Wontakal, A. V. Emelyanov, P. Morcillo, A. Y. Konev, D. V. Fyodorov, and A. I. Skoultschi. (2009). Linker histone H1 is essential for *Drosophila* development, the establishment of pericentric heterochromatin, and a normal polytene chromosome structure. *Genes Dev* 23:452-465.

Stopka, T., D. F. Amanatullah, M. Papetti, and A. I. Skoultschi. (2005). PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. *Embo J* 24:3712-3723.

Fan, Y., Nikitina, T., Zhao, J., Fleury, T.J., Bhattacharyya, R., Bouhassira, E.E., Stein, A., Woodcock, C.L., and Skoultschi, A.I. (2005). Histone H1 depletion in mammals alters global chromatin structure but causes specific changes in gene regulation. *Cell* 123:1199-1212.

**PAMELA STANLEY, Ph.D.**  
**Horace W. Goldsmith Foundation Chair**  
**Professor**

**CHANIN BLDG. – ROOM 516**  
**(718) 430-3346**

***pamela.stanley@einsteinmed.edu***

**<http://www.einstein.yu.edu/departments/cell-biology/faculty/stanley/home/>**



### **Glycan Functions in Development, Spermatogenesis and Notch Signaling**

Glycosylation is the most abundant and varied post-translational modification of proteins and is a critical factor in regulating their biological functions. The complement of glycans that may be produced by an organism is called the GLYCOME. Changes in glycans expressed on the cell surface occur during development and differentiation. Specific glycans on Notch receptors modulate signal transduction by Notch ligands. This is a novel paradigm of signal transduction whereby the transfer of a single sugar residue alters the ability of Notch receptors to signal. We are using cell-based glycosylation mutants, Notch signaling assays, glycosyltransferase gene knockout mice, and biochemical approaches including MALDI-TOF mass spectrometry, to identify biological functions of growth factor receptor and Notch glycans, and the underlying mechanisms by which glycans mediate biological events.

Notch receptors span the cell membrane. When a Notch ligand like Delta or Jagged on a neighboring cell, binds to a Notch receptor, it induces cleavage of Notch extracellular domain, followed by a second cleavage that releases Notch intracellular domain. The Notch intracellular domain goes to the nucleus and activates target genes that ultimately lead to a change in cell fate or cell growth control. Using a CHO glycosylation mutant that adds few O-fucose glycans to Notch extracellular domain, we showed that Notch signaling is markedly reduced when fucose is limiting. Using a panel of different CHO glycosylation mutants developed in this lab, we showed that inhibition of Notch signaling by the Fringe glycosyltransferase requires the addition of a Gal residue to O-fucose glycans on Notch. We are continuing to use Notch signaling assays to define the mechanisms of action of Fringe and other glycosyltransferases that modulate Notch signaling. We are also targeting glycosyltransferase genes that encode enzymes that modify Notch in the mouse and generating Notch mutants that cannot accept an O-fucose glycan at a specific site in Notch. Mice lacking O-fucose in the ligand binding domain have defective T cell development and are being investigated for other immunological defects. Mice lacking the three Fringe activities are affected in T and B cell development. The most recent modification of Notch is by O-GlcNAc and we are now exploring its functions in the regulation of Notch signaling in mammals.

We are also investigating roles for glycans in reproduction. We have found that MGAT1 and complex N-glycans are essential for spermatogenesis and male fertility, and we are testing the hypothesis that they play an important role in spermatid/Sertoli cell interactions. Small molecule inhibitors are being sought using an in silico docking screen of ~1 million compounds. Candidates will be tested in cell-based assays and ultimately in mice for contraceptive effects. We have shown that deletion of the glycoprotein basigin (CD147) in spermatogonia gives rise to a similar block in spermatogenesis and are investigating whether the N-glycans on basigin are responsible for that phenotype. We are also examining the consequences of deleting MGAT2 in spermatogonia to allow hybrid but not complex N-glycan synthesis.

Finally, Chinese hamster ovary (CHO) cell glycosylation mutants developed in this laboratory are used by us and many academic and biotech laboratories for a variety of purposes including to develop new methods such as a novel approach to tracking glycan epitopes on the cell surface, a method to analyse glycans expressed using scRNA-seq termed sgRNA-seq, assays for Notch and growth factor signaling, and assays to characterize glycosylation mutations that cause rare congenital disorders of glycosylation (CDG).

## Recent Publications

### [Genetics of glycosylation in mammalian development and disease.](#)

**Stanley P.** Nat Rev Genet. 2024 May 9. doi: 10.1038/s41576-024-00725-x. Online ahead of print. PMID: 38724711  
Review.

Nauman M, Varshney S, Choi J, Augenlicht A, **Stanley P.** (2023) EOGT enables residual Notch signaling in mouse intestinal cells lacking POFUT1. Sci Rep, 13(1):17473. doi: 10.1038/s41598-023-44509-5.

Tanwar A, **Stanley P** (2023) Synergistic regulation of Notch signaling by different O-glycans promotes hematopoiesis. Front Immunol 14:1097332. doi: 10.3389/fimmu.2023.1097332.-

Lu L, Varshney S, Yuan Y, Wei, H-X, Tanwar A, Sundaram S, Nauman M, Haltiwanger RS, **Stanley P.** (2023) In vivo evidence for GDP-fucose transport in the absence of transporter SLC35C1 and putative transporter SLC35C2. J Biol Chem 299:105406. doi: 10.1016/j.jbc.2023.105406.

Nauman M, and **Stanley P.** (2022) Glycans that regulate Notch signaling in the intestine. Biochem Soc Trans. 50(2):689-701. doi:10.1042/BST20200782 PMCID: PMC9370068

Matsumoto K, Kumar V, Varshney S, Nairn AV, Ito A, Pennarubia F, Moremen KW, \***Stanley P.** \*Haltiwanger RS. (2022) Fringe GlcNAc-transferases differentially extend O-fucose on endogenous NOTCH1 in mouse activated T cells. J Biol Chem. Epub 2022/05/28. doi:10.1016/j.jbc.2022.102064. Co-corresponding authors.

Nauman, M. and **Stanley, P.** (2022) Glycans that Regulate Notch Signaling in the Intestine. Biochem Soc Trans 50:689-701.

Akintayo A, Liang M, Bartholdy B, Batista F, Aguilan J, Prendergast J, Sabrin A, Sundaram S, **Stanley P.** (2020) The Golgi Glycoprotein MGAT4D is an Intrinsic Protector of Testicular Germ Cells From Mild Heat Stress. Sci Rep. 2020 Feb 7;10(1):2135. doi: 10.1038/s41598-020-58923-6.

Hong S, Feng L, Yang Y, Jiang H, Hou X, Guo P, Marlow FL, **Stanley P** and Wu P. (2020) In Situ Fucosylation of the Wnt Co-receptor LRP6 Increases Its Endocytosis and Reduces Wnt/ $\beta$ -Catenin Signaling. Cell Chem Biol S2451-9456(20)30238-5

Akintayo, A, Mayoral, J. Asada, M, Tang, J. Sundaram, S. and **Stanley, P.** (2020) Point Mutations that Inactivate MGAT4D-L, an Inhibitor of MGAT1 and Complex N-Glycan Synthesis. J Biol Chem 295, 14053-14064.

Biswas B, Barista F, Akintayo A, Aguilan J and **Stanley P.** (2020) Transgenic Rescue of Spermatogenesis in Males with *Mgat1* Deleted in Germ Cells. Front Cell Dev Biol 8:212. doi: 10.3389/fcell.2020.00212. PMCID: PMC714224

Biswas B, Batista F, Sundaram S, **Stanley P.** (2018) MGAT1 and Complex N-Glycans Regulate ERK Signaling During Spermatogenesis. Sci Rep. 2018 Jan 31;8(1):2022. doi: 10.1038/s41598-018-20465-3.

Sawaguchi S, Varshney S, Ogawa M, Sakaidani Y, Yagi H, Takeshita K, Murohara T, Kato K, Sundaram S, **Stanley P\***, Okajima T\*. (2017) O-GlcNAc on NOTCH1 EGF repeats regulates ligand-induced Notch signaling and vascular development in mammals. Elife Apr 11;6. pii: e24419. doi: 10.7554/eLife.24419.\*Co-corresponding authors.

A complete list of publications can be found at

<https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/40358567/?sort=date&direction=ascending>

**Ulrich Steidl, M.D., Ph.D.**  
**Professor & Chair**

**Chanin Bldg. – Room 601-605**  
**(718) 430-3437**  
**ulrich.steidl@einsteinmed.edu**  
**@SteidlUli www.steidl-lab.com**



## **Molecular Mechanisms in Normal, Pre-Malignant, and Leukemia Stem Cells**

Hematopoiesis maintains a life-long supply of the entire spectrum of highly specialized blood cells dependent on systemic needs. This process relies on a tightly regulated balance of self-renewal, commitment, and differentiation of a small number of pluripotent hematopoietic stem cells (HSC).

Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) arise from transformed hematopoietic stem (HSC) and progenitor cells. Cell-intrinsic as well as cell-extrinsic aberrations give rise to a highly diverse pool of pre-leukemic stem cells (pre-LSC), preceding the formation of fully transformed leukemia stem cells (LSC). Pre-LSC as well as LSC are characterized by a relative resistance to chemotherapy and thereby contribute to treatment failure. As a consequence, and despite the use of poly-chemotherapy and newer agents that transiently reduce the tumor burden, relapse continues to be the most common cause of death in most subtypes of MDS and AML. Defining the molecular characteristics, plasticity, and regulatory mechanisms governing pre-LSC and their subclonal diversity, dynamics, and progression to fully transformed LSC is critical to understanding the genesis of leukemia and to developing therapeutic strategies by which these cells can be eradicated.

Recent findings from our own group and others have demonstrated a critical role of key transcriptional regulators and mediators of aberrant signaling in the genesis and function of pre-LSC and LSC in AML and MDS in mouse and human model systems.

The goal of our research is to delineate mechanisms in HSC that drive formation, progression, and therapeutic resistance of pre-LSC and LSC. To identify and functionally study implicated pathways we are utilizing stem and progenitor cell subsets isolated by means of multi-parameter high-speed fluorescence-activated cell sorting (FACS). We are using experimental tools including at the single-molecule and single-cell level, as well as molecular biological methods for forced expression or inactivation of molecular targets, followed by in vitro as well as in vivo assays for stem and progenitor cell functions. This allows for assessing the function of candidate mechanisms in normal and leukemic stem cells. We are studying murine genetic models as well as primary human samples from patients with pre-leukemic conditions and leukemia. Our studies ultimately aim at the development of targeted, pre-LSC- and LSC-directed therapies.

### **Project areas in the lab include:**

- Mechanisms of leukemia pathogenesis at the (pre-leukemic) stem cell level
- Identification and study of novel molecular mechanisms and pathways governing normal and malignant hematopoiesis, including stem cell subclonal diversity, plasticity, and competition (focusing on transcription dynamics and signaling, incl. single-molecule and single-cell studies)
- Niche-mediated, cell-extrinsic mechanisms of stem cell regulation and identification
- Development and preclinical testing of novel therapeutics targeting aberrant stem cells
- Translational computational biology (e.g. integrated analysis of scRNA-seq, CUT&Tag, ATAC-seq, CITE-seq data etc.; including from longitudinally sampled, sorted / single stem cells from patients and mouse genetic models)

## Selected publications:

Taylor SJ, Stauber J, Bohorquez O, Tatsumi G, Kumari R, Chakraborty J, Bartholdy BA, Schwenger E, Sundaravel S, Farahat AA, Wheat JC, Goldfinger M, Verma A, Kumar A, Boykin DW, Stengel KR, Poon GMK, Steidl U. Genomic binding site restriction redirects pioneer transcription factor activity.

**Nat Genet.** 2024 (in press)

Gao X\*, Carpenter RS\*, Boulais PE\*, Zhang D, Marlein CR, Li H, Smith M, Chung DJ, Maryanovich M, Will B#, Steidl U#, Frenette PS#. Regulation of the hematopoietic stem cell pool by c-Kit-mediated trogocytosis.

**Science.** 2024 (in press)

Piszczałowski RT\*, Schwenger E\*, Sundaravel S, Stein CM, Liu Y, Stanley P, Verma A, Zheng D, Seidel RD, Almo SC, Townley RA#, Bülow HE#, Steidl U#. A glycan-based approach to cell characterization and isolation: hematopoiesis as a paradigm. **J Exp Med.** 2022 Nov 7;219(11):e20212552.

Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, ..., Montagna C, Pellagatti A, Boulwood J, Xiong S, Lozano G, Verma A, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. **Cancer Cell.** 2021; 39:529-547

Wheat JC, Sella Y, Willcockson M, Skoutchi AI, Bergman A, Singer R, Steidl U. Single Molecule Imaging of Transcription Dynamics in Somatic Stem Cells. **Nature.** 2020; 583:431-436.

Chen J, Kao Y, Sun D, Todorova TI, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A\*, Steidl U\*. MDS progression to AML at the stem cell level. **Nat Med.** 2019; 25:103-110

Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U. IL1RAP potentiates multiple oncogenic signaling pathways in AML. **J Exp Med.** 2018; 215:1709-1727

Carvajal LA, Ben-Neriah D, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell KM, ..., Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia. **Science Transl Med.** 2018; 10:eaao3003

Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, ..., Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GMK, Steidl U. Inhibition of the myeloid master regulator PU.1 as a therapeutic strategy in acute myeloid leukemia. **J Clin Invest.** 2017; 127(12):4297-4313

Stanley RF\*, Piszczałowski RT\*, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari SR, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, Maciejewski JP, Kitsis RN, Steidl U. A myeloid tumor suppressor role for NOL3. **J Exp Med.** 2017; 214:753-771 \* contributed equally

Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, ..., Schaezlein S, McMahon C, Edelmann W, Verma A, Steidl U. Minimal Reduction of PU.1 is Sufficient to Induce a Preleukemic State and Promote Development of Acute Myeloid Leukemia. **Nat Med.** 2015 Oct; 21(10):1172-81

Okoye-Okafor UC, Bartholdy B, Cartier J, ..., Verma A, Steidl U. Novel IDH1 Mutant Inhibitors for Treatment of Acute Myeloid Leukemia. **Nat Chem Biol.** 2015; 11(11):878-86.

Pandolfi A\*, Stanley RF\*, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boulwood J, Chernoff J, Verma A, Steidl U. PAK1 is a Therapeutic Target in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

**Blood.** 2015; 126(9):1118-27.


Bartholdy B\*, Christopheit M\*, Will B, Mo Y, Barreyro L, ..., Grealley JM, Levine RL, Melnick A, Verma A#, Steidl U#. A human hematopoietic stem cell-commitment related DNA cytosine methylation signature is prognostic for overall survival in acute myeloid leukemia. **J Clin Invest.** 2014; 124(3):1158-67.

Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, ..., Verma A, Figueroa ME, Melnick A, Roth M, Steidl U. Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. **Nat Immunol.** 2013; 14:437-45.

Kawahara M\*, Pandolfi A\*, Bartholdy B\*, Barreyro L, Will B, Roth M, Okoye-Okafor UC, Todorova TI, Figueroa ME, Melnick A, Mitsiades CS, Steidl U. H2.0-like homeobox (HLX) regulates early hematopoiesis and promotes acute myeloid leukemia. **Cancer Cell.** 2012; 22:194-208



## Using CRISPR-mediated Chemical Genetics to Define Oncogenic Transcription Networks



**Degron tags promote rapid degradation of endogenous proteins.** (A) The strategy for editing the AML1-ETO locus utilizes Cas9, gRNA targeting the last exon, and an HDR plasmid that will integrate an FKBP-based degron tag, 2xHA, and an mCherry selectable marker. (B) The resulting AML1-ETO-FKBP12<sup>F36V</sup> is then sensitive to the bifunctional small molecule, dTAG-47. One half of the molecule binds the FKBP tag and the second half binds and recruits the CRBN E3 ubiquitin ligase, leading to AML1-ETO degradation. (C) dTAG-47 treatment results in the rapid degradation of the endogenous AML1-ETO protein.

PROTAC (e.g., dTAG-47, see figure above) treatment, and effectively collapses the timeframe for assaying transcriptional changes, chromatin states, and genome-wide transcription factor occupancy from days to hours. We also incorporate proteomics-based methods to identify associated protein complexes and cooperating transcription factors. Combined, these approaches are allowing us to define the mechanism of action of specific oncogenic transcription factors (e.g., AML1-ETO and PAX3-FOXO1). Moreover, we aim to address fundamental questions in the transcription field including how oncogenic transcription factors are influenced by and exert influence over the chromatin landscape, how multiple sequence-specific transcription factors cooperate to fine-tune gene expression, and how enhancer activity functions to control gene transcription.

### Selected Publications:

1. Layden HM, Ellis JD<sup>1</sup>, Bomber ML, Bartlett LN, Hiebert SW\*, and **Stengel KR\***. (2024) Mutant FOXO1 Controls an Oncogenic Network via Enhancer Accessibility. *Cell Genomics*. 4(4): 100537. PMID: 38604128 \*Corresponding Author.

The disruption of normal gene expression programs is a hallmark of all cancers. One common way in which this occurs is through chromosomal translocation that results in the generation of gain-of-function transcription factor fusion proteins. For example, PAX3-FOXO1, arises from the t(2;13) translocation, and is the defining feature of a subset of highly aggressive, pediatric rhabdomyosarcoma (RMS), while AML1-ETO arises from the t(8;21) translocation in acute myeloid leukemia (AML). Both of these translocations target transcription factors that regulate critical cell fate decisions, and both are thought to be the initiating event and an ideal therapeutic target in the cancer in which they arise. Thus, it is essential to understand how these oncogenic transcription factors alter transcriptional programs to drive cancer development.

Historically, our ability to understand how sequence-specific transcription factors rapidly and specifically alter transcriptional programs has been limited by a toolbox of very slow genetic and knockdown strategies that take days to weeks before transcription factor activity can be assayed. Therefore, while direct transcriptional effects occur within minutes to hours, these models take days to establish, which results in the detection of secondary and/or compensatory transcriptional changes that often mask the direct/immediate effects of transcription factor disruption. In order to overcome these technical limitations, we use CRISPR-mediated genome editing to introduce degron tags into endogenous transcription factor loci. This chemical-genetic approach allows rapid transcription factor degradation (minutes to hours) following

2. Bomber ML, Wang J, Liu Q, Barnett KR, Layden HM, Hodges E, **Stengel KR\***, Hiebert SW\*. (2023) Human SMARCA5 is continuously required to maintain nucleosome spacing. *Mol Cell*. 83(4): P507-522. PMID: 36630954 \*corresponding author
3. Zhang S, Wang J, Liu Q, McDonald WH, Bomber ML, Layden HM, Ellis J, Borinstein SC, Hiebert SW\*, **Stengel KR\***. (2022) PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select target genes. *Mol Cell*. 82(23):4428-4442. PMID: 36395771. \*corresponding author
4. Layden HM, Eleuteri NA, Hiebert SW, **Stengel KR**. (2021) A protocol for rapid degradation of endogenous transcription factors in mammalian cells and identification of direct regulatory targets. *STAR Protoc*. 2(2): 100530. PMID: 34041503.
5. **Stengel KR\***, Ellis JD, Spielman C, Bomber M, Hiebert SW\*. (2021) Definition of a Small Core Transcriptional Circuit Regulated by AML1-ETO. *Mol. Cell*. 81(3): 530-545. PMID: 33382982 \*co-corresponding author

**Complete publication list available at:**

<https://www.ncbi.nlm.nih.gov/myncbi/kristy.stengel.1/bibliography/public/>

**Zijie (ZJ) Sun, M.D., Ph.D.**  
**Professor of Cell Biology and Oncology**  
**Director of Prostate Cancer Research Program**

**Ullmann Building Rms 515A**  
**718 430-2115**  
**zijie.sun@einsteinmed.edu**



***Transcriptional regulation, cell signaling, stem/progenitor cells and their niches in prostate development and tumorigenesis.***

Transcriptional control is a key step in the regulation of eukaryotic gene expression. Our research group is focusing on understanding the molecular mechanism of transcription factors that govern the transformation of normal mammalian cells to a neoplastic state. We are especially interested in the biological roles of steroid hormone receptors and their coregulators in development and oncogenesis. We use targeted conditional and inducible mouse models and other cellular and molecular approaches to uncover gene expression and genomic and epigenetic alteration during tumor development and progression. In recent years, we have demonstrated crucial roles and underlying mechanisms for androgen signaling in interacting with Wnt, Sonic hedgehog, IGF, HGF, and other signaling pathways to regulate prostate development and tumorigenesis. Ongoing projects in the lab are investigating several novel and important questions regarding stromal androgen action as tumor niches in supporting prostate cancer growth and progression, and the molecular mechanisms underlying current androgen deprivation therapy (ADT) induced castration resistant prostate cancer (CRPC) development. Our foremost scientific goal is to translate our scientific discoveries from bench to bedside to improve clinical outcomes and help prostate cancer patients.

***Ongoing Projects in the lab:***

- 1) Investigating the regulatory mechanisms for prostate stromal cells in prostate epithelial development and morphogenesis.
- 2) Investigating a non-autonomous role of AR action as stromal cell niches in supporting prostate development and tumorigenesis.
- 3) Developing a therapeutic strategy using androgen analogs to directly target androgen-receptor (AR) positive prostate cancer cells for treating advanced prostate cancer to reduce CRPC development.
- 4) Developing a chem-prevention trial via inhibiting aberrant IGF1 activation to prevent prostate cancer development, particularly for African American men.
- 5) Identifying new therapeutic targets in AR-negative and neuroendocrine-negative CRPC, DNPC, for developing new and effective treatment.
- 6) Investigating the regulatory role of AR signaling in CD4+ T cells to develop new and effective CAR-T therapeutic strategies for prostate cancer and other GU malignancies.
- 7) Transcriptomic profiling earlier prostate cancer lesions to define risk factors for aggressive PCa using “spatial single cell RNA sequencing approaches”.

**Related Publications:**

Kim WK, Buckley AJ, Lee DH, Hiroto A, Nenninger CH, Olson AW, Wang J, Adzavon YM, Bao Y, Kahn M, Xiao GQ, Geradts J, **Sun ZJ** (2024). Androgen Deprivation Induces Double-Null Prostate Cancer via aberrant Activating Nuclear Exporting and Ribosomal Biogenesis by HGF and Wnt Axes. **Nat Commun** 15(1):1231. PMID: 383363745

Kim J, Freeman K, Ayala A, Mullen M, **Sun ZJ**, Rhee JW (2023). Cardiovascular impact of androgen deprivation therapy: from basic biology to clinical practice. **Current Oncol Rep**. doi: 10.1007/s11912-023-01424-2. PMID: 37273124

Alghamdi TA, Krentz NAJ, Smith N, Spigelman AF, Rajesh V, Jha A, Ferdaoussi M, Suzuki K, Yang J, Manning Fox JE, Sun H, **Sun ZJ**, Gloyd AL, MacDonald PE (2022). Zmiz1 is required for mature  $\beta$ -cell

function and mass expansion upon high fat feeding. *Mol Metab.* 2022 Dec;66:101621. doi: 10.1016/j.molmet.2022.101621. Epub 2022 Oct 26. PMID: 36307047

Hiroto A, Kim WK, Pineda A, He Y, Lee DH, Le V, Olson AW, Aldahl J, Nenninger CH, Buckley AJ, Xiao GQ, Geradts J, **Sun ZJ** (2022). Stromal androgen signaling acts as tumor niches to drive prostatic basal epithelial progenitor-initiated oncogenesis. *Nat Commun.* 13(1):6552. PMID: 36323713

Kim WK, Olson AW, Le V, Mi J, Wang J, Lee DH, Le V, Hiroto A, Aldahl J, Nenninger CH, Buckley AJ, Cardiff RD, You SY, **Sun ZJ**. (2022). Aberrant androgen action in prostatic progenitor cells induces oncogenesis and tumor development through IGF1 and Wnt axes. *Nat Commun.*, 28;13 (1) :4364. PMID:35902588, PMCID: PMC9334353

Olson AW, Le V, Wang J, Hiroto A, Kim WK, Lee DH, Aldahl J, Wu X, Kim M, Cunha GR, You S, **Sun ZJ** (2021). Stromal androgen and hedgehog signaling regulates stem cell niches in pubertal prostate development. *Development.* PMID: 34427305

Lee DH, Olson AW, Wang J, Kim WK, Mi J, Zeng H, Le V, Aldahl J, Hiroto A, Wu X, **Sun ZJ** (2021). Androgen action in cell fate and communication during prostate development at single-cell resolution. *Development.* doi: 10.1242/dev.196048. PMID: 33318148

He Y, Mi J, Olson A, Aldahl J, Hooker E, Yu EJ, Le V, Lee DH, Kim WK, Robins DM, Geradts J, **Sun ZJ** (2020). Androgen receptor with short polyglutamine tract preferably enhances Wnt/ $\beta$ -catenin-mediated prostatic tumorigenesis. *Oncogene.* 39(16):3276-3291. PMID: 32089544

Le V, He Y, Aldahl J, Hooker E, Yu EJ, Olson A, Kim WK, Lee DH, Wong M, Sheng R, Mi J, Geradts J, Cunha GR, **Sun ZJ** (2020). Loss of androgen signaling in mesenchymal sonic hedgehog responsive cells diminishes prostate development, growth, and regeneration. *PLoS Genet.* 16(1):e1008588. PMID: 31929563, PMCID: PMC6980684

Aldahl J, Mi J, Pineda A, Kim WK, Olson A, Hooker E, He Y, Yu EJ, Le V, Lee DH, Geradts J, **Sun ZJ** (2020). Aberrant activation of hepatocyte growth factor/MET signaling promotes  $\beta$ -catenin-mediated prostatic tumorigenesis. *J Biol Chem.* 295(2):631-644. doi: 10.1074/jbc.RA119.011137. PMID: 31819003

He YF, Hooker E, Yu EJ, Wu H, Xu JM, Cunha GR, **Sun ZJ** (2019). Androgen signaling is essential for development of prostate cancer initiated from prostatic basal cells. *Oncogene.* 38(13):2337-2350. doi: 10.1038/s41388-018-0583-7. PMID: 30510232

He YF, Johnson DT, Yang JS, Wu H, You S, Yoon J, Lee DH, Kim WK, Aldahl J, Le V, Hooker E, Yu EJ, Geradts J, Cardiff RD, **Sun ZJ** (2019). Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate. *Oncogene.* 38(38):6507-20. doi: 10.1038/s41388-019-0901-8. Epub 2019 Jul 29. PMID: 31358900

Olson A, Le V, Aldahl J, Yu EJ, Hooker E, He Y, Lee DH, Kim WK, Cardiff RD, Geradts J, **Sun ZJ** (2019). The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression. *PLoS Genet.* 15(10):e1008451. doi: 10.1371/journal.pgen.1008451. PMID: 31658259,

Aldahl J, Yu EJ, He YF, Hooker E, Wong M, Le V, Olson A, Lee DH, Kim WK, Murtaugh CL, Cunha GR, **Sun ZJ** (2019). A pivotal role of androgen signaling in notch-responsive cells in prostate development, maturation, and regeneration. *Differentiation*, 2019 May-Jun;107:1-10. PMID: 309276418.

He YF, Hooker E, Yu EJ, Wu H, Cunha GR, **Sun ZJ** (2018). An indispensable role of androgen receptor in Wnt responsive cells during prostate development, maturation, and regeneration. *Stem Cells.* Jun; 36(6):891-902. doi: 10.1002/stem.2806. PMID: 29451339

Mi J, Hooker E, Balog S, Zeng H, Johnson DT, He YF, Yu EJ, Wu H, Le V, Lee DH, Aldahl J, Gonzalgo M, **Sun ZJ** (2018). Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor progression in the murine prostate. *J Biol Chem.* 293(52):20123-20136. PMID: 30401749

**BRITTA WILL, Ph.D.**  
**Associate Professor**

**Chanin Cancer Research Building**  
LAB / Rooms 401 & 417 OFFICE / 401a  
PHONE | (718) 430-3786  
[britta.will@einsteinmed.edu](mailto:britta.will@einsteinmed.edu)



## MECHANISMS OF STEM CELL AGING AND TRANSFORMATION

Key Words: Hematopoietic stem cells, cell fate determination, hematopoietic malignancies.

Hematopoietic stem cells (HSC) maintain blood formation throughout our lifetime. Balancing stem cell regeneration and differentiation commitment to produce mature blood cells is quintessential for a healthy hematopoietic system. Dysregulation of such HSC fate determination processes can lead to loss of immune function, bone marrow failure, and malignant transformation during aging. Up to date, very little is known about the molecular events driving age-related HSC changes and how they contribute to disease. Understanding age-associated molecular alterations will not only uncover fundamental mechanisms guiding function of HSC, but may also allow for therapeutic intervention to “rejuvenate” aged hematopoietic systems and possibly even prevent age-associated hematopoietic diseases. **Our mission is to clarify the central mechanisms establishing and guarding sustained hematopoietic stem cell function, particular those that drive leukemogenesis, if disrupted.** We develop innovative genetic mouse models, use *ex vivo* and *in vivo* primary mouse and human stem cell assay systems, exploit lentiviral gene transfer, and apply state-of-the-art molecular biology and next generation sequencing techniques.

### Identification of novel molecular safeguards of adult and cancer stem cells

We previously uncovered a key role of the amount of readily accessible intracellular iron (termed labile iron pool, LIP) in HSC regeneration ([Kao et al., Science TM 2018](#)). Follow-up work elucidated the underlying molecular mechanism of action and discovered a novel fatty acid metabolism-dependent gene regulatory circuit which erodes during aging ([Kao et al. Cell Stem Cell 2024](#)). We moreover described an important role for another superordinate regulator of fatty acid metabolism, chaperone-mediated autophagy (CMA), in the maintenance of functional HSC ([Dong et al., Nature 2021](#)) in collaboration with Dr. Ana Maria Cuervo and team. Furthermore, we demonstrated a causative role of minimal dosage alterations of a key transcription factor instructing hematopoiesis, PU.1, observed in hematopoietic stem cell aging to myeloid leukemia evolution ([Will et al., Nature Med 2015](#)). Our current efforts focus on understanding how such slight deviations from optimal PU.1 dosage lead to the erosion of PU.1-dependent gene expression programs ([Aivalioti et al., Blood Cancer Discovery 2022](#)), and whether these changes can be used as biomarkers for myeloid leukemia and early cancer interception. We also investigate how CMA as well other stress-related and iron-dependent molecular defense mechanisms drive leukemic stem cell evolution and maintenance.

### Improving stem cell-directed therapies

In collaboration with the late Dr. Paul Frenette, and Drs. Ulrich Steidl and Xin Gao (U Madison), we have recently uncovered that HSC employ trogocytosis (unidirectional active transfer for membrane material) from macrophages to achieve bone marrow residency ([Gao, Carpenter, Boulais et al., Science 2024](#)) opening new avenues for augmenting pharmacologic stem cell mobilization protocols which are the bedrock of successful hematopoietic stem cell transplantation-based therapies combatting life-threatening diseases including cancer, immune deficiency syndromes, and bone marrow failure. Last but not least, we actively engage with academic and commercial research partners to develop, test and evaluate novel therapeutic options for patients with hematologic malignancies ([Kao et al., Science TM 2018](#); [Shastri et al., JCI 2018](#); [Okoye-Okafor et al., JEM 2022](#)).

## Selected Publications

Gao X\*, Carpenter RS, Boulais PE, Zhang D, Marlein CR, Li H, Smith M, Chung DJ, Maryanovich M, Will B\*, Steidl U\* and Frenette PS. **Regulation of the mobilizable hematopoietic stem cell pool by c-Kit-mediated trogocytosis.** Science 2024. *In press.* [\* co-corresponding authors]

Kao YR, Chen J, Kumari R, Ng A, Zintiridou A, Tatiparthi M, Ma Y, Aivalioti MM, Moulik D, Sundaravel S, Sun D, Reisz JA, Grimm J, Martinez-Lopez N, Stransky S, Sidoli S, Steidl U, Singh R, D'Alessandro A, Will B. **An iron rheostat controls hematopoietic stem cell fate.** Cell Stem Cell. 2024 Mar 7;31(3):378-397.e12. doi: 10.1016/j.stem.2024.01.011. Epub 2024 Feb 22. PubMed PMID: [38402617](#); PubMed Central PMCID: PMC10939794.

Okoye-Okafor UC, Javarappa KK, Tsallos D, Saad J, Yang D, Zhang C, Benard L, Thiruthuvanathan VJ, Cole S, Ruiz S, Tatiparthi M, Choudhary G, DeFronzo S, Bartholdy BA, Pallaud C, Ramos PM, Shastri A, Verma A, Heckman CA, Will B. **Megakaryopoiesis impairment through acute innate immune signaling activation by azacitidine.** J Exp Med. 2022 Nov 7;219(11):e20212228. doi: 10.1084/jem.20212228. Epub 2022 Sep 2. PMID: [36053753](#).

Aivalioti MM, Bartholdy BA, Pradhan K, Bhagat TD, Zintiridou A, Jeong JJ, Thiruthuvanathan VJ, Pujato M, Paranjpe A, Zhang C, Levine RL, Viny AD, Wickrema A, Verma A, Will B. **PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.** Blood Cancer Discov. 2022 Sep 6;3(5):444-467. doi: 10.1158/2643-3230.BCD-21-0226. PubMed PMID: [35820129](#); PubMed Central PMCID: PMC9894728.

Dong S, Wang Q, Kao YR, Diaz A, Tasset I, Kaushik S, Thiruthuvanathan V, Zintiridou A, Nieves E, Dzieciatkowska M, Reisz JA, Gavathiotis E, D'Alessandro A, Will B\* and Cuervo AM\*. **Chaperone-mediated autophagy sustains haematopoietic stem-cell function.** Nature. 2021 Mar;591(7848):117-123. doi: 10.1038/s41586-020-03129-z. Epub 2021 Jan 13. PubMed PMID: [33442062](#) [\* co-corresponding authors]

Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti M, Ferreira M, Ramos-Marques P, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B. **Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.** Science Translational Medicine 2018; 10(458). PubMed PMID: [30209246](#) [\* co-corresponding authors]

Shastri A\*, Choudhary GS, Ferreira-Teixeira M, Gordon-Mitchell S, Ramachandra N, Benard L, Bhattacharyya S, Lopez R, Pradhan K, Gircz O, Ravipati G, Wong L, Cole SL, Bhagat T, Feld J, Dhar J, Bartenstein M, Thiruthuvanathan VJ, Wickrema A, Ye H, Frank DA, Pellagatti A, Boultonwood J, Zhou T, Kim Y, MacLeod AR, Epling-Burnette P, Ye M, McCoon P, Woessner R, Steidl U, Will B\*, Verma A\*. **Antisense inhibition of STAT3 as a therapeutic strategy against MDS and AML stem cells.** JCI 2018; 128(12):5479-5488. PubMed PMID: [30252677](#) [\* co-corresponding authors]

Will B\*, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, da Silva Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Neriah DB, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U\*. **Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia.** Nat Med. 2015 Oct;21(10):1172-81. PubMed PMID: [26343801](#). [\* co-corresponding authors]

Will B., Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, Steidl U. **Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.** Nat Immunol. 2013 May;14(5):437-45. PubMed PMID: [23563689](#); PubMed Central PMCID: [PMC3633104](#).

Will B., Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat TD, Bhattacharyya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultonwood J, Montagna C, Silverman L, Maciejewski J, Grealley JM, Ye BH, List AF, Steidl C, Steidl U, Verma A. **Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.** Blood. 2012 Sep 6;120(10):2076-86. PubMed PMID: [22753872](#); PubMed Central PMCID: [PMC3437595](#).

Full list of publications can be found at:

<https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/47490382/?sort=date&direction=descending>

**B. HILDA YE, Ph.D.**  
**Associate Professor**

**CHANIN BLDG. – ROOM 302C**  
**(718) 430-3339**  
***hilda.ye@einsteinmed.edu***



### **Transcription Regulation and Cell Signaling Control in Normal B/T Cells and Lymphomas**

Molecular pathogenesis of lymphomas situates at the crossroad of lymphocyte development, and cancer genetics, and involves all aspects of tumor-host interactions. Thus, we constantly draw upon the most recent advances in these fields to address mechanism questions that are related to lymphoma initiation, development, and therapeutic response. As each lymphoma entity often relates to a specific B/T cell activation/differentiation state that is phenotypically “frozen” by the malignant transformation process, our research also provides valuable insights to the regulatory processes that govern the normal immune system. **Our studies have three major goals:** to better understand B and T cell development in molecular terms, to decipher how this process is perturbed during lymphomagenesis, and to develop mechanism-based novel therapies to improve patient outcome.

The germinal center (**GC**) response is a crucial stage in B cell development that is specifically evolved to support the production of high affinity antibodies and B cell memory. Dysregulated GC responses underlie the development of many types of B cell lymphomas and autoimmune diseases. The genome of GC B cells is subject to two types of genetic alterations catalyzed by AID (activation induced cytidine deaminase), e.g. Ig class switch recombination and somatic hypermutation. Mutated B cells then undergo positive and negative selections through interactions with follicular dendritic cells, follicular T helper (Tfh) and T follicular regulatory (Tfr) cells. Only the fittest B cells are licensed to terminally differentiate into memory or plasma cells. At the single cell level, the acquisition and termination of GC phenotype is a coordinated response to various extracellular and intracellular stimuli; yet the precise sequence and nature of these stimuli are incompletely understood.

Our previous studies have revealed important mechanisms that govern the expression and activity of BCL6, the master regulator of GC response, and demonstrated functional interactions between BCL6 and several cell signaling pathways including RhoA, NF- $\kappa$ B, and Jak/STAT3. In the context of diffuse large B-cell lymphomas (**DLBCL**), another focus of our investigation was on the IL-6/Jak/STAT3 signaling pathway. We have characterized expression regulation of STAT3, cause and consequences of its aberrant activity in DLBCL development and therapeutic response. The functional contribution of this pathway to normal plasma cell maturation was also investigated.

Since 2016, the major focus of our research program has switched to adult T-cell leukemia/lymphoma (ATLL), a disease of malignant CD4+ T cells that develops in 4-5% of individuals infected with the human T-cell lymphotropic virus 1 (**HTLV-1**). The median survival of ATLL patients diagnosed in North America is only about 7 months, pointing to an urgent unmet need in the therapeutic space. Because of the Bronx’s immigrant makeup, the Montefiore Medical Center treats a sizable fraction of all ATLL cases in the U.S., and thus we have unique access to ATLL patient samples and unmatched opportunities to perform preclinical and clinical studies. We recently reported that ATLL patients diagnosed in North American (**NA-ATLL**) have a distinct genomic landscape compared to the Japanese cohort (**J-ATLL**). Specifically, NA-ATLL is characterized by a much higher frequency of prognostic epigenetic mutations and is targetable

preclinically with DNA de-methylation drugs. Ongoing studies in our laboratory support the concept that NA- and J-ATLL share similarities in clinical behavior and pathogenesis but also have clear distinctions in mutation pattern, cell cycle regulation, immunophenotype, and response to experimental therapeutics. Since host anti-HTLV-1/anti-ATLL immune response plays a key role in ATLL development, we have also begun to examine how host immunity, in particular CD8<sup>+</sup> cytotoxic response, is impacted during ATLL development and therapeutic response. Our preliminary findings support the concept that for an ATLL treatment to be most effective, ATLL-induced immunosuppression must be overcome along with functional restoration of anti-ATLL CD8<sup>+</sup> T cell effector and memory responses. Looking forward, insights uncovered from our ongoing projects are expected to pave the way for novel pathway-targeted and immune-modulatory therapies for ATLL patients and possibly other types of T-cell malignancies.

**Working with several Einstein-Montefiore research teams as well as other U.S. and international collaborators, we are asking the following research questions:**

1. How does BCL6 contribute to the pathogenesis and cell identity of NA-ATLL?
2. How do the ATLL leukemic cells drive Ag-specific CD8<sup>+</sup> T cells into functional impairment during ATLL development?
3. What is the genetic and clonal evolution basis that may contribute to the differences between NA- and J-ATLL?

**Selected Publications:**

- Kogure, Y., Kameda, Y., Koya, J., Yoshimitsu, M., ..... Braunschweig, I., **Ye, B.H.\***, Shimoda, K.\*, and Kataoka, K.\*. Whole-genome landscape of adult T-cell leukemia/lymphoma. ***Blood***. 139(7):967-982, 2022. PMID: 34695199 (Plenary Paper; \*corresponding authors)
- Chung EY, Mai Y, Shah UA, Wei Y, Ishida E, Kataoka K, Ren X, Pradhan K, Bartholdy B, Wei X, Zou Y, Zhang J, Ogawa S, Steidl U, Zang X, Verma A, Janakiram M, **Ye BH**. PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. ***Clin Cancer Res***. 25:3589–601, 2019. PMID: 30862694 (Cover Article)
- Shah UA, Chung EY, Giricz O, Pradhan K, ....., Verma A\*, **Ye BH\***, Janakiram M\*. North American ATLL has a Distinct Mutational and Transcriptional Profile and responds to epigenetic therapies. ***Blood***. 132:1507-1518, 2018. PMID: 30104217. (\*corresponding authors)
- Mai Y, Yu JJ, Bartholdy B, Xu-Monette ZY, Knapp EE, Yuan F, Chen H, Ding BB, Yao Z, Das B, Zou Y, Young KH, Parekh S, **Ye BH**. Subtype-specific mechanism for Doxorubicin-triggered cytotoxicity in diffuse large B cell lymphomas. ***Blood***. 128:2797-2807, 2016. PMID: 27737889
- Alvarez, M J, Shen, Y., Giorgi, FM, Lachmann, A., Ding, BB, **Ye, BH**, Califano, A. Network-based inference of protein activity helps functionalize the genetic landscape of cancer. ***Nature Genet.***, 48:838-4, 2016. PMID: 27322546.
- Huang, X., Meng, B., Iqbal, J., Ding, B.B., ..... Chan, W., **Ye, BH\***, Fu, K\*. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma patients treated with R-CHOP. ***J Clin Oncol.***, 31:4520-8, 2013. PMID: 24220563. (\*corresponding authors)
- Ye, BH**, Lista, F., Lo Coco, F., Knowles, D. M., Offit, O., Chaganti, R.S.K. and Dalla-Favera, R. Alterations of a zinc-finger encoding gene, BCL-6, in diffuse large-cell lymphoma. ***Science***. 262:747-750, 1993. PMID: 8235596